Novel Compounds

ABSTRACT

Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

SUMMARY OF THE INVENTION

This invention relates to novel 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-[1H]-one compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of certain diseases and conditions.

BACKGROUND OF THE INVENTION

Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e.g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phospholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell, 80, 179-278 (1995)]. Protein kinases can be categorized into five classes with the two major classes being tyrosine kinases and serine/threonine kinases, depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine/threonine(s) residues [Hunter, T., Methods in Enzymology (Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].

Three major related intracellular pathways, the mitogen-activated kinases, or MAPKs, are now understood to transduce signals from many extracellular stimuli such as environmental stress, infectious agents, cytokines and growth factors. The MAPKs modulate the activity of numerous cell functions such as translocation and activation of transcription factors that control transcription of effector molecules such as cytokines, COX-2, iNOS; the activity of downstream kinases that effect translation of mRNAs; and cell cycle pathways through transcription or modification of enzymes. One of these three major pathways is the p38 MAPK pathway, which refers in most cell types to the isoform p38a which is ubiquitously expressed. The role of p38 in a multitude of functions, particularly related to inflammatory response has been elucidated using selective p38 inhibitors in numerous in vitro and in vivo studies. These functions have been extensively reviewed and a summary can be found in Nature Reviews [Kumar, S. Nature Rev. Drug Discovery, 2:717 (2003)]

Extracellular stimuli such as those described above are generated in a number of chronic diseases which are now understood to have a common underlying pathophysiology termed inflammation. An environmental insult or local cell damage activates cellular response pathways, including but not limited to p38; local cells then generate cytokines and chemokines, in turn recruiting lymphocytes such as neutrophils and other granulocytes. In a secondary response, the consequences include recruitment of additional lymphocytes such as additional phagocytic cells or cytotoxic T cells, and ultimately the adaptive immune response is initiated through activation of T cells. It is not currently fully understood how this acute inflammatory response becomes a chronic response leading to diseases such as rheumatoid arthritis (RA), atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), etc. Nevertheless, the features of inflammation are recognized to contribute to a large number of chronic diseases and pathways such as the p38 pathway are accepted to contribute to the initiation of inflammatory diseases.

For example, atherosclerosis is regarded as a chronic inflammatory disease, which develops in response to injury of the vessel wall and is characterized by the complex development of an occlusive and prothrombotic atheroma. The pathogenesis of this lesion generally involves endothelial dysfunction (reduced bioavailable NO), adhesion molecule expression, adhesion and infiltration of leukocytes, cytokine and growth factor generation, accumulation of foam cells, expansion of extracellular lipid and matrix, activation of matrix metalloproteases (MMPs) and proliferation of vascular smooth muscle cells.

The discovery of p38 (initially termed CSBP, now p38; the isoforms p38α and p38β are the targets of the compounds described) provided a mechanism of action of a class of anti-inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL-1 and TNF synthesis in human monocytes at concentrations in the low uM range [Lee, et al., Int. J. Immunopharmac. 10(7), 835 (1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee; et al., Annals N.Y. Acad. Sci., 696, 149 (1993)].

The mechanism by which stress signals (including bacterial and viral infection, pro-inflammatory cytokines, oxidants, UV light and osmotic stress) activate p38 is through activation of kinases upstream from p38 which in turn phosphorylate p38 at threonine 180 and tyrosine 182 resulting in p38 activation. MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp27 and other substrates. Additional downstream substrates known to be phosphorylated by p38 include kinases (Mnk1/2, MSK1/2 and PRAK) and transcription factors (CHOP, MEF2, ATF2 and CREB). While many of the signaling pathways required for transduction of stress stimuli remain unknown it appears clear that many of the substrates for p38 listed above are involved. [Cohen, P. Trends Cell Biol., 353-361 (1997) and Lee, J. C. et al, Pharmacol. Ther. vol. 82, nos. 2-3, pp. 389-397, 1999]. There is also emerging evidence that p38 is involved in modulation of the activity of the NF-kB signaling pathway through a role in histone phosphorylation or acetylation, or through reduction of transcription competence of the NF-kB complex [Saccini, S. Nature Immunol., 3: 69-75, (2002); Carter, A B et al J Biol Chem 274: 30858-63 (1999)]. Finally, a role for p38 in generation of response to IFNs through activation by the Type I IFN receptor has been described [Platanias, Pharmacol. Therap. 98:129-142 (2003)]. Activation of p38 is involved in the transcriptional regulation of IFN sensitive genes through modification of specific transcription factors binding to promoter elements in these genes. Direct phosphorylation of STATs by p38 has not been conclusively demonstrated.

In addition to inhibiting IL-1 and TNF upregulation in response to inflammatory stimuli, p38 kinase inhibitors (e.g., SK&F 86002 and SB-203580) are effective in a number of different cell types in decreasing the synthesis of a wide variety of pro-inflammatory proteins including, IL-6, IL-8, GM-CSF, RANTES and COX-2. Inhibitors of p38 kinase have also been shown to suppress the TNF-induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the IL-1-stimulated synthesis of collagenase and stromelysin. These and additional data demonstrate that p38 is involved not only cytokine synthesis in response to stress, but also in propagating the consequent cytokine signaling [CSBP/P38 kinase reviewed in Cohen, P. Trends Cell Biol., 353-361 (1997)].

Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are important inflammatory cytokines produced by a variety of cells, such as monocytes, macrophages, and smooth muscle cells. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.

There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Evidence also links IL-1 activity to diabetes and pancreatic β cells [review of the biological activities which have been attributed to IL-1 Dinarello, J. Clinical Immunology, 5 (5), 287-297 (1985)].

Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic obstructive pulmonary disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.

Inflammatory diseases are also marked by increases in IL-6 and C-reactive protein (CRP), both of which are sensitive to inhibition by p38 inhibitors. IL-6 stimulation of CRP production is directly inhibited by p38 inhibitors in human vascular endothelial cells, and CRP is produced by hepatocytes in response to IL-6. CRP is considered a major risk factor for cardiovascular disease [Circulation 2003.107: 363-369] and may be a significant independent risk factor for chronic obstructive pulmonary disease [Circulation 2003. 107:1514-1519]. IL-6 is also upregulated in endometriosis [Bedaiwy et al., 2002, Human Reproduction 17:426-431; Witz, 2000, Fertility and Sterility 73: 212-214].

Interleukin-8 (IL-8) and RANTES are chemotactic factors produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, epithelial cells, neutrophils and T cells. Chemokine production is induced by pro-inflammatory stimuli such as IL-1, TNF, or lipopolysaccharide (LPS), or viral infection. IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysosomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis, which may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions such as chronic obstructive pulmonary disease associated with an increase in IL-8 production would benefit by compounds which are suppressive of IL-8 production. RANTES is produced by cells such as epithelial cells and airway smooth muscle in response to infection or cytokine stimulation. Its main chemoattraction is for T cell subtypes and blood-borne monocytes.

IL-1, TNF and other cytokines affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important as critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.

In addition to the involvement of p38 signaling in the production of IL-1, TNF, IL-8, IL-6, GM-CSF, COX-2, collagenase and stromelysin, signal transduction via CSBP/p38 is required for the effector functions of several of these same pro-inflammatory proteins plus many others. For example, growth factors such as VEGF, PDGF, NGF signal through surface receptors which in turn activate cellular signaling pathways including p38 MAPK [Ono, K. and Han, J., Cellular Signalling, 12 1-13 (2000); Kyriakis, J M and Avruch, J. Physiol Rev 81: 807-869 (2001)]. TGFχ, a key molecule in the control of inflammatory response, also activates p38 as a consequence of engagement of the TGFβ receptor. The involvement of CSBP/p38 in multiple stress-induced signal transduction pathways provides additional rationale for the potential utility of CSBP/p38 in the treatment of diseases resulting from the excessive and destructive activation of the immune system, or chronic inflammation. This expectation is supported by the potent and diverse activities described for CSBP/p38 kinase inhibitors [Badger, et al., J. Pharm. Exp. Thera. 279 (3): 1453-1461. (1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996); Jackson, et al., J. Pharmacol. Exp. Ther. 284, 687-692 (1998); Underwood, et al., J. Pharmacol. Exp. Ther. 293, 281-288 (2000); Badger, et al., Arthritis Rheum. 43, 175-183 (2000)].

Chronic inflammation is also characterized by ongoing remodeling and repair of affected tissue, leading in some cases to excess fibrotic tissue. A role for p38 MAPK in fibrosis is supported by findings that this enzyme mediates signaling of transforming growth factor beta (TGF-β) on markers and proteins of fibrosis. For example, it has been shown that TGF-β increases the kinase activity of p38 MAPK through the TGF-β activated kinase TAK-1 (Hanafusa et al., 1999, J. Biol. Chem. 274:27161-27167). Furthermore, the p38 inhibitor SB-242235 inhibited the TGF-β-induced increases in fibronectin and thrombospondin (Laping et al., 2002, Molec. Pharmacol. 62:58-64). These results show that p38 MAPK is a key signaling intermediate for the effect of the pro-fibrotic cytokine TGF-β on components of the extracellular matrix and markers of fibrosis.

P38 also plays a role in directing survival and apoptosis of cells in response to various stimuli. Both survival and apoptosis can be p38 regulated depending on the stimulus and the cell type [Morin and Huot, Cancer Research. 64:1893-1898 (2004)]. For example, TGF-beta can stimulate apoptosis in murine hepatocytes through activation of gadd45b, a protein involved in cell-cycle control, in a p38 mediated process [Yoo et al, J. Biol. Chem. 278:43001-43007, (2003)]. In a different response pathway, UV-stress can activate p38 and trigger apoptosis of a damaged cell. P38 has also been shown to promote survival of lymphocytes in response to stress, including neutrophils and CD8+ T cells.

There remains a need for treatment, in this field, for compounds which are cytokine suppressive anti-inflammatory drugs, i.e. compounds which are capable of inhibiting the CSBP/p38/RK kinase. The present invention is directed to such novel compounds which are inhibitors of p38 kinase.

SUMMARY OF THE INVENTION

This invention relates to the novel compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof; and pharmaceutical compositions comprising a compound of Formula (I) and (Ia), (II) and (Ia), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

This invention relates to a method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

This invention also relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A₁), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

This invention also relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (Ia), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A₁), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

This invention also relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (Ia), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A₁), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

This invention also relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A₁), (B), and (B1), and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

Accordingly, the present invention provides for a compound of Formula (I) and (Ia) having the structure:

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NRqRq′; -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a     heterocyclylC₁₋₁₀alkyl moiety, and wherein each of these moieties     may be optionally substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is independently selected at each occurrence from 0 or an integer     having a value of 1 to 10; -   m is independently selected at each occurrence from 0 or an integer     having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is independently selected at each occurrence from 0 or an integer     having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; or     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

DETAILED DESCRIPTION OF THE INVENTION

The novel compound of Formula (I) are discussed in greater detail described below.

The present invention is directed to novel compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), (A), (A₁), (B), (BI), (VI), (Via), (VIII) and (VIIIa), (IX) and (IXa), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof. As will be readily recognized, the difference between compounds of Formula (I) and (Ia) lies in unsaturation of the ring system. The difference between compound of Formula (I) and (Ia) and compounds of Formula (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), (A), (A1), (B), (B1), (VI), (VIa), (VIII) and (VIIIa) lies in ring substitution of the R₁ substituent on the aryl (or heteroaryl moiety when G5 and/or G6, etc are nitrogen), and the ring position of the nitrogen(s) for the pyridyl or pyrimidine pharmacophore where applicable. It is recognized that the ring position numbering may change due to the nitrogen's in the pharmacophore ring and or in the ring that the R₁ substituent is attached in.

The respective R₁, R_(1′), R₂, R₃, R_(x), X and R₃, etc., terms are the same for both groups within the formulas themselves, for instance, in Formula (I) and (Ia), and except for the additional G5/G6/G7/G8 terms, applicable across all formulas herein. For purposes herein, everything applicable to Formula (I) is also applicable to Formula (Ia) unless otherwise indicated, and for the remaining compounds of Formula (II) and (IIa), etc. unless specified otherwise.

It is recognized that for compounds of Formula (I) and (Ia) wherein G₃ and G₄ are both nitrogen and G₁ and G₂ are both nitrogen, the ring system is considered to be a 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-[1H]-one.

Compounds of Formula (I) and (Ia) are further represented by the structure:

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from hydrogen,     halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))R_(h)NH—C(═N—CN)NRqRq′; -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted; or R_(q) and R_(q′)     together with the nitrogen to which they are attached form an     optionally substituted heterocyclic ring of 5 to 7 members, which     ring may contain an additional heteroatom selected from oxygen,     nitrogen or sulfur; -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally C₁₋₁₀ alkyl; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     -   wherein these moieties, excluding hydrogen, may be optionally         substituted 1 to 4 times, independently at each occurrence from         C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀         alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,         C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl C₁₋₁₀ alkyl, halogen, —C(O),         cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heteroaryl,         heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclylC₁₋₁₀ alkyl,         (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇,         (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkyl NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆,         (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆,         (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; or wherein     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     -   wherein each of these moieties, excluding hydrogen, may be         optionally substituted 1 to 4 times, independently at each         occurrence from C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀         alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl,         C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl         C₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀         alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl,         heteroaryl C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH,         (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇,         (CR₁₀R₂₀)_(n)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′), (CR₁₀R₂₀)_(n)CN,         (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(Z)R₆,         (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆,         (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆,         (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)OC(Z)         NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     -   wherein these moieties, excluding hydrogen, may be optionally         substituted 1 to 4 times, independently at each occurrence from         C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀         alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,         C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl C₁₋₁₀ alkyl, halogen, —C(O),         cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heteroaryl,         heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclylC₁₋₁₀ alkyl,         (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇,         (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkyl NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆,         (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆,         (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′),         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or heterocyclylC₁₋₁₀ alkyl moiety, and     -   wherein these moieties are all optionally substituted one or         more times, independently at each occurrence from hydrogen,         halogen, nitro, C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀         alkenyl, C₂₋₁₀alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀         alkyl, C₅₋₇cycloalkenyl, C₅₋₇cycloalkenylC₁₋₁₀ alkyl,         (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇,         (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR₁₆R₂₆,         (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR₁₆R₂₆, (CR₁₀R₂₀)_(n)C(Z)R₆,         (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆,         (CR₁₀R₂₀)_(n)C(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆,         (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR₁₆R₂₆,         (CR₁₀R₂₀)_(n)OC(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n1)N(R_(10′))C(Z)NR₁₆R₂₆,         or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or heteroaryl C₁₋₄ alkyl; or the R₄ and R₁₄ together with     the nitrogen which they are attached form an unsubstituted or     substituted heterocyclic ring of 4 to 7 members, which ring     optionally contains an additional heteroatom selected from oxygen,     sulfur or nitrogen; and     -   wherein the C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄         alkyl, aryl, aryl-C₁₋₄ alkyl, heteroaryl and heteroaryl C₁₋₄         alkyl moieties, and the R₄ and R₁₄ cyclized ring are optionally         substituted, 1 to 4 times, independently at each occurrence, by         halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy;         halosubstituted C₁₋₁₀ alkoxy; C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀         alkyl; SR₅; S(O)R₅; S(O)₂R₅; C(O)Rj; C(O)ORj;         C(O)NR_(4′)R_(14′); (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇;         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(d)R_(d′); NR_(4′)C(O)C₁₋₁₀alkyl;         NR_(4′)C(O)aryl; NR_(4′)R_(14′); cyano; nitro; C₃₋₇cycloalkyl;         C₃₋₇cycloalkyl C₁₋₁₀ alkyl; an unsubstituted or substituted         aryl, or arylC₁₋₄ alkyl; an unsubstituted or substituted         heteroaryl, or heteroaryl C₁₋₄ alkyl; an unsubstituted or         substituted heterocyclic, or heterocyclic C₁₋₄ alkyl, and         wherein these aryl, heterocyclic and heteroaryl containing         moieties are substituted one to two times independently at each         occurrence by halogen; C₁₋₄ alkyl, hydroxy; hydroxy substituted         C₁₋₄ alkyl; C₁₋₄ alkoxy; S(O)_(m)alkyl; amino, mono &         di-substituted C₁₋₄ alkyl amino, or CF₃; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) can     cyclize together with the nitrogen to which they are attached to     form a 5 to 7 membered ring which optionally contains an additional     heteroatom selected from oxygen, sulfur or NR_(9′); -   R_(4″) and R_(14″) are independently selected at each occurrence     from hydrogen or C₁₋₄ alkyl, or R_(4″) and R_(14″) together with the     nitrogen to which they are attached, cyclize to form a 5 to 7     membered ring which optionally contains an additional heteroatom     selected from oxygen, sulfur or NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R₆ is independently selected at each occurrence from hydrogen, C₁₋₁₀     alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, aryl,     arylC₁₋₁₀ alkyl, heteroaryl or heteroarylC₁₋₁₀ alkyl, wherein each     of these moieties, excluding hydrogen are optionally substituted; -   R₇ is independently selected at each occurrence from C₁₋₆alkyl,     aryl, arylC₁₋₆alkyl, heterocyclic, heterocyclylC₁₋₆ alkyl,     heteroaryl, or heteroarylC₁₋₆alkyl moiety, and wherein each of these     moieties may be optionally substituted; -   R₈ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein these moieties, excluding hydrogen, may be     optionally substituted; -   R₉ is independently selected at each occurrence from hydrogen,     C(Z)R₆, optionally substituted C₁₋₁₀ alkyl, optionally substituted     aryl, optionally substituted aryl-C₁₋₄ alkyl; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or heterocyclylC₁₋₄ alkyl, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₅ and R₂₅ are independently selected at each occurrence from     hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, or aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl     heteroaryl or heteroaryl C₁₋₄ alkyl moiety, and wherein these     moieties, excluding hydrogen may be optionally substituted; or R₁₅     and R₂₅ together with the nitrogen which they are attached form an     optionally substituted heterocyclic ring of 4 to 7 members, which     ring optionally contains an additional heteroatom selected from     oxygen, sulfur or NR₉; and     -   wherein these moieties, excluding hydrogen, are optionally         substituted 1 to 4 times, independently at each occurrence from         halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy;         halosubstituted C₁₋₁₀alkoxy; halosubstituted C₁₋₄ alkyl; SR₅,         S(O)R₅, S(O)₂R₅; C(O)R_(j); C(O)OR_(j); C(O)NR_(4′)R_(14′);         NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; NR_(4′)R_(14′); cyano;         nitro; C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl;         halosubstituted C₁₋₁₀ alkyl; aryl, aryl C₁₋₄ alkyl,         heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl, or hetero         C₁₋₄ alkyl, and wherein these aryl, heterocyclic, and heteroaryl         containing moieties may also be substituted one to two times         independently at each occurrence by halogen, C₁₋₄ alkyl,         hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy, S(O)_(m)         C₁₋₄ alkyl, amino, mono & di-substituted C₁₋₄ alkylamino, C₁₋₄         alkyl, or CF₃; -   R₁₆ and R₂₆ are each independently selected at each occurrence from     hydrogen, or C₁₋₄ alkyl; or the R₁₆ and R₂₆ together with the     nitrogen which they are attached form an unsubstituted or     substituted heterocyclic ring of 4 to 7 members, which ring     optionally contains an additional heteroatom selected from oxygen,     sulfur or NR_(9′); -   R_(21′) and R_(31′) are independently selected at each occurrence     from hydrogen or C₁₋₄ alkyl, or R_(21′) and R_(31′) together with     the nitrogen to which they are attached cyclize to form a 5 to 7     membered ring which optionally contains an additional heteroatom     selected from oxygen, sulfur or NR_(9′); -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl     moiety; and     -   which moieties may all be optionally substituted 1 to 4 times         independently at each occurrence from halogen; hydroxy; hydroxy         substituted C₁₋₁₀alkyl; C₁₋₁₀ alkyl; C₁₋₁₀ alkoxy;         halosubstituted C₁₋₁₀ alkoxy; ORS, SR₅, S(O)R₅, S(O)₂R₅;         C(O)R_(j); C(O)OR_(j); C(O)NR₁₅R₂₅; cyano; nitro; NR₁₅R₂₅;         -Z′-(CR₁₀R₂₀)s-Z′—, C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl;         halosubstituted C₁₋₁₀ alkyl; an optionally substituted aryl or         arylalkyl, an optionally substituted heteroaryl and         heteroarylC₁₋₁₀ alkyl, and an optionally substituted         heterocyclic and heterocyclicC₁₋₁₀ alkyl, and wherein these         aryl, heteroaryl and heterocyclic containing moieties may also         be substituted one to two times independently at each occurrence         from halogen, hydroxy, hydroxy substituted alkyl, C₁₋₁₀ alkoxy,         S(O)_(m)C₁₋₄ alkyl, amino, mono & di-substituted C₁₋₄ alkyl         amino, C₁₋₄ alkyl, or CF₃; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆     cycloalkylC₁₋₄alkyl, or the R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′);     and     -   wherein the R_(d) and R_(d′) moieties which are C₁₋₄ alkyl,         C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄ alkyl, and the R_(d) and         R_(d′) cyclized ring are substituted, 1 to 4 times,         independently at each occurrence by halogen; halosubstituted         C₁₋₄ alkyl; hydroxy; hydroxy substituted C₁₋₄alkyl; C₁₋₄ alkoxy;         halosubstituted C₁₋₄ alkoxy; S(O)mRf; C(O)Rj; C(O)ORj;         C(O)NR_(4′)R_(14′); NR_(4′)C(O)C₁₋₄alkyl;         S(O)₂NR_(4′)R_(14′)C₁₋₄ alkyl; NR_(4′)R_(14′)S(O)₂C₁₋₄ alkyl; or         NR_(4′)R_(14′); -   R_(e) are R_(e′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic,     heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl     moiety; or R_(e) and R_(e′) together with the nitrogen which they     are attached form an optionally substituted heterocyclic ring of 4     to 7 members, which ring optionally contains an additional     heteroatom selected from oxygen, sulfur or nitrogen; and     -   wherein each of these moieties, excluding hydrogen, may be         substituted 1 to 4 times, independently at each occurrence by         halogen; hydroxy; hydroxy substituted C₁₋₁₀ alkyl; C₁₋₁₀ alkoxy;         halosubstituted C₁₋₁₀ alkoxy; amino, mono & di-substituted C₁₋₄         alkyl amino; S(O)_(m)R_(f′); C(O)R_(j); C(O)OR_(j);         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇;         (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(d)R_(d′); C(O)NR₄R_(14′);         NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; cyano; nitro; C₁₋₁₀         alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl;         halosubstituted C₁₋₁₀ alkyl; aryl, aryl C₁₋₄ alkyl,         heterocyclic, heterocyclicC₁₋₄ alkyl, heteroaryl, or         heteroC₁₋₄alkyl, and wherein these aryl, heterocyclic, and         heteroaryl containing moieties may be optionally substituted one         to two times independently at each occurrence by halogen, C₁₋₄         alkyl, hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy,         S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino,         C₁₋₄ alkyl, or CF₃; -   R_(f) is independently selected at each occurrence from C₁₋₁₀ alkyl,     aryl, aryl C₁₋₁₀alkyl, heteroaryl, heteroaryl C₁₋₁₀alkyl,     heterocyclic, or a heterocyclic C₁₋₁₀ alkyl moiety, and wherein     these moieties may all be optionally substituted; -   R_(f′) is independently selected at each occurrence from hydrogen,     C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀alkyl, heteroaryl, heteroaryl     C₁₋₁₀alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl or     NR_(4′)R_(14′); and wherein these moieties, excluding hydrogen, and     NR_(4′)R_(14′), may be optionally substituted; -   R_(j) is independently selected at each occurrence from hydrogen,     C₁₋₄alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl, heteroaryl C₁₋₄alkyl,     heterocyclic, or a heterocyclic C₁₋₄alkyl moiety, and wherein these     moieties, excluding hydrogen, may be optionally substituted; -   g is 0, or integer having a value of 1, 2, 3, or 4; -   n is independently selected at each occurrence from 0 or an integer     having a value of 1 to 10; -   n′ is independently selected at each occurrence from 0 or an integer     having a value of 1 to 10; -   m is independently selected at each occurrence from 0 or an integer     having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is independently selected at each occurrence from 0 or an integer     having a value of 1 or 2; -   s is independently selected at each occurrence from an integer     having a value of 1, 2, or 3; -   t is an integer having a value of 2 to 6; -   Z is independently selected at each occurrence from oxygen or     sulfur; -   Z′ is independently selected at each occurrence from oxygen, or     sulfur; and     a pharmaceutically acceptable salt thereof, solvate or     physiologically functional derivative thereof.

Suitably, for compounds of Formula (I), and (Ia), and the remaining formulas described herein R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b).

In one embodiment of the invention, R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), or N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b). In another embodiment of the invention R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b).

Suitably, R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃.

In one embodiment, R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, or halo-substituted-C₁₋₄ alkyl. In another embodiment, R_(1′) is independently selected at each occurrence from fluorine, chlorine, methyl, or CF₃.

Suitably, g is 0 or an integer having a value of 1, 2, 3, or 4. In one embodiment of the invention, g is 0, 1 or 2.

For compounds of Formula (I) and (Ia), when R_(1′) is substituted on a phenyl ring in the ortho position, and a second R_(1′) moiety is also substituted on the ring, then preferably the second substitution is not in the other ortho position. Suitably, the phenyl ring is substituted in the 2-position and if a second substituent is present, in the 3-position with the R₁ moiety in the 5-position. Alternatively, the R_(1′) moiety may be in the other ortho 2-position and the R₁ moiety in the 3-position, which will change the ring position numbering.

Suitably, R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₅ cycloalkyl, C₃₋₅ cycloalkylC₁₋₄alkyl, or the R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′), and wherein the R_(d) and R_(d′) moieties which are C₁₋₄ alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄ alkyl, and the R_(d) and R_(d′) cyclized ring are optionally substituted, 1 to 4 times, independently at each occurrence by halogen; halosubstituted C₁₋₄ alkyl; hydroxy; hydroxy substituted C₁₋₄alkyl; C₁₋₄ alkoxy; halosubstituted C₁₋₄ alkoxy; S(O)mRf; C(O)Rj; C(O)ORj; C(O)NR_(4′)R_(14′), NR_(4′)OC(O)C₁₋₄alkyl; S(O)₂NR_(4′)R_(14′)C₁₋₄ alkyl; NR_(4′)R_(14′)S(O)₂C₁₋₄ alkyl; or NR_(4′)R_(14′).

Suitably R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl.

Suitably, Z is independently selected at each occurrence from oxygen or sulfur.

Suitably, v is 0 or an integer having a value of 1 to 2.

Suitably, v′ is 0 or an integer having a value of 1 or 2.

Suitably, R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₄ alkyl.

Suitably, R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄ alkyl.

Suitably, R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or heterocyclylC₁₋₄ alkyl, and wherein these moieties, excluding hydrogen, may be optionally substituted.

Suitably, R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted and wherein these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times by halogen; halosubstituted C₁₋₄ alkyl; C₁₋₄ alkyl; hydroxy; hydroxy substituted C₁₋₄alkyl; C₁₋₄alkoxy; halosubstituted C₁₋₄ alkoxy; S(O)_(m)C₁₋₄ alkyl; —C(O), C(O)C₁₋₄ alkyl; or NR_(21′)R_(31′).

Suitably, R₂₁, and R₃₁, are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R₂₁, and R_(31′) together with the nitrogen to which they are attached cyclize to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, nitrogen, or sulfur.

Suitably R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, which moieties, excluding hydrogen, are all optionally substituted.

The R_(b) moieties, excluding hydrogen, may be optionally substituted, one or more times, preferably 1 to 4 times independently at each occurrence by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted C₁₋₁₀ alkyl; C₁₋₁₀ alkoxy, such as methoxy or ethoxy; halosubstituted C₁₋₁₀ alkoxy; OR₈, such as methoxy, ethoxy or phenoxy; SR₅, S(O)R₅, S(O)₂R₅, such as methyl thio, methylsulfinyl or methyl sulfonyl; C(O)R_(j); C(O)OR_(j); C(O)NR_(4″)R_(14″); cyano; nitro; NR₁₅R₂₅; -Z′-(CR₁₀R₂₀)s-Z′; C₁₋₁₀alkyl; C₃₋₇cycloalkyl or a C₃₋₇cycloalkyl C₁₋₁₀ alkyl group, such as cyclopropyl, or cyclopropyl methyl, or cyclopropylethyl, etc.; halosubstituted C₁₋₁₀ alkyl, such CF₂CF₂H, CH₂CF₃, or CF₃; an optionally substituted aryl, such as phenyl, or an optionally substituted arylC₁₋₁₀ alkyl, such as benzyl or phenethyl; an optionally substituted heterocyclic or heterocyclic C₁₋₁₀alkyl, or an optionally substituted heteroaryl or heteroaryl C₁₋₁₀alkyl, and wherein these aryl, heteroaryl, and heterocyclic containing moieties may also be substituted one to two times independently at each occurrence by halogen, hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

The moiety -Z′-(CR₁₀R₂₀)s-Z′ forms a cyclic ring, such as a dioxolane ring.

Suitably Z′ is independently selected at each occurrence from oxygen, or sulfur.

Suitably, s is independently selected at each occurrence from an integer having a value of 1, 2, or 3.

Suitably, R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR₄R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH.

Suitably, R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) can cyclize together with the nitrogen to which they are attached to form an optionally substituted 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′). Suitably, when R_(4′) and R_(14′) cyclize to form an optionally substituted ring, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine (including oxidizing the sulfur).

Suitably, R_(4″) and R_(14″) are each independently selected at each occurrence from hydrogen or C₁₋₁₀ alkyl, or R_(4″) and R_(14″) can cyclize together with the nitrogen to which they are attached to form an optionally substituted 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′). Suitably, when R_(4″) and R_(14″) cyclize to form an optionally substituted ring, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine (including oxidizing the sulfur).

Suitably, R_(f) is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀alkyl, heteroaryl, heteroaryl C₁₋₁₀alkyl, heterocyclic, or a heterocyclic C₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted.

Suitably, R_(j) is independently selected at each occurrence from C₁₋₁₀alkyl, aryl, aryl C₁₋₁₀alkyl, heteroaryl, heteroaryl C₁₋₁₀alkyl, heterocyclic, or a heterocyclic C₁₋₁₀alkyl moiety, which moieties may all be optionally substituted.

Suitably, when R_(b) is an optionally substituted C₁₋₁₀alkyl, the moiety includes but is not limited to a methyl, ethyl, n-propyl, isopropyl, t-butyl, n-butyl, isobutyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, heptyl, 2-methylpropyl; a halosubstituted alkyl, such as 2,2,2-trifluoroethyl, trifluoromethyl, 2-fluoroethyl; a cyano substituted alkyl, such as cyanomethyl, cyanoethyl; an alkoxy, thio or hydroxy substituted alkyl, such as 2-methoxy-ethyl, 2-hydroxy propyl or serinol, or an ethylthioethyl.

In an alternative embodiment, when R_(b) is an optionally substituted C₁₋₁₀ alkyl the moiety is a methyl, ethyl, n-propyl, isopropyl, t-butyl, n-butyl, or 2,2-dimethylpropyl or 2-hydroxy propyl group.

Suitably, when R_(b) is an optionally substituted heteroaryl, or heteroarylalkyl, the heteroaryl containing moiety includes but is not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and uracil, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, purinyl, and phthalazinyl.

In one embodiment, when R_(b) is an optionally substituted heteroaryl it is a 1,3-thiazol-2-yl or 5-methyl-1,3-thiazol-2-yl, isoquinolinyl, thiophene, e.g. a 3-thiophene, indol-5-yl, pyridinyl, e.g. a pyridin3-yl, or pyridine-4-yl, indazolyl, benzothiazolyl, 2-methyl-1,3-benzothiazol-5-yl, 1H-imidazol-4-yl or 1H-imidazol-4-ylethyl. Further to this, the heteroaryl ring is an optionally substituted thiazolyl, pyridyl, or thiophene ring. Preferably, R_(b) is an optionally substituted 1,3-thiazol-2-yl.

Suitably, when R_(b) is an optionally substituted heterocyclic, or heterocyclicalkyl, the heterocyclic containing moiety includes but is not limited to tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety). In one embodiment, the heterocyclic, or heterocyclic alkyl group is pyrazol-3-yl, 4-morpholino, unsubstituted and substituted 2-furanyl, or 2-furanylmethyl, 2-thienyl or 2-thienylmethyl, tetrahydro-2H-pyran-4-yl, or tetrahydro-2H-pyran-4-yl methyl, tetrahydro-2-furanyl, or tetrahydro-2-furanylmethyl.

Suitably, when R_(b) is an optionally substituted aryl or arylalkyl moiety, the aryl containing moiety is unsubstituted or substituted independently at each occurrence one or more times by halogen, alkyl, cyano, OR₈, SR₅, S(O)₂R₅, C(O)R_(j), C(O)OR_(j), -Z′-(CR₁₀R₂₀)s-Z′, halosubstituted C₁₋₁₀ alkyl, or an optionally substituted aryl.

In one embodiment, R_(b) is a phenyl, or napthylene, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 2-methyl phenyl, 3-methylphenyl, 4-methylphenyl, 6-methyl phenyl, 2-methyl phenyl, 3-amino phenyl, 3,4-dimethyl phenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, benzyl, phenethyl, phenylpropyl, 2,3-difluoro-benzyl, 3,5-difluoro-benzyl, biphenyl, 4′-fluorobiphenyl, 4-sulfonamido-2-methylphenyl, or 3-phenyloxyphenyl, 4-phenyloxyphenyl, 4-(1-piperidinylsulfonyl)-phenyl, or 3-(aminocarbonyl)phenyl.

In another embodiment, R_(b) is a phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 2-methylphenyl, 3-methylphenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, biphenyl, 4′-fluorobiphenyl, 4-sulfonamido-2-methylphenyl, 3-phenyloxyphenyl, benzyl, or phenethyl. Further to this R_(b) is a 4-fluorophenyl.

Suitably, when R_(b) is an optionally substituted cycloalkyl or cycloalkyl alkyl moiety, the moiety is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, or a cyclopentylmethyl. In another embodiment, R_(b) is a cyclopropyl or cyclopropylmethyl group.

In another embodiment, R_(b) is C₁₋₁₀ alkyl, heteroaryl, or aryl, all optionally substituted.

In another embodiment, R_(b) is hydrogen, or an optionally substituted alkyl.

In one embodiment of the invention R_(b) is an alkyl, such as propyl or isopropyl; heteroaryl, such as a thiazolyl; an aryl, such phenyl, or 4-F phenyl; an arylalkyl, or a cycloalkylalkyl moiety, all optionally substituted. In another embodiment, R_(b) is alkyl, heteroaryl, or aryl, all optionally substituted.

Suitably, m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2.

For each of the integer variables where appropriate, e.g. n, n′, m, q′, s, t, or v′, etc. they are independently chosen at each occurrence.

Suitably, R₈ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted independently at each occurrence, 1 to 4 times, by halogen; halosubstituted C₁₋₄ alkyl; C₁₋₄ alkyl; C₃₋₅cycloalkyl; C₃₋₅cycloalkyl C₁₋₄alkyl; halosubstituted C₁₋₄ alkyl; hydroxy; hydroxy substituted C₁₋₄alkyl; C₁₋₄alkoxy; halosubstituted C₁₋₄ alkoxy; S(O)_(m)C₁₋₄ alkyl; —C(O), C(O)C₁₋₄ alkyl; NR_(21′)R_(31′); or an aryl or aryl C₁₋₄ alkyl, and wherein these aryl containing moieties may also be substituted one to two times independently at each occurrence, by halogen, hydroxy, hydroxy substituted alkyl, C₁₋₄ alkoxy, S(O)_(m)C₁₋₄alkyl, amino, mono & di-substituted C₁₋₄ alkylamino, C₁₋₄ alkyl, or CF₃.

Suitably, R₁₅ and R₂₅ are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, or aryl-C₁₋₄ alkyl, heteroaryl or heteroaryl C₁₋₄ alkyl moiety, and wherein these moieties, excluding hydrogen may be optionally substituted; or R₁₅ and R₂₅ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR₉; and wherein these moieties are optionally substituted 1 to 4 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; SR₅, S(O)R₅, S(O)₂R₅; C(O)R_(j); C(O)OR_(j); C(O)NR_(4′)R_(14′); NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; NR_(4′)R_(14′); cyano; nitro; C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; aryl, arylC₁₋₄ alkyl, heteroaryl, or heteroC₁₋₄ alkyl, heterocyclic and heterocyclicC₁₋₄ alkyl and wherein these aryl, heterocyclic and heteroaryl containing moieties may also be substituted one to two times independently at each occurrence by halogen, C₁₋₄ alkyl, hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

Suitably, R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or heteroaryl C₁₋₄ alkyl; or the R₄ and R₁₄ together with the nitrogen which they are attached form an unsubstituted or substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen.

The R₄ and R₁₄ moieties, excluding hydrogen, of C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, aryl, aryl-C₁₋₄ alkyl, heteroaryl and heteroaryl C₁₋₄ alkyl moieties, heterocyclic, or heterocyclic C₁₋₄ alkyl moieties, and the R₄ and R₁₄ cyclized ring are optionally substituted, one or more times, preferably 1 to 4 times, independently at each occurrence, by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; SR₅; S(O)R₅; S(O)₂R₅; C(O)Rj; C(O)ORj; C(O)NR_(4′)R_(14′); (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(d)R_(d′); NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; NR_(4′)R_(14′); cyano; nitro; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; C₁₋₁₀ alkyl substituted one or more times by an optionally substituted aryl; an unsubstituted or substituted aryl, or arylC₁₋₄ alkyl; an unsubstituted or substituted heteroaryl, or heteroaryl C₁₋₄ alkyl; an unsubstituted or substituted heterocyclic, or heterocyclic C₁₋₄ alkyl, and wherein these aryl, heterocyclic and heteroaryl containing moieties are substituted one to two times independently at each occurrence by halogen; C₁₋₄ alkyl, hydroxy; hydroxy substituted C₁₋₄ alkyl; C₁₋₄ alkoxy; S(O)_(m)alkyl; amino, mono & di-substituted C₁₋₄ alkyl amino, or CF₃.

Suitably, when R₄ and R₁₄ together with the nitrogen cyclize to form an optionally substituted ring, such as described above, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, diazepine, morpholine, and thiomorpholine (including oxidizing the sulfur).

Suitably, R₆ is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl or a heteroarylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen may be optionally substituted independently at each occurrence, one or more times, suitably 1 to 2 times, by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; S(O)_(m) alkyl; C(O); NR_(4′)R_(14′); C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; an unsubstituted or substituted aryl or aryl C₁₋₄ alkyl, an unsubstituted or substituted heteroaryl or heteroaryl C₁₋₄ alkyl, or a unsubstituted or substituted heterocyclic or heterocyclic C₁₋₄ alkyl, and wherein these aryl, heterocyclic, or heteroaryl containing moieties may be substituted independently at each occurrence, one or two times by halogen, hydroxy, hydroxy substituted alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

Suitably, R₉ is independently selected at each occurrence from hydrogen, C(Z)R₆, optionally substituted C₁₋₁₀ alkyl, optionally substituted aryl or optionally substituted aryl-C₁₋₄ alkyl. These alkyl, aryl and arylalkyl moieties may be optionally substituted 1 or 2 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; S(O)_(m) alkyl; —C(O); NR_(4′)R_(14′); C₁₋₁₀ alkyl, C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; an aryl or aryl C₁₋₄ alkyl, and wherein these aryl containing moieties may also be substituted one or two times independently by halogen, hydroxy, hydroxy substituted alkyl, C₁₋₁₀ alkoxy, S(O)_(m)C₁₋₄ alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

Suitably, R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl moiety, which moieties may be optionally substituted one or more times, suitably 1 to 4 times, independently at each occurrence by hydrogen, halogen, nitro, C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀ alkyl, C₅₋₇cycloalkenyl, C₅₋₇cycloalkenylC₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR₁₆R₂₆, (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR₁₆R₂₆, (CR₁₀R₂₀)_(n)OC(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR₁₆R₂₆, or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.

In one embodiment, the R₃ moieties are optionally substituted 1 to 4 times, independently at each occurrence by halogen, nitro, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄ alkyl, C₅₋₆cycloalkenyl, C₅₋₆cycloalkenylC₁₋₄ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)NHS(O)₂R₇, (CR₁₀R₂₀)_(n)S(O)₂NR₁₆R₂₆, (CR₁₀R₂₀)_(n)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, or (CR₁₀R₂₀)_(n)C(Z)NR₁₆R₂₆

In one embodiment the R₃ moieties are optionally substituted independently, one or more times, suitably 1 to 4 times, independently at each occurrence by the R₃ optional substitutent is independently selected from halogen, C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)NR₁₆R₂₆, or halo-substituted C₁₋₁₀ alkyl.

In another embodiment the optional substitutents are independently selected at each occurrence from halogen, C₁₋₁₀ alkyl, hydroxy, C₁₋₁₀ alkoxy, cyano, nitro, amino, or halosubstituted C₁₋₁₀ alkyl. In another embodiment, the R₃ substituents are selected independently from halogen, such as fluorine, chlorine, bromine or iodine, or C₁₋₁₀ alkyl, such as methyl.

In one embodiment the R₃ moieties are an optionally substituted C₁₋₁₀ alkyl, optionally substituted C₃₋₇cycloalkyl, optionally substituted C₃₋₇cycloalkylalkyl, or optionally substituted aryl. In another embodiment, the R₃ moiety is an optionally substituted C₁₋₁₀ alkyl, or an optionally substituted aryl. In another embodiment, R₃ is an optionally substituted phenyl. Further to this embodiment, R₃ is a phenyl ring substituted one or more times by independently at each occurrence by fluorine, chlorine, hydroxy, methoxy, amino, methyl, or trifluoromethyl. Preferably, R₃ is a 2,6-difluorophenyl.

Suitably, in one embodiment when R₃ is an aryl moiety, it is an optionally substituted phenyl ring. The phenyl is optionally substituted one or more times, independently at each occurrence, suitably 1 to 4 times by halogen, C₁₋₄ alkyl, or halo-substituted-C₁₋₄ alkyl. The phenyl ring may be substituted in the 2,4, or 6-position, or di-substituted in the 2,4-position or 2,6-position, such as 2-fluoro, 4-fluoro, 2,4-difluoro, 2,6-difluoro, or 2-methyl-4-fluoro; or tri-substituted in the 2,4,6-position, such as 2,4,6-trifluoro.

Suitably, R₇ is independently selected at each occurrence from C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heterocyclic, heterocyclylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆alkyl; and wherein each of these moieties may be optionally substituted one or two times independently at each occurrence, by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; S(O)_(m) alkyl; C(O); NR_(4′)R_(14′); C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkylC₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; an aryl or aryl C₁₋₄ alkyl moiety, and wherein these aryl containing moieties may also be substituted independently at each occurrence, one to two times by halogen, hydroxy, hydroxy substituted alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

Suitably, R₁₆ and R₂₆ are each independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; or the R₁₆ and R₂₆ together with the nitrogen which they are attached form an unsubstituted or substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′).

Suitably, n is 0, or an integer having a value of 1 to 10.

Suitably, X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n)N(R₁₁)S(O)_(m)R_(2′), (CH₂)_(n)N(R₁₁)C(O)R_(2′), (CH₂)_(n)NR₄R₁₄, (CH₂)_(n)N(R_(2′))(R_(2″)), or N(R_(10′))R_(h)NH—C(═N—CN)NRqRq′.

In one embodiment of the invention X is N(R_(10′))R_(h)NH—C(═N—CN)NRqRq′.

Suitably, X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀. In one embodiment of the invention, X₁ is N(R₁₁), or O.

Suitably, R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—.

Suitably, R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring of 5 to 7 members, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulphur.

Suitably, R₁₁ is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl.

Suitably, R₂ is independently selected from hydrogen, optionally substituted C₁₋₁₀ alkyl, optionally substituted C₃₋₇ cycloalkyl, optionally substituted C₃₋₇cycloalkylalkyl, optionally substituted aryl, optionally substituted arylC₁₋₁₀alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC₁₋₁₀ alkyl, optionally substituted heterocyclic, optionally substituted heterocyclylC₁₋₁₀ alkyl moiety; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃).

Suitably q′ is 0, or an integer having a value of 1 to 6.

The R₂ moieties, excluding hydrogen, may be optionally substituted one or more times, preferably 1 to 4 times, independently at each occurrence by C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl C₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′), (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.

Suitably, R_(e) and R_(e′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, which moieties may be optionally substituted; or R_(e) and R_(e′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; and wherein each of these moieties, including the cyclized ring and excluding hydrogen, may be substituted 1 to 4 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; C₁₋₁₀ alkyl; halosubstituted C₁₋₄ alkyl; S(O)_(m)R_(f′); C(O)R_(j); C(O)OR_(j); (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(d)R_(d′); C(O)NR_(4′)R_(14′); NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; cyano; nitro; NR_(4′)R_(14′); C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; aryl, arylC₁₋₄alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl, or hetero C₁₋₄ alkyl, and wherein these aryl, heterocyclic or heteroaryl containing moieties may be optionally substituted one to two times independently at each occurrence by halogen, C₁₋₄ alkyl, hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃.

Suitably, R_(f′) is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀alkyl, heterocyclic, heterocyclic C₁₋₁₀alkyl or NR_(4′)R_(14′), and wherein these moieties, excluding hydrogen, and NR_(4′)R₁₄, may be optionally substituted.

When X is R₂ and R₂ is an optionally substituted heterocyclic or heterocyclic alkyl, the heterocyclic containing moiety is suitably selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).

In one embodiment, R₂ is an optionally substituted piperidinyl or piperazinyl ring.

In another embodiment, when R₂ is an optionally substituted heterocyclic or heterocyclic alkyl ring the ring is substituted one or mores times independently by an optionally substituted heterocyclic, heterocyclic alkyl, aryl, arylalkyl, alkyl, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇. The second heterocyclic ring is suitably selected from an optionally substituted tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, diazepine, morpholino or thiomorpholino (including oxidized versions of the sulfur moiety). Suitably, the second heterocyclic ring is selected from morpholino, piperidine, or pyrrolidinyl.

In one embodiment, R₂ is a 4-amino-1-piperidinyl, 1,1-dimethylethyl)oxy]-carbonyl}amino)-1-piperidinyl, 4-methyl-1-piperazinyl, 4-ethyl-1-piperazinyl, 4-propyl-1-piperazinyl, 4-butyl-1-piperazinyl, 4-(methylamino)-1-piperidinyl, 1,1-dimethylethyl-4-piperidinyl}methylcarbamate, 4-phenyl-1-piperazinyl, 1,4′-bipiperidin-1′-yl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-methyl-1,4′-bipiperidin-1′-yl, 4-(4-morpholinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, or 4-methylhexahydro-1H-1,4-diazepin-1-yl.

Suitably, R_(2′) is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times, independently, at each occurrence, by C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenylC₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclylC₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′), (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇

In one embodiment, when X is (CH₂)_(n)N(R_(2′))(R_(2″)), one of R_(2′), or R_(2″) is hydrogen, or methyl.

In one embodiment, when R_(2′) is an optionally substituted heterocyclic or heterocyclylC₁₋₁₀ alkyl the heterocyclic containing moiety is substituted one or more time independently by C₁₋₁₀ alkyl, aryl, heterocyclic, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇, or (CR₁₀R₂₀)_(n)C(Z)OR₆. More specifically, methyl, ethyl, NHC(O)O—CCH₃, N(CH₃)C(O)O—CCH₃, amino, methylamino, dimethylamino, phenyl, piperidine, pyrrolidine, 1-ethylpropyl, 4-methyl-1,4′-bipiperidin-1′-yl, 1,4′-bipiperidin-1′-yl, morpholino,

In one embodiment, when X is (CH₂)_(n)N(R_(2′))(R_(2″)), R_(2′) is an optionally substituted C₁₋₁₀ alkyl, cycloalkyl, heterocyclic, heterocyclyl C₁₋₁₀ alkyl, heteroarylalkyl. Suitably, when R_(2′) is an optionally substituted cycloalkyl it is a cyclohexyl ring. In one embodiment the cyclohexyl ring is optionally substituted one or more times by (CR₁₀R₂₀)_(n)NR_(e)R_(e′).

Suitably, when R_(2′) is an optionally substituted heterocyclic, or a heterocyclylC₁₋₁₀ alkyl, the ring is selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, diazepine, hexahydro-1-H-azepine, morpholino or thiomorpholino (including oxidized versions of the sulfur moiety). Preferably, the ring is a piperidine, piperazine, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, morpholino, hexahydro-1-H-azepine ring. In one embodiment, the rings are substituted one or more times, suitably 1 to 4 times, independently by C₁₋₁₀ alkyl, aryl, arylalkyl, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.

In one embodiment, (CH₂)_(n)N(R_(2′))(R_(2″)) is 1-(phenylmethyl)-4-piperidinamine, 2-[4-(phenylmethyl)-1-piperazinyl]ethylamine, 2-(1-piperidinyl)ethylamine, 2-(1-methyl-2-pyrrolidinyl)ethylamine, 1-[(phenylmethyl)-3-pyrrolidinyl]amine, 3-[(1-pyrrolidinyl)propyl]amine, 3-[(hexahydro-1H-azepin-1-yl)propyl]amine, (1-methyl-4-piperidinyl)amine, 3-[(4-morpholinyl)propyl]amine, 3-[(2-oxo-1-pyrrolidinyl)propyl]-amine, 2-[(4-morpholinyl)ethyl]amine, 2-[(1-pyrrolidinyl)ethyl]-amine, or [(1-ethyl-2-pyrrolidinyl)methyl]amino.

In one embodiment when X is (CH₂)_(n)N(R_(2′))(R_(2″)), and R_(2′) is an optionally substituted C₁₋₁₀ alkyl, the alkyl is substituted one or more times independently by (CR₁₀R₂₀)_(n)NR_(e)R_(e′) or (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′). In one embodiment R_(e) and R_(e′) are independently an optionally substituted C₁₋₄ alkyl, such as methyl, ethyl, isopropyl, n-butyl, or t-butyl. Preferably, (CH₂)_(n)N(R_(2′))(R_(2″)) is 3-(dimethylamino)propyl(methyl)amine, 3-(diethylamino)propylamine, propylamine, (2,2-dimethylpropyl)amine, (2-hydroxypropyl)amino, 2-(dimethylamino)ethylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(dimethylamino)propylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(diethylamino)propylamine, 2-(methylamino)ethylamine, [(1-methylethyl)amino]ethylamine, 3-(diethylamino)propylamine, 3-(dibutylamino)propylamine, 3-[(1-methylethyl)amino]propylamine, 3-(1,1-dimethylethyl)aminopropylamine, 3-(dimethylamino)-2,2-dimethylpropylamine, 4-(diethylamino)-1-methylbutylamine, or 3-[[3-(dimethylamino)propyl]-(methyl)amino]propyl(methyl)amine.

Suitably R_(2″) is selected from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times, independently at each occurrence, by C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl C₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, heterocyclylC₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′), (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃);

Suitably, t is an integer having a value of 2 to 6.

Suitably, q is 0 or an integer having a value of 1 to 10.

Suitably, A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl.

Suitably, A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl.

Suitably, A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl.

The A₁, A₂, and A₃ C₁₋₁₀ alkyl moieties may optionally substituted one or more times independently at each occurrence, preferably from 1 to 4 times, with halogen, such as chlorine, fluorine, bromine, or iodine; halo-substituted C₁₋₁₀alkyl, such as CF₃, or CHF₂CF₃; C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenylC₁₋₁₀alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR₄R₁₄, (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR₄R₁₄, (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR₄R₁₄, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR₄R_(14′)(CR₁₀R₂₀)_(n)OC(Z)NR₄R₁₄, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR₄R₁₄, or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.

In another embodiment of the present invention, X is R₂, and R₂ is (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃). In a further embodiment, q′ is 0.

In another embodiment when R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), q′ is 0, X₁ is nitrogen, q is 0 or 1, A₁ is an optionally substituted heterocyclic or heterocyclic alkyl, and A₂ is an optionally substituted aryl. More specifically, R₂ is 2-phenyl-2-(1-pyrrolidinyl)ethyl]amino, or 1-phenyl-2-(1-pyrrolidinyl)ethyl]amino.

In one embodiment of the invention, one or more of the A₁, A₂ and A₃ moieties are substituted with (CR₁₀R₂₀)_(n)OR₆. In another embodiment of the invention, the R₆ substituent in (CR₁₀R₂₀)_(n)OR₆ is hydrogen.

In yet another embodiment of the present invention, X is R₂ and R₂ is (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃), such as CH(CH₂OH)₂, or C(CH₃)(CH₂OH)₂; or wherein R₂ is (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃) and q′ is 0, and the moiety is X₁ (CR₁₀R₂₀)_(q)CH(CH₂OH)₂, or X₁ (CR₁₀R₂₀)_(q)C(CH₃)(CH₂OH)₂; in another embodiment X₁ is oxygen or nitrogen.

In one embodiment of the present invention X is R₂, OR_(2′), (CH₂)_(n)NR₄R₁₄, or (CH₂)_(n)N(R_(2′))(R_(2″)).

In another embodiment X is S(O)_(m)R_(2′), (CH₂)_(n)NR₄R₁₄, or (CH₂)_(n)N(R_(2′))(R_(2″)).

In yet another embodiment, X is (CH₂)_(n)NR₄R₁₄, or (CH₂)_(n)N(R_(2′))(R_(2″)).

In yet another embodiment, X is (CH₂)_(n)NR₄R₁₄.

In yet another embodiment, X is (CH₂)_(n)N(R_(2′))(R_(2″)).

In one embodiment of the present invention X is R₂, OR_(2′), (CH₂)_(n)NR₄R₁₄, or (CH₂)_(n)N(R_(2′))(R_(2″)).

Suitably, when X is (CH₂)_(n)NR₄R₁₄, and R₄ and R₁₄ are C₁₋₁₀ alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or heteroaryl C₁₋₄ alkyl, the C₁₋₄ alkyl is suitably substituted one or more times, independently at each occurrence with NR_(4′)R_(14′); halogen, hydroxy, alkoxy, C(O)NR_(4′)R_(14′); or NR_(4′)C(O)C₁₋₁₀alkyl. Preferably, the C₁₋₄ alkyl is substituted with NR_(4′)R_(14′).

In one embodiment at least one of R₄ and R₁₄ may be hydrogen when R₄ and R₁₄ are not cyclized. In another embodiment neither R₄ nor R₁₄ is hydrogen.

In one embodiment when X is (CH₂)_(n)NR₄R₁₄, one of R₄ and R₁₄ are hydrogen, and the other is an optionally substituted heteroaryl C₁₋₄ alkyl. Suitably, the optionally substituted heteroaryl alkyl is an imidazolyl alkyl, such as a 1H-imidazol-2-yl-methyl group.

In another embodiment when X is (CH₂)_(n)NR₄R₁₄ and one of R₄ and R₁₄ is a heteroaryl C₁₋₄ alkyl moiety, the heteroaryl ring is selected from an optionally substituted thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl. Suitably, the heteroaryl C₁₋₄ alkyl is selected from an optionally substituted pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.

In another embodiment when X is (CH₂)_(n)NR₄R₁₄ and one of R₄ and R₁₄ is a heterocyclic C₁₋₄ alkyl moiety, then the heterocyclic ring is selected from an optionally substituted tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholino. Suitably, the heterocyclic C₁₋₄ alkyl moiety is selected an optionally substituted from pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholino.

In another embodiment when X is (CH₂)_(n)NR₄R₁₄ and R₄ and R₁₄ together with the nitrogen cyclize to form an optionally substituted ring, such as described above, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, diazepine, and morpholine.

In one embodiment when X is (CH₂)_(n)NR₄R₁₄, the R₄ and R₁₄ substituents cyclize to form a heterocyclic 5 or 6 membered ring, which ring is optionally substituted as defined herein. When the R₄ and R₁₄ substituents cyclize to form a 4 to 7 membered ring, the optional substitutents are suitably selected from an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocyclic, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇, NR_(4′)R_(14′), or a C₁₋₁₀ alkyl substituted one or more times by an optionally substituted aryl. Such substitutents more specifically include phenyl, pyrrolidinyl, morpholino, piperazinyl, 4-methyl-1-piperazinyl, piperidinyl, 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, 5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, diphenylmethyl, methyl, ethyl, propyl, butyl, amino, methylamino, and dimethylamino.

In one embodiment the X substituent is a 1,4′-bipiperin-1-yl ring which may be optionally substituted such as in 4-methyl-1,4′-bipiperin-1-yl; 4-piperidinylamino, 4-amino-1-piperidinyl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-methyl-1-piperazinyl, (4-morpholinyl)-1-piperidinyl, (4-methyl-1-piperazinyl)-1-piperidinyl, 4-ethyl-1-piperazinyl, (2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 5-chloro-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, 4-methylhexahydro-1H-1,4-diazepin-1-yl, 4-propyl-1-piperazinyl, or 4-butyl-1-piperazinyl. In a further embodiment, the X substituent is an optionally substituted 1,4′-bipiperin-1′yl ring, a 4-amino-1-piperidinyl, or a 2,2,6,6-tetramethyl-4-piperidinyl)amino.

In another embodiment, when X is (CH₂)_(n)N(R_(2′))(R_(2″)), and R_(2′) is an optionally substituted C₁₋₁₀ alkyl moiety, and the alkyl is substituted by (CR₁₀R₂₀)_(n)NR_(e)R_(e′), and R_(e) and R_(e′) are hydrogen, or an optionally substituted C₁₋₁₀ alkyl. Suitably, the X moiety is 3-(diethylamino)propylamino, 3-(dimethylamino)propyl(methyl)amino, 3-(dimethylamino)propyl(methyl)amino, 2-(dimethylamino)ethylamino, 1-(methylethyl)amino-propylamino, (1,1-dimethylethyl)aminopropylamino, (1-methylethyl)aminoethylamino, 2-(methylamino)ethylamino, 2-aminoethyl(methyl)amino, or a 2-(dimethylamino)ethyl(methyl)amino.

In another embodiment when X is (CH₂)_(n)N(R_(2′))(R_(2″)), and R_(2′) moiety is an optionally substituted heteroarylC₁₋₁₀ alkyl, the heteroaryl moiety is suitably an optionally substituted imidazole.

In one embodiment of the invention at least one of R₄ and R₁₄ may be hydrogen when R₄ and R₁₄ are not cyclized.

In one embodiment R₃ is a 2,6-difluoro phenyl, R_(1′) is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2; and R₁ is selected from C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), or C(Z)O(CR₁₀R₂₀)_(v)R_(b), or N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b). Further to this embodiment, R₁ is selected from C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b). In another embodiment, the R_(b) moiety is selected from thiazolyl, C₁₋₁₀ alkyl or an optionally substituted aryl. In another embodiment the R_(b) moiety is propyl or 4-fluorophenyl.

In another embodiment, X is suitably selected from (1H-imidazol-2-ylmethyl)amino or 4-methyl-1,4′-bipiperidin-1′-yl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-amino-1-piperidinyl, 3-(diethylamino)propylamino, 3-(dimethylamino)propyl(methyl)amino, 3-(dimethylamino)propyl(methyl)amino, 2-(dimethylamino)ethylamino, 1-methylethyl)amino-propylamino, (1,1-dimethylethyl)aminopropylamino, (1-methylethyl)aminoethylamino, 2-(methylamino)ethylamino, 2-aminoethyl(methyl)amino, or 2-(dimethylamino)ethyl(methyl)amino.

In one embodiment, R₃ is a 2,6-difluoro phenyl, R_(1′) is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2; and R₁ is selected from C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), R_(b) moiety is C₁₋₁₀ alkyl or an optionally substituted aryl, preferably propyl or 4-fluorophenyl, X is (CH₂)_(n)N(R_(2′))(R_(2″)), and n is 0. In another embodiment, X is (CH₂)_(n)N(R_(2′))(R_(2″)), R_(2″) is hydrogen, n is 0, and R_(2′) is an alkyl substituted by (CR₁₀R₂₀)_(n)NR_(e)R_(e′). In a further embodiment, R_(e) and R_(e′) are independently selected from an optionally substituted C₁₋₄ alkyl, such as methyl, ethyl, isopropyl, n-butyl, or t-butyl, preferably ethyl.

Another embodiment of the invention is the genus of compounds of formula (Ic), a subgenus of compounds of Formula (I) and (Ia) wherein R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), and R_(b) is an optionally substituted heteroaryl, an optionally substituted heteroaryl C₁₋₁₀ alkyl, an optionally substituted heterocyclic or an optionally substituted heterocyclic C₁₋₁₀ alkyl. The remaining groups are the same as enumerated above for Formula (I) and (Ia).

In another embodiment for compounds of Formula (Ic), R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), and R_(b) is an optionally substituted heteroaryl, or an optionally substituted heteroaryl C₁₋₁₀ alkyl.

Suitably, the heteroaryl, heteroarylalkyl, heterocyclic and heterocyclicalkyl moieties are as defined above for Formula (I) and (Ia). A preferred heteroaryl ring is an optionally substituted thiazolyl ring, pyridyl, or thiophene ring.

In one embodiment of this invention, for compounds of Formula (I), (Ia), and (Ic), as well as the remaining formulas herein, R_(1′) is independently selected hydrogen, halogen, C₁₋₄ alkyl, or halo-substituted-C₁₋₄alkyl. In another embodiment, R_(1′) is independently selected from hydrogen, fluorine, chlorine, methyl, or CF₃. In one embodiment when R_(1′) is substituted on the phenyl ring in the ortho position, and a second R_(1′) moiety is also substituted on the ring, then preferably the second substitution is not in the other ortho position.

In one embodiment of the invention, g is 1 or 2.

Suitably, in one embodiment when R₃ is an aryl moiety, it is a phenyl ring, and the phenyl ring is optionally substituted, independently at each occurrence, one or more times, suitably 1 to 4 times by halogen, C₁₋₄ alkyl, or halo-substituted-C₁₋₄ alkyl. The phenyl ring may suitably be substituted in the 2,4, or 6-position, or di-substituted in the 2,4-position, such as 2-fluoro, 4-fluoro, 2,4-difluoro, 2,6-difluoro, 6-difluoro, or 2-methyl-4-fluoro; or tri-substituted in the 2,4,6-position, such as 2,4,6-trifluoro. Preferably, R₃ is a 2,6-difluoro phenyl.

In one embodiment, R₃ is a 2,6-difluoro phenyl, R_(1′) is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2.

In another embodiment of the present invention, for compound of Formula (s) (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), (VIII) and (VIIIa), (A), (A1), (B) and (BI) the X term may also be the B-Non-Ar-cyc moiety as disclosed in U.S. Pat. No. 6,809,199 whose disclosure is incorporated by reference herein.

As represented by the disclosure in U.S. Pat. No. 6,809,199, Non-Ar-Cyc is suitably selected from;

wherein

d is an integer having a value of 1, 2, 3, or 4;

d′ is 0, or an integer having a value of 1, 2, or 3;

d″ is 0, or an integer having a value of 1, 2, or 3;

e is 0, or is an integer having a value of 1, 2, 3, or 4;

e′ is 0, or an integer having a value of 1, 2, or 3;

e″ is 0, or an integer having a value of 1, 2, or 3;

f is 0, or is an integer having a value of 1, 2, or 3;

d+e is 2,3,4,5, or 6;

d′+e″=d

e′+e″=m

Suitably, R_(7′), R₇₇ and R_(77″) are each independently selected from hydrogen, C₁₋₆ alkyl-group, C₂₋₆ alkenyl-group, C₄₋₆ cycloalkyl-C₀₋₆ alkyl-group, N(C₀₋₄ alkyl)(C₀₋₄ alkyl)-C₁₋₄ alkyl-N(C₀₋₄ alkyl)-group, —N(C₀₋₄ alkyl)(C₀₋₄ alkyl) group, C₁₋₃ alkyl-CO—C₀₋₄ alkyl-group, C₀₋₆ alkyl-O—C(O)—C₀₋₄ alkyl-group, C₀₋₆ alkyl-C(O)—O—C₀₋₄alkyl-group, N(C₀₋₄ alkyl)(C₀₋₄ alkyl)-(C₀₋₄ alkyl)C(O)(C₀₋₄ alkyl)-group, phenyl-C₀₋₄ alkyl-group, pyridyl-C₀₋₄ alkyl-group, pyrimidinyl-C₀₋₄ alkyl-group, pyrazinyl-C₀₋₄ alkyl-group, thiophenyl-C₀₋₄ alkyl-group, pyrazolyl-C₀₋₄ alkyl-group, imidazolyl-C₀₋₄ alkyl-group, triazolyl-C₀₋₄ alkyl-group, azetidinyl-C₀₋₄ alkyl-group, pyrrolidinyl-C₀₋₄ alkyl-group, isoquinolinyl-C₀₋₄alkyl-group, indanyl-C₀₋₄ alkyl-group, benzothiazolyl-C₀-4 alkyl-group, any of the groups optionally substituted with 1-6 substituents, each substituent independently being —OH, —N(C₀₋₄ alkyl)(C₀₋₄alkyl), C₁₋₄alkyl, C₁₋₆ alkoxyl, C₁₋₆ alkyl-CO—C₀₋₄ alkyl-, pyrrolidinyl-C₀₋₄ alkyl-, or halogen; or R₇, together with a bond from an absent ring hydrogen is ═O.

Suitably, B is —C₁₋₆alkyl-, —C₀₋₃ alkyl-O—C₀₋₃alkyl-, —C₀₋₃ alkyl-NH—C₀₋₃alkyl-, —C₀₋₃alkyl-NH—C₃₋₇cycloalkyl-, —C₀₋₃alkyl-N(C₀₋₃alkyl)-C(O)—C₀₋₃ alkyl-, —C₀₋₃ alkyl-NH—SO₂—C₀₋₃ alkyl-, —C₀₋₃ alkyl-, —C₀₋₃alkyl-S—C₀₋₃ alkyl-, —C₀₋₃ alkyl-SO₂—C₀₋₃alkyl-, —C₀₋₃alkyl-PH—C₀₋₃ alkyl-, C₀₋₃ alkyl —C(O)—C₀₋₃ alkyl, or a direct bond.

Suitably, E₁ is CH, N, or CR₆₆; or B and E₁ together form a double bond, i.e., —CH═C.

Suitably, E₂ is CH₂, CHR₇₇, C(OH)R₇₇ NH, NR₇₇, O, S, —S(O)—, or —S(O)₂—.

Suitably, R₆₆ is independently selected from at each occurrence from halogen, C₀₋₄ alkyl, —C(O)—O(C₀₋₄ alkyl), or —C(O)—N(C₀₋₄ alkyl)-(C₀₋₄ alkyl).

In an alternative embodiment of this invention, Non-Ar-Cyc is:

In another embodiment of the present invention, for compound of Formula (s) (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), (VIII) and (VIIIa), (A), (A1), (B) and (B1) the X term may also be the X moiety as disclosed in WO 2004/073628, published September 2004, Boehm et al., whose disclosure is incorporated by reference herein.

In another embodiment of the present invention, compounds of Formula (II) and (IIa) are represented by the structures:

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NRqRq′; -   X₁ is N(R₁₁) O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R₁₄, are each independently selected at each occurrence     from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the     nitrogen to which they are attached form a heterocyclic ring of 5 to     7 members, which ring optionally contains an additional heteroatom     selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.     Representative examples of compounds of Formula (II) and (IIa) are: -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-1,3-thiazol-2-ylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic     acid -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(1-methylethyl)benzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-propylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-phenylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)benzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-dimethylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-methylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-(t-methylethyl)benzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic     acid -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-propylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-phenylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-3-methylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N,3-trimethylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,3-dimethylbenzamide -   4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzamide;     or     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds Formula (III) and (IIa):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₅ and G₆ are independently selected from nitrogen or CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(—N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁) O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

It should be recognized that the difference between compounds of Formula (I) and (Ia), and Formula (II) and (IIa) and those of Formulas (III) and (IIIa) through Formula (V) and (Va) lie not only in the in the ring substitution of the R1 group, but that the ring position of the nitrogen in the pyridyl ring. All of the remaining variables have the same meaning for Formulas (III) and (IIIa) through Formula (V) and (Va) as those described herein for Formula (I) and (Ia), etc.

Another aspect of the invention are compounds of Formula (IV) and (IVa):

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₅ and G₆ are independently selected from nitrogen or CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR₁₀)—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or     —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds Formula (V) and (Va):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₅ and G₆ are nitrogen and CH, provided that only one of G5 or G6 is     nitrogen and the other is CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇     cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl,     heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds formula (VI) and (VIa):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   one of G₅, G₆, G₇ and G₈ is nitrogen and the others are CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R₁₋₁₀)CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R₁₄, are each independently selected at each occurrence     from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the     nitrogen to which they are attached form a heterocyclic ring of 5 to     7 members, which ring optionally contains an additional heteroatom     selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

It should be recognized that the difference between compounds of Formula (I) and (Ia), and Formula (II) and (IIa) and those of Formulas (VII) through Formula (VIi) lie not only in the in the ring substitution of the R1 group, but that the ring position of the two nitrogen's in the pyrimidine ring. All of the remaining variables have the same meaning for Formulas (VI) through Formula (VIi) as those described herein for Formula (I) and (Ia), etc.

Another aspect of the invention are compounds of Formula (VIb) and (VIc):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₅ and G₆ are nitrogen; and -   G₇ and G₈ are CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R₁₄ are each independently selected at each occurrence     from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the     nitrogen to which they are attached form a heterocyclic ring of 5 to     7 members, which ring optionally contains an additional heteroatom     selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds Formula (VId) and (VIe):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₆ and G₈ are nitrogen; -   G₅ and G₇ are CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″), is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″), is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds Formula (VIf) and (VIg):

-   wherein -   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₅ and G₈ are nitrogen; -   G₆ and G₇ are CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀-alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀-alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R₉, is independently selected at each occurrence from hydrogen, or     C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₁₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds of the formula (VIh) and (VIi):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   G₆ and G₇ are nitrogen; -   G₅ and G₈ are CH; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Another aspect of the invention are compounds of Formula (A) and (A1):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   Y is C(R_(x))(R_(z)), C(O), N(R_(z)), N(R_(w))C(R_(y))(R_(z)),     oxygen, OC(R_(y))(R_(z)), S(O)_(m), or S(O)_(m)C(R_(y))(R_(z)); -   R_(x) is hydrogen, C₁₋₂ alkyl, N(R_(v))₂, hydroxy, thio, C₁₋₂     alkoxy, or S(O)_(m)C₁₋₂ alkyl; -   R_(y) is hydrogen or C₁₋₂ alkyl; -   R_(z) is hydrogen or C₁₋₂ alkyl; -   R_(w) is hydrogen or C₁₋₂ alkyl; -   R_(v) is independently selected from hydrogen or C₁₋₂ alkyl; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or     -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or         (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₀ alkyl moiety, and wherein     these moieties, excluding hydrogen, may be optionally substituted;     or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SRS being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R₉, is independently selected at each occurrence from hydrogen, or     C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

The present invention is directed to novel compounds of Formula (A) and Formula (A1), or a pharmaceutically acceptable derivative thereof. As will be readily recognized, the difference between compounds of Formula (A) and Formula (A1), and that of Formula (I) and (Ia) lies in the linker Y. The respective R₁, R₂, and R₃, etc. terms are the same for both groups. For purposes herein, everything applicable to Formula (I) is also applicable to Formula (A) unless otherwise indicated.

Another aspect of the invention are compounds of Formulas (B) and (B1):

wherein

-   G₁, and G₂ are independently nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   Y is C(R_(x))(R_(z)), C(O), N(R_(z)), N(R_(w))C(R_(y))(R_(z)),     oxygen, OC(R_(y))(R_(z)), S(O)m, or S(O)_(m)C(R_(y))(R_(z)); -   R_(x) is hydrogen, C₁₋₂ alkyl, N(R_(v))₂, hydroxy, thio, C₁₋₂     alkoxy, or S(O)_(m)C₁₋₂ alkyl; -   R_(y) is hydrogen or C₁₋₂ alkyl; -   R_(z) is hydrogen or C₁₋₂ alkyl; -   R_(w) is hydrogen or C₁₋₂ alkyl; -   R_(v) is independently selected at each occurrence from hydrogen or     C₁₋₂ alkyl; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an     integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

As will be readily recognized, the differences between compounds of Formula (B) and Formula (B1), and that of Formula (II) and (IIa) lie in the linker Y. The respective R₁, R₂, and R₃, etc. terms are the same for both groups. For purposes herein, everything applicable to Formula (II) is also applicable to Formula (B) unless otherwise indicated.

In another aspect of the invention, it is the linker Y may be present in a similar manner in the same position for all of the remaining formulas, Formula's (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), herein. The respective R₁, R₂, and R₃, etc. terms will be the same for all the groups.

Another aspect of the invention are compounds of Formula (VIII) and (VIIIa):

wherein

-   G₁, G₂ are independently nitrogen or CH, but G₁, and G₂ are not both     nitrogen; -   G₃ is NH; -   G₄ is nitrogen; -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); -   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; -   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR₁₀)—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or     —CH₂—CH₂—O—C(O)CH₂—; -   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl,     C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀     alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur; -   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or -   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); -   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted; -   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); -   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl; -   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted; -   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   g is 0 or an integer having a value of 1, 2, 3, or 4; -   n′ is 0 or an integer having a value of 1 to 10; -   m is 0 or an integer having a value of 1 or 2; -   q is 0 or an integer having a value of 1 to 10; -   q′ is 0, or an integer having a value of 1 to 6; -   t is an integer having a value of 2 to 6; -   v is 0 or an integer having a value of 1 or 2; -   v′ is 0 or an integer having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

In another embodiment of the present invention, for compounds of Formula (VIII) and (VIIIa), and any of the other remaining formulas, the X term may also be the B-Non-Ar-cyc moiety as disclosed above.

In another embodiment of the present invention, for compound of Formula (VIII) and (VIIIa), and any of the other remaining formulas, the X term may also be the X moiety as disclosed in WO 2004/073628, published September 2004, Boehm et al., whose disclosure is incorporated by reference herein.

For purposes herein the template containing the G₁ and G₂ moieties will have a numbering system that allows for different (R₁ and R_(1′)) substituents on the phenyl or pyridyl or pyrimidine ring at the C₄ position; the X term at the C₂ position, and at the R₃ substituent in the N₈ position.

The respective R₁, R₂, R_(x), X and R₃, etc., terms are the same for both groups within the formulas themselves, for instance, in Formula (VIII) and (VIIIa). For purposes herein, everything applicable to Formula (VIII) is also applicable to Formula (VIIIa) unless otherwise indicated.

It is recognized that for compounds of Formula (I) and (Ia), etc. and those of Formula (VIII) and (VIIIa) the difference is in the allowance of the G₁ and G₂ moieties to be carbon or nitrogen, independently. For purposes of brevity herein, the remaining compounds of Formulas (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi), may also have the same pharmacophore template of:

Illustrative of this would be the C4 substitution from compounds of formula (II) and (IIa) on this pharmacophore template, represented by the structure:

wherein

-   -   G₁, and G₂ are independently nitrogen or CH, but G₁, and G₂ are         not both nitrogen;

-   G₃ is NH;

-   G₄ is nitrogen;

-   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b);

-   R_(1′) is independently selected at each occurrence from halogen,     C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃;

-   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted;

-   X is R₂, OR_(2′), S(O)_(m)R_(2′),     (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′),     (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or     N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′);

-   X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀;

-   R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl,     —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—,     —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—,     or —CH₂—CH₂—O—C(O)CH₂—;

-   R_(q) and R_(q′) are independently selected at each occurrence from     hydrogen, C₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇     cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl,     heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a     heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties,     excluding hydrogen, are optionally substituted, or R_(q) and R_(q′)     together with the nitrogen to which they are attached form a 5 to 7     membered optionally substituted ring, which ring may contain an     additional heteroatom selected from oxygen, nitrogen or sulfur;

-   R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties, excluding hydrogen, may be optionally     substituted; or

-   R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or     (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃);

-   R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein each of these moieties, excluding hydrogen, may be     optionally substituted;

-   R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀     alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and     wherein these moieties, excluding hydrogen, may be optionally     substituted; or     -   wherein R_(2″) is the moiety         (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃);

-   A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl;

-   A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic,     heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl,     or aryl C₁₋₁₀ alkyl;

-   A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl;

-   R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀     alkyl moiety, and wherein each of these moieties may be optionally     substituted;

-   R₄ and R₁₄ are each independently selected at each occurrence from     hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl,     aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl,     heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of     these moieties, excluding hydrogen, may be optionally substituted;     or the R₄ and R₁₄ together with the nitrogen which they are attached     form an optionally substituted heterocyclic ring of 4 to 7 members,     which ring optionally contains an additional heteroatom selected     from oxygen, sulfur or nitrogen;

-   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′);

-   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH;

-   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl;

-   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₄alkyl;

-   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl;

-   R₁₁ is independently selected at each occurrence from hydrogen or     C₁₋₄alkyl;

-   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted;

-   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted;

-   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′);

-   g is 0 or an integer having a value of 1, 2, 3, or 4;

-   n′ is 0 or an integer having a value of 1 to 10;

-   m is 0 or an integer having a value of 1 or 2;

-   q is 0 or an integer having a value of 1 to 10;

-   q′ is 0, or an integer having a value of 1 to 6;

-   t is an integer having a value of 2 to 6;

-   v is 0 or an integer having a value of 1 or 2;

-   v′ is 0 or an integer having a value of 1 or 2;

-   Z is independently selected at each occurrence from oxygen or     sulfur; and     a pharmaceutically acceptable salt, solvate or physiologically     functional derivative thereof.

Therefore, compounds having the C4 position substitution from Formula (III) and (IIIa) with the G1/G₂ pharmacophore template of carbon or nitrogen, would be considered compounds of Formula (X) and (Xa), etc.

Suitably synthesis to make compounds of Formula (VIII), (IX), (X), etc., are known to the skilled artisan in this field. Similar processes are provided for in WO 2004/073628, published September 2004, Boehm et al., and in U.S. Pat. No. 6,809,199 whose disclosures are incorporated herein by reference. It is also recognized that in order to have the variety of different R₁, R₂, X, and R₃ groups, etc. some optional substituents may need to be suitably protected to achieve compatibility with the reactions as outlined therein. Subsequent deprotection in those cases would then afford compounds of the nature generally disclosed.

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R₅, R₆, R₉, R₁₀, R₁₁, R₁₂, R₁₃, p, n, or q, etc. may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed. When any variable occurs more than one time in a Formula (as described herein), its definition on each occurrence is independent of its definition at every other occurrence.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically derivatives.

As used herein, the term “pharmaceutically acceptable” means a compound which is suitable for pharmaceutical and veterinary usage. Salts and solvates of compounds of the invention which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.

As used herein, the term “pharmaceutically acceptable derivative”, means any pharmaceutically acceptable salt, solvate or prodrug e.g. ester, of a compound of the invention, which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5^(th) Edition, Vol. 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives. In one embodiment pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters. In another embodiment pharmaceutically acceptable derivatives are salts, solvates and esters. In yet another embodiment of the invention pharmaceutically acceptable derivatives are salts and esters, in particular salts.

The compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge et al., J. Pharm. Sci., 1977, 66, 1-19.

Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Salts of the compounds of the present invention may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I). Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention. Suitable addition salts are formed from acids which form non-toxic salts and examples are acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanesulphonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen phosphate, hydroiodide, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, oxaloacetate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, piruvate, polygalacturonate, saccharate, salicylate, stearate, subacetate, succinate, sulphate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate and valerate.

Pharmaceutically acceptable base salts include ammonium salts such as a trimethylammonium salt, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as “solvates”. As used herein, the term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of Formula (I), or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water. A complex with water is known as a “hydrate”. Solvates of the compound of the invention are within the scope of the invention.

As used herein, the term “prodrug” means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series; Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; and in D. Fleisher, S. Ramon and H. Barbra “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs”, Advanced Drug Delivery Reviews (1996) 19(2) 115-130, each of which are incorporated herein by reference.

Prodrugs are any covalently bonded carriers that release a compound of formula (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy or amine groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy or amine groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of formula (I). Further, in the case of a carboxylic acid (—COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and/or be hydrolysable under in vivo conditions in the human body. Suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

As used herein, “optionally substituted” unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted C₁₋₁₀alkyl; C₁₋₁₀ alkoxy, such as methoxy or ethoxy; halosubstituted C₁₋₁₀ alkoxy; S(O)_(m) alkyl, such as methyl thio, methylsulfinyl or methyl sulfonyl; a ketone (—C(O)), or an aldehyde (—C(O)R_(6′)), such as C(O)C₁₋₁₀ alkyl or C(O)aryl, wherein R_(6′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl or heteroarylC₁₋₁₀ alkyl (and wherein the R_(6′) moieties, excluding hydrogen, may themselves be optionally substituted 1 or 2 times, independently by halogen; hydroxy; hydroxy substituted alkyl; C₁₋₄ alkoxy; S(O)_(m)C₁₋₄ alkyl; amino, mono & di-substituted C₁₋₄ alkyl amino; C₁₋₄ alkyl, or CF₃); C(O)OR_(6′); NR_(4′)R_(14′), wherein R_(4′) and R₁₄, are each independently hydrogen or C₁₋₄ alkyl, such as amino or mono or -disubstituted C₁₋₄ alkyl or wherein the R_(4′)R_(14′) can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from O/N/S; C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, or C₃₋₇cycloalkyl C₁₋₁₀ alkyl group, such as methyl, ethyl, propyl, isopropyl, t-butyl, etc. or cyclopropyl methyl; halosubstituted C₁₋₁₀ alkyl, such CF₂CF₂H, or CF₃; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl containing moieties may also be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; C₁₋₄ alkoxy; S(O)_(m) C₁₋₄ alkyl; amino, mono & di-substituted C₁₋₄ alkyl amino; C₁₋₄ alkyl, or CF₃.

Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include salts formed with both organic and inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, alkyl sulphonic acid derivatives, such as methanesulphonic, or ethanesulphonic, arylsulphonic acid derivatives, such as p-toluenesulphonic, m-toluenesulphonic, benzenesulphonic, camphor sulphonic, 4-chlorobenzenesulphonic, 4-bromobenzenesulphonic, 4-phenylbenzenesulphonic, naphthalenesulphonic or naphthalenedisulphonic), phenylacetic, mandelic, salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, phenyl, methyl, cyano, methoxy or halo substituted cinnamic, including 4-methyl and 4-methoxycinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), naphthaleneacrylic (for example naphthalene-2-acrylic), benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-phenylbenzoic, benzeneacrylic (for example 1,4-benzenediacrylic) and isethionic acids.

Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexyl amine and N-methyl-D-glucamine.

In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.

The term “halo” or “halogens” is used herein to mean the halogens, chloro, fluoro, bromo and iodo.

As used herein, the term “C₁₋₁₀alkyl” or “alkyl” or “alkyl₁₋₁₀” is used herein to mean both straight and branched hydrocarbon chain containing the specified number of carbon atoms, e.g. C₁₋₁₀alkyl means a straight of branched alkyl chain of at least 1, and at most 10, carbon atoms, unless the chain length is otherwise limited. Examples of “alkyl” as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, sec-butyl, tert-butyl or t-butyl and hexyl and the like.

As used herein, the term “alkenyl” refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and containing at least one double bond. For example, C₂₋₆alkenyl means a straight or branched alkenyl containing at least 2, and at most 6, carbon atoms and containing at least one double bond. Examples of “alkenyl” as used herein include, but are not limited to ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-methylbut-2-enyl, 3-hexenyl, 1,1-dimethylbut-2-enyl and the like.

As used herein, the term “alkoxy” refers to straight or branched chain alkoxy groups containing the specified number of carbon atoms. For example, C₁₋₆alkoxy means a straight or branched alkoxy containing at least 1, and at most 6, carbon atoms. Examples of “alkoxy” as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy and hexyloxy.

As used herein, the term “cycloalkyl” refers to cyclic radicals, such as a non-aromatic hydrocarbon ring containing a specified number of carbon atoms. For example, C₃₋₇cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Representative examples of “cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl and the like.

The term “cycloalkenyl” is used herein to mean cyclic radicals, such as a non-aromatic hydrocarbon ring containing a specified number of carbon atoms preferably of 5 to 7 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.

The term “alkenyl” is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.

The term “aryl” is used herein to mean phenyl, naphthyl, and indene.

The terms “heteroaryl ring”, “heteroaryl moiety”, and “heteroaryl” are used herein to mean a monocyclic five- to seven-membered unsaturated hydrocarbon ring containing at least one heteroatom selected from oxygen, nitrogen and sulfur. Examples of heteroaryl rings include, but are not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and uracil. The terms “heteroaryl ring”, “heteroaryl moiety”, and “heteroaryl” shall also used herein to refer to fused aromatic rings comprising at least one heteroatom selected from oxygen, nitrogen and sulfur. Each of the fused rings may contain five or six ring atoms. Examples of fused aromatic rings include, but are not limited to, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, purinyl, and phthalazinyl.

The terms “heterocyclic rings”, “heterocyclic moieties”, and “heterocyclyl” is used herein to mean a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom selected from nitrogen, oxygen, sulphur or oxidized sulphur moieties, such as S(O)_(m), and m is 0 or an integer having a value of 1 or 2. The terms “heterocyclic rings”, “heterocyclic moieties”, and “heterocyclyl” shall also refer to fused rings, saturated or partially unsaturated, and wherein one of the rings may be aromatic, or heteroaromatic. Each of the fused rings may have from four to seven ring atoms. Examples of heterocyclyl groups include, but are not limited to, the saturated or partially saturated versions of the heteroaryl moieties as defined above, such as tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).

The term “arylalkyl” or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean a C₁₋₄ alkyl (as defined above) attached to an aryl, heteroaryl or heterocyclic moiety (as also defined above) unless otherwise indicated.

The term “sulfinyl” is used herein to mean the oxide S(O) of the corresponding sulfide, the term “thio” refers to the sulfide, and the term “sulfonyl” refers to the fully oxidized S(O)₂ moiety.

The term “aroyl” is used herein to mean C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are not limited to benzyl and phenethyl.

The term “alkanoyl” is used herein to mean C(O)C₁₋₁₀ alkyl wherein the alkyl is as defined above.

As used herein, the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R₅, R₆, R₉, R₁₀, R₁₁, R₁₂, R₁₃, n, m, or t, etc. may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed. When any variable occurs more than one time in a Formula (as described herein), its definition on each occurrence is independent of its definition at every other occurrence.

With regard to stereoisomers, the compounds of the Formulas herein may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.

Cis (E) and trans (Z) isomerism may also occur. The present invention includes the individual stereoisomers of the compound of the invention and where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.

Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. A stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

Furthermore, some of the crystalline forms of the compounds of the Formulas herein may exist as polymorphs, which are included in the present invention.

Exemplified compounds of the compounds of this invention include the racemates, or optically active forms of the compounds of the working examples herein, and pharmaceutically acceptable salts thereof.

The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.

Methods of Manufacture

The compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (A), (A1), (B) and (B1) may be obtained by applying the synthetic procedures described herein. The synthesis provided for is applicable to producing compounds of the Formulas herein having a variety of different R₁, R₂, X, and R₃ groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While a particular formula with particular substituent groups is shown herein, the synthesis is applicable to all formulas and all substituent groups herein.

Once the nucleus has been established, further compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi) may be prepared by applying standard techniques for functional group inter-conversion, well known in the art. For instance: C(O)NR₄R₁₄ from CO₂CH₃ by heating with HNR₄R₁₄ in CH₃OH with or without catalytic or stoichiometric metal cyanide or Aluminum trimethyl, e.g. NaCN; OC(O)R₆ from OH with e.g., ClC(O)R₆ in bases such as triethylamine and pyridine; NR₁₀—C(S)NR₄R₁₄ from NHR₁₀ with an alkylisothiocyanate, or thiocyanic acid and ClC(S)NR₄R₁₄; NR₁₀C(O)OR₆ from NHR₁₀ with an alkyl or aryl chloroformate; NR₁₀C(O)NR₄H from NHR₁₀ by treatment with an isocyanate, e.g. R₄N═C═O; NR₁₀—C(O)R₆ from NHR₁₀ by treatment with Cl—C(O)R₆ in pyridine; C(═NR₁₀)NR₄R₁₄ from C(NR₄R₁₄)S with H₃NR₁₀ ⁺OAc⁻ by heating in alcohol; C(NR₄R₁₄)SR₆ from C(S)NR₄R₁₄ with R₆—I in an inert solvent, e.g. acetone; NR₁₀SO₂R₇ from NHR₁₀ by treatment with ClSO₂R₇ by heating in bases such as pyridine; NR₁₀C(S)R₆ from NR₁₀C(O)R₆ by treatment with Lawesson's reagent [2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide]; NR₁₀SO₂CF₃ from NHR₁₀ with triflic anhydride and base wherein R₆, R₁₀, R₄ and R₁₄ are as defined in Formula (I) herein.

Precursors of the groups R₁, R₂ and R₃, can be other R₁, R₂ and R₃, etc. groups that may be interconverted by applying standard techniques for functional group interconversion. For example, wherein a moiety is a halo substituted C₁₋₁₀ alkyl can be converted to the corresponding C₁₋₁₀ alkylN₃ derivative by reacting with a suitable azide salt, and thereafter if desired can be reduced to the corresponding C₁₋₁₀ alkylNH₂ compound, which in turn can be reacted with R₇S(O)₂X′ wherein X′ is halo (e.g., chloro) to yield the corresponding C₁₋₁₀alkylNHS(O)₂R₇ compound.

Alternatively wherein the moiety is a halo-substituted C₁₋₁₀-alkyl it can be reacted with an amine R₄R₁₄NH to yield the corresponding C₁₋₁₀-alkylNR₄R₁₄ compound, or can be reacted with an alkali metal salt of R₇SH to yield the corresponding C₁₋₁₀alkylSR₇ compound.

As noted above, it may be desirable during the synthesis of the compounds of this invention, to derivatize reactive functional groups in the molecule undergoing reaction so as to avoid unwanted side reactions. Functional groups such as hydroxy, amino, and acid groups are typically protected with suitable groups that can be readily removed when desired. Suitable common protecting groups for use with hydroxyl groups and nitrogen groups are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene et al., John Wiley & Sons, New York, N.Y., (2nd edition, 1991 or the earlier 1981 version). Suitable examples of hydroxyl protecting groups include ether forming groups such as benzyl, and aryl groups such as tert-butoxycarbonyl (Boc), silyl ethers, such as t-butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CR₁₀R₂₀)_(n). Amino protecting groups may include benzyl, aryl such as acetyl and trialkylsilyl groups. Carboxylic acid groups are typically protected by conversion to an ester that can easily be hydrolyzed, for example, trichloethyl, tert-butyl, benzyl and the like.

Pharmaceutically acid addition salts of compounds of the various Formulas described herein may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.

An illustration of the preparation of compounds of the present invention is shown in the scheme below. For purposes herein, the compounds in the Schemes are shown with an S-methyl, or S(O)₂-methyl group which is deemed representative of the S(O)m-Rg group, wherein R₉ is a C₁₋₁₀ alkyl as described in the Formulas below.

Preparation of Compounds with Formula (I) can be Achieved Through compound 6, which in turn may be constructed from either aldehyde 1 or nitrile 2 as shown in Scheme 1. Leaving groups (LG, described as Leaving group 1 (LG1) & LG2) in 1 (or 2), or elsewhere, can be independently selected from —Cl, —Br, —I, or —OTf and these groups can be installed through the transformation of another functional group (e.g. —OH) by following the methods well known in the art (e.g., treatment of the —OH compound with POCl₃).

Method A is for conversion of 1 to 2. Examples of the methods include, but are not limited to condensation with NH₂OH followed by treatment with thionyl chloride (SOCl₂) [e.g., Santilli et al., J. Heterocycl. Chem. (1971), 445-53] or oxidation of —CHO group to —COOH followed by formation of a primary amide (—CONH₂) and treatment with POCl₃. Suitable Method A can also be utilized to furnish the conversion of 4 to 3—Scheme I.

Method B is for selective displacement of suitable aldehyde 1 or nitrile 2 with an amine (R₃—NH₂). This type of displacement may be achieved using triethylamine and the desired amine R₃NH₂ in chloroform at room temperature for 10 minutes. The reaction was very effective for a range of alkyl amines (78-95% yield). For aryl or heteroaryl amines, elevated temperatures (reflux), longer reaction time (24 hours) and presence of NaH (or Na) may be necessary for reaction completion. Use of the base could be omitted when 3 or more equivalent of the desired amine were used. Other suitable bases include but are not limited to pyridine, diisopropyl ethylamine or pyrrolidine, which may also be used in an appropriate organic solvent, including but not limited to THF, diethyl ether, DCM, DMF, DMSO, toluene or dioxane.

Method C is for the reduction of nitrile 3 to amine 5. 5 may be considered a primary amine (NH₂), a secondary amine (because of —NH(R3)) or an amine (as it contains basic nitrogen). This method includes, but is not limited to BH₃ in appropriate organic solvent, such as THF, DCM, toluene, DMSO, diethyl ether or dioxane. Other suitable reduction reagents, include but are not limited to NaBH₄, LAH or DIBAL. Method C may require elevated temperatures (e.g., heating, refluxing or irradiating with microwave). Another example of the method is hydrogenation (H₂) in the presence of transition metals (e.g., Pd/C, Raney-Ni, PdCl₂).

Method D is for the cyclization of 5 to 6. This method requires the presence of a cyclization reagent (e.g., CDI, COCl₂, tri-phosgene, or phenyl chloroformate methyl chloroformate). Presence of a suitable base may help the reaction to go to completion and examples of the base include, but not limited to triethyl amine, diisopropylethylamine or pyrrolidine. Reaction solvent can be DCM, THF, toluene, DMSO, or DMF.

Method E is for the installation of group -X [e.g., 6 to 7, 10 to (I), 11 to (I) or 9 to 12]. This may or may not require first conversion of sulfide (—SMe) to sulfoxide (—SOMe) or sulfone (—SO₂Me). This conversion can be achieved using meta-chloroperoxybenzoic acid (mCPBA) in high yield and purity. Suitable oxidation methods for use herein include use of one or two equivalents of meta-chloroperoxybenzoic acid (mCPBA) or Oxone® to afford either the sulfoxides or sulfones. Oxidation of the sulfides to sulfoxides or sulfones can also be effected by OsO₄ and catalytic tertiary amine N-oxide, hydrogen peroxide, hydrogen peroxide/NaWO4, and other peracids, oxygen, ozone, organic peroxides, potassium and zinc permanganate, potassium persulfate, and sodium hypochlorite. The subsequent displacement of sulfone group —SO₂Me (likewise, all displacement reactions mentioned below may be achieved using the sulfide —SMe or sulfoxide —SOMe) requires a suitable nucleophile (e.g., amine, alcohol) containing the unit —X. Displacements with amines were usually done with an excess of amine in N-methylpyrrolidine (Barvian et al., J. Med. Chem. (2000), 4606-4616). A wide range of primary amines underwent this reaction with excellent yields. In some cases (in O-displacement or sulfonamide formation) an anion of the nucleophile was prepared with base (usually sodium hydride) in DMF (or DMSO) and then added to the sulfone. Yields for these reactions were usually lower. The sulfone may be displaced by primary and secondary alkylamines without additional base catalysis, preferably in a polar aprotic solvent, such as but not limited to, N-methylpyrrolidin-2-one (NMP), and at varying temperatures depending upon the nucleophilicity of the amine. For instance displacement of the sulfone with ethanolamine, in NMP, occurred in 30 min. at 65° C., while a more hindered amine such as tris(hydroxymethyl)-aminomethane may require elevated temperatures and extended reaction times (80° C. over a 24 hour reaction time). The sulfone can also be displaced by a primary or secondary amine with an additional non-nucleophilic base (e.g. DIPEA) in aprotic solvents like DCM, CH₃CN, NMP, and at varying temperatures depending upon the nucleophilicity of the amine.

The sulfone may also be displaced with a substituted arylamine, or heteroarylamine at elevated temperatures, sometimes requiring formation of the aryl or heteroarylamine anion with sodium hydride, or other suitable base, in DMSO. In addition, the sulfone may be readily displaced with aluminum salts of aryl or heteroaryl amines as previously described in the patent literature (see for example WO 99/32121, whose disclosure is incorporated by reference herein). Likewise, sulfone may be displaced with aryl or heteroaryl or alkyl thiols or alkyl or aryl or heteroaryl alcohols. Analogs containing sulfones as the X substituents may be displaced with sodium alkoxide in the alcohol, or alternatively reactive alkoxide or phenoxide nucleophiles that may be generated from the alcohol or phenol with a suitable base such as sodium, NaH or sodium bistrimethylsilyl amide in a polar aprotic solvent such as DMSO, or run as a neat reaction. Similarly the sulfone may be displaced with carbon nucleophiles. Suitable carbon nucleophiles include, but not limited to aryl Grignard reagents, alkyl Grignard reagents or related organometallics such as organo lithium, zinc, tin, copper or boron. These reactions may, in some cases, require transition metal catalysis such as with Pd or Ni catalysts.

Method F is for coupling with appropriate aryl groups to convert 7 to compounds of Formula (I) (or 6 to 10). This transformation may be achieved using, but not limited to boronic acids (e.g., F1A) under Suzuki cross-coupling conditions, employing a palladium catalyst, such as tetrakis(triphenylphosphine) palladium(0). The coupling conditions include the use of appropriate solvents. These solvents include, but are not limited to dioxane, THF, DMF, DMSO, NMP, acetone, water, or a combination or a mixture thereof. Preferably, the solvent is THF/H₂O, or dioxane/H₂O. The coupling conditions also include the presence of catalytic amount of catalysts and these catalysts include, but not limited to tetrakis(triphenyl-phosphine)-palladium (0), PdCl2, Pd(OAc)₂, (CH3CN)₂PdCl2, Pd(dppf)₂, or [1,1′-bis(diphenylphosphino)-ferrocene]-dichloropalladium(II).

The coupling reaction may or may not require the presence of a base. Suitable bases include, but are not limited to NaHCO₃, KHCO₃, Na₂CO₃, K₂CO₃, KOAc or combination or mixture thereof. Preferably, the base is K₂CO₃ and KOAc.

The coupling reaction may or may not require heating. The heating can be carried out with a regular oil bath or microwave irradiations and the temperature can be varied from room temperature to >100° C., i.e. reflux temperature of the solvent. The coupling reaction may or may not require a sealed reaction vessel and the internal pressure can be varied from one atmosphere to 100 atmospheres. Alternatively, the cross-coupling may be performed using aryl or heteroaryl organozinc [e.g., aryl/heteroaryl-ZnBr, aryl/heteroaryl —ZnCl, aryl/heteroaryl-Zn-aryl/heteroaryl], organocopper [e.g., (aryl/heteroaryl)₂-CuLi], organotin [e.g., aryl/heteroaryl-Sn(CH₃)₃, aryl/heteroaryl —Sn(CH₂CH₂CH₂CH₃)₃], (e.g., F1C), or other organometallic reagents (e.g., FIB) known in the art [see for example Solberg, J.; Undheim, K. Acta Chemica Scandinavia 1989, 62-68]. These types of coupling reactions require the use of appropriate solvents. Such solvents include, but are not limited to dioxane, THF, methylene chloride, chloroform, benzene, hexane, ethyl ether, tert-butyl methyl ether or a combination or a mixture thereof. The coupling reaction may, or may not, require the presence of catalytic amount of a catalyst. Such catalysts include, but are not limited to tetrakis(triphenylphosphine)palladium (0), PdCl₂, Pd(OAc)₂, (CH₃CN)₂PdCl₂, Pd(dppf)₂. The reaction temperature can be varied from −78° C. to >100° C., i.e. reflux temperature of the solvent. Alternatively, this reaction process step may be performed under suitable microwave irradiation conditions, if needed. This reaction may, or may not, require a sealed reaction vessel and the internal pressure can be varied from one atmosphere to 100 atmospheres.

Method G is for coupling of 7 (or 6 or 16) with an aryl group whose structure has a suitable precursor (e.g., acidic group —CO₂H) to the final substituent R₁ in Formula (I). This transformation may be achieved using, but not limited to boronic acids (e.g., G1A) or protected acids (e.g., G1C) under Suzuki coupling conditions, (THF/H₂O, and K₂CO₃) employing a palladium catalyst, such as tetrakis(triphenylphosphine) palladium(0). If desired, these Suzuki coupling reactions may be run under microwave conditions. The boronic acid (D1A or D1E) or ester can be synthesized either by the palladium catalyzed coupling of an aryl halide and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi1,3,2-dioxaborolane or the transmetalation of an aryl halide with a Grignard reagent, e.g., isopropylmagnesium bromide followed by a trialkylborate (e.g., triethylborate) in a suitable solvent like THF. Alternatively, the cross-coupling may be performed using aryl or heteroaryl organozinc, organocopper, organotin (e.g., G1B), or other organometallic reagents (e.g., G1D) known in the art [see for example Solberg, J.; Undheim, K. Acta Chemica Scandinavia 1989, 62-68]. Suitable de-protection is followed if a protected precursor (e.g., G3, G4) is used.

Method H is for the transformation of the suitable precursor (e.g., acidic group —COOH in 8, 9, or 12) to the final substituent R₁. This type of transformations can be achieved by utilizing well-established strategies in the art. The transformation may be done in one step (such as coupling with amines HN(R_(10′))R_(b) under standard coupling conditions e.g. EDC/HOBT/ET₃N in CH₃CN; coupling with alcohol, HOR_(b) under standard coupling conditions, e.g. DCC, DMAP in DCM to form esters or reduction to alcohol) or in more than one step (e.g., Curtuis rearrangement to form isocyanates followed by urea formation with amines or acid chloride formation followed by addition of an amine, HN(R_(10′))R_(b) or an alcohol, HOR_(b) plus a non-nucleophilic base, e.g. DIPEA in an aprotic solvent like DCM. This conversion may require a deprotection step to install the precursor at first (e.g., hydrolysis of —CO₂Me with LiOH/THF/water to prepare —COOH).

Preparation of Compounds with Formula (Ia) can be Achieved Through compound 14, which in turn may be constructed from aldehyde 1 as shown in Scheme 2. Suitable methods from Methods A-H can be utilized to furnish appropriate conversions in Scheme 2.

Method I is for urea formation to convert 4 to 13. This can be achieved by following strategies well-established in the art. Strategies include, but are not limited to reaction with ClSO₂NCO (or Me₃SiNCO) followed by treatment with H₂O, reaction with COCl₂ (CDI, or triphosgene) followed by treatment with NH₃ (or NH₄OH), reaction with ClCO₂Me (or ClCO₂Et) followed by treatment with NH₃ (or NH₄OH) or reaction with NH₂CO₂(t-Bu).

Method J is for imine formation to convert 13 to 14. This can be achieved by following various strategies known in the art. Strategies include, but are not limited to treatment with an acid including TFA, HOAc, HCl, H₂SO₄ or a Lewis acid (e.g., AlCl3). This conversion may require elevated temperatures (e.g., heat, solvent reflux, microwave irradiation) in appropriate organic solvents (e.g., THF, CH₂Cl₂, toluene, DMSO, CH₃CN or dioxane).

Method K is an alternative strategy to prepare compounds in Scheme 2. This method is for the de-saturation (lose of 2H in the formula) of compounds in Scheme 1 resulting in the corresponding compounds in Scheme 2. This conversion includes, but not limited to Formula (Ia)-Scheme 2 from Formula (I)-Scheme 1,14-Scheme 2 from 6-Scheme 1. This type of transformations can be achieved by following methods well-known in the art (e.g., treatment with NBS and AIBN in CCl₄ under elevated temperatures, treatment with MnO₂ in chlorobenzene under elevated temperatures).

Method L is for reduction of compounds in Scheme 2. This method provides an alternative strategy to synthesize compounds in Scheme 1 [e.g., Formula (Ia)-Scheme 2 to Formula (I)-Scheme 1, 14-Scheme 2 to 6-Scheme 1]. This type of conversion can be achieved by using suitable imine reduction methods published in the art (e.g., treatment with Et₃SiH, NaBH₄, H₂—Pd/C).

The compounds of Formula (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa) may be obtained by applying the synthetic procedures described above in Scheme 1 &2 except suitable reagents in

Method F & G should be utilized. Examples of these reagents include, but not limited to those shown in Scheme 3. Suitable reagents in Method F & G for the preparation of compounds with Formula (VIb-VIi) require the presence of G5-8 in appropriate position.

Preparation of compounds with Formula (A), (A1), (B) or (B1) can be achieved from appropriate intermediates in Scheme 1 (or Scheme 2) using proper synthetic methods known to the scientists with appropriate training in the literature. An example of these types of preparations is demonstrated, but not limited to, in Scheme 4. The preparation can be achieved by reacting compound 7 (for A or B) or 16 (for A1 or B1) with another reagent with appropriate structures as shown in Scheme 4 employing Method M.

Method M is for the substitution of -LG₂ with appropriate compound containing the structural unit of —Y—H. This can be achieved by heating the reaction mixtures in appropriate solvents. The heating method can be selected from either a regular oil bath or microwave irradiations. Solvents can be CH₂Cl₂, DMSO, DMF, toluene, benzene, CH₃CN or NMP. The reaction may or may not require the presence of bases. An example of the base can be selected from, but not limited to triethyl amine, diisopropyl ethyl amine, NaH, n-BuLi, tert-BuLi, tert-BuOK, Li₂CO₃, Cs₂CO₃ and pyridine. This transformation may also require the presence of catalytic amount of catalysts containing transition metals (e.g., Pd, Cu, Ni, or W). These catalysts include, but not limited to Pd/C, Pd(PPh₃)₄ and PdCl₂. Compounds that have Y═S(O)_(m) or S(O)_(m)C(R_(y))(R_(z)) may also be prepared by the oxidation of their corresponding compounds with Y═S or SC(R_(y))(R_(z)). Suitable oxidation methods for use herein include, but not limited to mCPBA, Oxone, OsO₄, H₂O₂, potassium and zinc permanganate.

One aspect of the invention are the novel compounds of Formula (C) and (C1):

wherein,

-   G1, G₂, G3 and G4 are as described for Formula (I) herein; -   m is 0 or an integer having a value of 1 or 2; -   R₉ is a C₁₋₁₀alkyl; -   LG₂ is chlorine, bromine, iodine, or O—S(O)₂CF₃; -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties may be optionally substituted (as defined for     Formula (I) herein.

In one embodiment, R₉ is methyl. In another embodiment, m is 0 or 1.

Another aspect of the invention are compounds of Formula (D) and (D1) represented by the structure:

wherein,

-   G1, G₂, G3, G4 and X are as described for Formula (I) herein; -   LG₂ is chlorine, bromine, iodine, or O—S(O)₂CF₃; -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties may be optionally substituted (and as defined for     Formula (I)).

Another aspect of the invention are compounds of Formula (E) and (E1) represented by the structure:

wherein,

-   G1, G₂, G3, G4, R₁ and (R₁)_(g) are as described for Formula (I)     herein; -   m is 0 or an integer having a value of 1 or 2; -   R₉ is a C₁₋₁₀alkyl; -   LG₂ is chlorine, bromine, iodine, or O—S(O)₂CF₃; -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties may be optionally substituted (as defined for     Formula (I) herein.     Representative examples of Formula (E) and (E1) are: -   3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylbenzoic     acid -   N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide -   N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide -   N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide -   N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide -   3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide -   3-[8-(2,6-Difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide -   N-{3-[g-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide -   N-{3-[S-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide -   3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylbenzoic     acid

It is also recognized that a similar set of formulas (F) and (F1) are contemplated when the R₁ moiety is substituted in the 3-position of the phenyl ring, as shown in compounds of Formula (II) and (IIa). Similar intermediates are also contemplated for the remaining Formulas herein wherein the C4 position of the pharmacophore is substituted with the various heteroaryl rings, e.g. G5/G6, etc. of the formulas described herein as Formula (III) and (IIIa), (IV) and (IVa), etc.

Another aspect of the invention are compounds of Formula (G):

wherein

-   LG₂ is chloro, bromo, iodo, O—S(O)₂CF₃; -   R₉ is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties may be optionally substituted.

Suitably R₃ is substituted as defined herein for compounds of Formula (I).

Another aspect of the invention are compounds of Formula (H):

wherein

-   G10 is an aryl, aryl C₂₋₁₀ alkyl, heteroaryl, heteroaryl C₂₋₁₀     alkyl; aryl C₂₋₁₀ alkenyl, arylC₂₋₁₀ alkynyl, heteroaryl C₂₋₁₀     alkenyl, heteroaryl C₂₋₁₀ alkynyl, C₂₋₁₀alkenyl, or C₂₋₁₀ alkynyl     moiety, which moieties may be optionally substituted with R₁ and     (R_(1′))_(g); -   R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b),     N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b);     N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or     N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); -   R_(1′) is independently selected at each occurrence from hydrogen,     halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro,     (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅,     S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; -   R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇     cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,     heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl     moiety, which moieties excluding hydrogen, may all be optionally     substituted; -   R₅ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the     moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅     being SOH; -   R_(4′) and R_(14′) are each independently selected at each     occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′)     together with the nitrogen to which they are attached form a     heterocyclic ring of 5 to 7 members, which ring optionally contains     an additional heteroatom selected from NR_(9′); -   R_(d) and R_(d′) are each independently selected at each occurrence     from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; or R_(d) and R_(d′) together with the     nitrogen which they are attached form an optionally substituted     heterocyclic ring of 5 to 6 members, which ring optionally contains     an additional heteroatom selected from oxygen, sulfur or NR_(9′); -   R_(9′) is independently selected at each occurrence from hydrogen,     or C₁₋₄ alkyl; -   R₁₀ and R₂₀ are independently selected at each occurrence from     hydrogen or C₁₋₁₄alkyl; -   R_(10′) is independently selected at each occurrence from hydrogen     or C₁₋₄alkyl; -   R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄     alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇     cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl,     C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl,     heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl     moiety, and wherein each of these moieties, excluding hydrogen, may     be optionally substituted; -   v is 0 or an integer having a value of 1 or 2; -   v′ is independently selected at each occurrence from 0 or an integer     having a value of 1 or 2; -   Z is independently selected at each occurrence from oxygen or     sulfur; -   Rg is an optionally substituted C₁₋₁₀ alkyl; -   R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl,     aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl,     heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each     of these moieties may be optionally substituted.

Suitably R₃ is substituted as defined herein for compounds of Formula (I).

Compounds of Formula (H) may be made by reacting the compound disclosed as structure 4 in Scheme I found in WO 02/059083 with a suitably substituted isocyanate, such as ClS(O)₂NCO, or TMS —NCO in a aprotic organic solvent, such as toluene, methylene chloride, chloroform, benzene, THF, hexane, optionally with a non-nucleophilic base, such as triethylamine, diisopropyl ethylamine, pyridine, followed by reaction with ammonia; or by reacting structure 4 with phosgene in an aprotic organic solvent, such as toluene, methylene chloride, chloroform, benzene, THF, hexane, optionally with a non-nucleophilic base, such as triethylamine, diisopropyl ethylamine, pyridine, followed by reaction with ammonia or by reacting structure 4 with COCl₂ or methylchloroformate or other chloroformates in an aprotic organic solvent, such as toluene, methylene chloride, chloroform, benzene, THF, hexane, optionally with a non-nucleophilic base, such as triethylamine, diisopropyl ethylamine, pyridine, followed by reaction with ammonia. This reaction may, or may not, require heating (e.g, temperature between r.t. and 250° C.). The heating can be carried out in any manner and may include the use of an oil bath or microwave irradiation.

EXPERIMENTALS

The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents are highest available purity and all reactions run under anhydrous conditions in an Ar atmosphere where necessary.

List of Abbreviations DMAP: 4-(Dimethylamino)pyridine SPE: Solid phase extraction DCM: Dichloromethane m-CPBA: 3-Chlorobenzene- carboperoxoic acid DMF: N,N-Dimethylformamide MDAP: Mass directed auto preparation dppf: 1,1′-Bis(diphenylphosphino)- NIS: N-Iodosuccinimide ferrocene DMSO: Dimethylsulfoxide HATU: O-(7-Azabenzotriazol-1- yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate DIPEA: N,N- HBTU: O-Benzotriazol-1-yl- Diisopropylethylamine N,N,N′,N′-tetramethyluronium hexafluorophosphate DSC: differential scanning HOBT: 1-Hydoxybenzotriazole calorimetry hydrate EtOAc: Ethyl acetate IPA: isopropyl alcohol EDC: 1-(3-Dimethylaminopropyl)- THF: Tetrahydrofuran 3-ethylcarbodiimide hydrochloride TFA: Trifluoroacetic anhydride mol: moles M: molar mmol: millimoles L: liters satd: saturated mL: milliliters eq: equivalents g: grams min: minutes mg: milligrams mp: melting point h: hours rt: room temperature Aq: aqueous NMP = 1-methyl-2-pyrrolidinone

LC-MS Experimental Conditions:

Liquid Chromatograph System: Shimadzu LC system with SCL-10A Controller and dual UV detector Autosampler: Leap CTC with a Valco six port injector Column: Aquasil/Aquasil (C18 40 × 1 mm) Inj. Vol. (uL): 2.0 Solvent A: H₂O, 0.02% TFA Solvent B: MeCN, 0.018% TFA Gradient: linear Channel A: UV 214 nm Channel B: ELS Time Dura. Flow Step (min) (min) (μL/min) Sol. A Sol. B 0 0.00 0.00 300.00 95.00  5.00 1 0.00 0.01 300.00 95.00  5.00 2 0.01 3.20 300.00 10.00 90.00 3 3.21 1.00 300.00 10.00 90.00 4 4.21 0.10 300.00 95.00  5.00 5 4.31 0.40 300.00 95.00  5.00 Mass Spectrometer: PE Sciex Single Quadrupole LC/MS API-150 Polarity: Positive Acquisition mode: Profile

General Procedures

Nuclear magnetic resonance spectra were recorded at 400 MHz using on a Bruker AC 400 spectrometer. CDCl₃ is deuteriochloroform, DMSO-d₆ is hexadeuteriodimethylsulfoxide, and CD₃OD (or MeOD) is tetradeuteriomethanol. Chemical shifts are reported in parts per million (δ) downfield from the internal standard tetramethylsilane (TMS) or the NMR solvent. Abbreviations for NMR data are as follows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, dt=doublet of triplets, app=apparent, br=broad. J indicates the NMR coupling constant measured in Hertz. Mass spectra were taken on a instruments, using electrospray (ES) ionization techniques. All temperatures are reported in degrees Celsius. All other abbreviations are as described in the ACS Style Guide (American Chemical Society, Washington, D.C., 1986).

Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thin layer plates were used for thin layer chromatography. Both flash and gravity chromatography were carried out on E. Merck Kieselgel 60 (230-400 mesh) silica gel. Preparative hplc were performed using a Gilson Preparative System using a Luna 5u C18(2) 100A reverse phase column eluting with a 10-80 gradient (0.1% TFA in acetonitrile/0.1% aqueous TFA) or a 10-80 gradient (acetonitrile/water). The CombiFlash system used for purification in this application was purchased from Isco, Inc. CombiFlash purification was carried out using a prepacked SiO₂ column, a detector with UV wavelength at 254 nm and mixed solvents.

Heating of reaction mixtures with microwave irradiations was carried out on a Smith Creator (purchased from Personal Chemistry, Forboro/MA, now owned by Biotage), a Emrys Optimizer (purchased from Personal Chemistry) or an Explorer (provided by CEM Discover, Matthews/NC) microwave.

General Procedure for Sulfoxide/Sulfone Displacement

The sulfoxide/sulfone of the template is dissolved in THF/CHCl₃ (1:1) and the amine (5 eq) and diisopropylethylamine (3 eq) are added and allowed to stir for 1 h. The mixture is concentrated in vacuo.

General Procedure for HATU Couplings

The acid is dissolved in DMF and HATU (1 eq) is added. DIEA is added (2 eq) followed by the amine (1.1 eq) and allowed to stir for 18 h. The reaction mixture is concentrated and redissolved in CHCl₃.

Example 1 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-cyclobutyl-4-methylbenzamide 1a) 4-chloro-6-[(2,6-fluorophenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile

To the solution of phosphorus oxychloride (65 mL, 0.70 mol) in trichloroethylene (46.5 mL) was added DMF (25 mL, 0.32 mol) slowly to keep the temperature between 5° C. to 10° C. The solution was then warmed up to room temperature before 6-hydroxy-2-(methylthio)-4(1H)-pyrimidinone (25 g, 0.16 mol) was added in portions. The resultant reaction mixture was heated at 80° C. overnight followed by concentration under vacuum. The resulting slurry like residue was poured into ice, stirred for about 2 hours then filtered to afford the crude product. The crude product was further purified by recrystallization with hexane to afford 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbaldehyde (21.3 g, 61%). ¹H-NMR (CDCl₃) δ 2.66 (s, 3H), 10.4 (s, 1H).

To the mixture of hydroxylamine hydrochloride (139 mg, 2.0 mmol), HOAc (0.113 mL, 2.0 mmol) and EtOH (5 mL) was added 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbaldehyde (223 mg, 1.0 mol) to room temperature. The solution was then heated at 50° C. for about 1 hour, 60° C. for about 30 minutes and 70° C. for about 30 minutes before it was concentrated under vacuum and washed with H₂O (10-20 mL) to afford 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbaldehyde oxime (190 mg, 80%). LC-MS m/z 238 (M+H)⁺ 1.57 minute, 1.65 minute; ¹H-NMR (CDCl₃) δ 2.62, 2.65 (3H), 7.53, 8.30 (1H).

To 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbaldehyde oxime (2.38 g, 10 mmol) was added SOCl₂ (21.8 mL, 0.30 mol) slowly at room temperature. The solution was then heated at 75° C. for about 3 hours before it was concentrated under vacuum. The residue SOCl₂ was removed by evaporation with toluene (5 mL) under vacuum. The resulting solid was washed with EtOH/H₂O (10 mL, 1:1) to afford 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbonitrile (2.04 g, 93%). LC-MS m/z 220 (M+H)⁺ 1.99 minute; ¹H-NMR (CDCl₃) δ 2.64 (3H).

To the solution of 4,6-dichloro-2-(methylthio)-5-pyrimidinecarbonitrile (2.20 g, 10.0 mmol) in DMF (10 mL) was added 2,6-difluoroaniline (2.17 mL, 20.0 mmol). The solution was stirred at 50° C. for about 60 minutes. The mixture was slowly added into a solution of MeOH (20 mL) and water (30 mL). The resultant solid was filtered and washed with MeOH/H₂O (20 mL, 1:1) to give 4-chloro-6-[(2,6-difluorophenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile as a white solid (2.82 g, 90%). LC-MS m/z 313 (M+H)⁺; ¹H-NMR (CDCl₃) δ 2.33 (s, 3H), 6.94 (s, 1H), 7.04 (m, 2H), 7.35 (m, 1H).

1b) 5-(Aminomethyl)-6-chloro-N-(2,6-difluorophenyl)-2-(methylthio)-4-pyrimidinamine

To the solution of 4-chloro-6-[(2,6-difluorophenyl)amino]-2-(methylthio)-5-pyrimidinecarbonitrile (0.938 g) was added borane.THF complex (1.0 M, 15 mL). The reaction mixture was then heated at reflux for about 4 h until all the starting material disappeared. The solution was cooled to r.t., mixed with HCl solution (6 M, 5 mL), and stirred at room temperature for about 30 minutes. The solution was then mixed with NaOH solution (3 M) to pH 9.0-10.0. The organic phase was separated and the aqueous layer was extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine (50 mL), collected, dried over Na₂SO₄ and concentrated to afford the title compound 0.97 g (quantitative). LC-MS m/z 317 (M+H)⁺, 1.5 min (ret. time).

1c) 5-Chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one

To the solution of 5-(aminomethyl)-6-chloro-N-(2,6-difluorophenyl)-2-(methylthio)-4-pyrimidinamine (0.317 g) in CH₂Cl₂ (5 mL) was added the mixture of carbonyl diimidazole (0.178 g) in CH₂Cl₂ (5 mL). The resultant mixture was stirred for about 3 hours at r.t., mixed with CH₂Cl₂ (10 mL) and washed with HCl (1 N, 2×10 mL) and H₂O (20 mL). The organic layers were collected, dried over Na₂SO₄, filtered and concentrated to provide the title compound (0.279 g, 81%). LC-MS m/z 343 (M+H)⁺, 1.75 min (ret. time); ¹H-NMR (400 MHz, CDCl₃) δ 7.44-7.40 (m, 1H), 7.07-7.03 (m, 2H), 5.84 (br, 1H), 4.62 (s, 2H), 2.19 (s, 3H).

1d) 3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid

To a stirring solution of 3-iodo-4-methylbenzoic acid (60 g, 0.22 mol, 1 eq) in degassed DMF (1400 mL, 23.3 vol.) was charged 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane (81.4 g, 0.32 mol, 1.4 eq) followed by potassium acetate (112 g, 1.14 mole, 5 eq) and [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (18.7 g, 0.02 mole, 0.1 eq). The resulting mixture was placed under a nitrogen atmosphere and was heated to 80° C. with the exclusion of light overnight. The mixture was then concentrated under high vacuum and the residue partitioned between EtOAc and 2M HCl. The mixture was then filtered and the layers separated. The aqueous phase was re-extracted with EtOAc. The combined organics were then washed with brine, dried and evaporated to yield a brown solid that was applied to a silica plug then eluted with 2:1 cyclohexane:ethyl acetate. Fractions were then combined and evaporated to yield a brown foam that was triturated with cyclohexane, collected by filtration then dried in vacuo to yield 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid. 6 (CDCl₃) 8.50-8.49 (1H, d), 8.04-8.02 (1H, dd), 7.27-7.25 (1H, d), 2.61 (3H, s), 1.36 (12H, s)

5-Chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (200 mg, 0.58 mmol) was mixed with 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.23 g), K₂CO₃ (0.485 g), dioxane (18 mL) and H₂O (6 mL). The resultant mixture was passed through by a stream of argon for 10 min, mixed with Pd(PPh₃)₄ (34 mg) and heated at 150° C. for 1 h. It was filtered through celite, mixed with 1 mL acetic acid and washed with brine. The organic layers were collected, dried over MgSO₄, filtered and concentrated and the residue was purified by flash column chromatography to provide the title compound (160 mg). LC-MS m/z 443.2 (M+H)⁺, 1.98 min (ret. time).

1e) 3-{8-(2,6-Difluorophenyl)-2-[4-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylbenzoic acid

To the solution of the title compound from Example 1d (100 mg) in methylene chloride (20 mL) was added m-CPBA (80 mg) at r.t, followed by 1 mL of MeOH. The reaction mixture was stirred for overnight, diluted with EtOAc, and washed with 5% Na₂CO₃, H₂O and brine. The organic phases were collected, dried over MgSO₄, concentrated to afford the mixture of sulfone and sulfoxide as a yellow solid that was used without further purification.

To the solution of the above sulfoxide and sulfone mixture in THF (20 mL) was added 1,1-dimethylethyl 4-piperidinylcarbamate (200 mg). The reaction mixture was heated at reflux for 4 h. The solution was then evaporated in vacuo and the residue was purified via flash column chromatography to provide the title compound as a white solid. LC-MS m/z 595.4 (M+H)⁺, 2.18 min (ret. time).

1f) 1,1-Dimethylethyl {1-[4-{5-[(cyclobutylamino)carbonyl]-2-methylphenyl}-8-(2,6-difluorophenyl)-7-oxo-5,6,78-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}carbamate

To the solution of the compound from Example 1d (200 mg) in methylene chloride (100 mL) were added EDC (80 mg), HOBt (60 mg) and cyclobutylamine (100 uL) at r.t. The reaction mixture was stirred overnight and evaporated in vacuo. Flash chromatography afforded the title compound as a white solid. LC-MS m/z 648 (M+H)⁺, 2.36 min (ret. time).

1g 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-cyclobutyl-4-methylbenzamide

To the solution of the title compound from Example 1f (50 mg) in CH₂Cl₂ (5 mL) was added TFA (1 mL) at r.t. The reaction mixture was stirred at r.t. for 3 h and concentrated. It was mixed with EtOAc (5 mL) and washed with 1 M NaOH solution (5 mL), followed by brine. The organic part was collected, dried over K₂CO₃ and concentrated in vacuo to afford the free base of the title compound as a white solid. LC-MS m/z 548 (M+H)⁺, 1.61 min (ret time).

Example 2 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide 2a) 1,1-Dimethylethyl {1-[4-(5-{[(cyclopropylmethyl)amino]carbonyl}-2-methylphenyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}carbamate

To a solution of 3-{8-(2,6-Difluorophenyl)-2-[4-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylbenzoic acid (250 mg) in methylenechloride (100 mL) were added EDC (100 mg), HOBt (70 mg) and cyclopropylmethylamine (110 uL). The reaction was stirred at r.t. overnight and evaporated in vacuo. Flash chromatography then provided the title compound as a white solid. LC-MS m/z 648 (M+H)⁺, 2.33 min (ret. time).

2b) 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide

To a solution of the title compound from Example 2a (50 mg) in CH₂Cl₂ (5 mL) was added TFA (1 mL) at r.t. The reaction mixture was stirred for 3 h and concentrated in vacuo. The residue was mixed with EtOAc (5 mL) and NaOH solution (1 M, 5 mL). The organic part was separated, washed with brine, dried over K₂CO₃ and concentrated in vacuo to yield the free base of the title compound as a white solid. LC-MS m/z 548 (M+H)⁺, 1.52 min (ret. time).

Example 3 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-[2-(4-fluorophenyl)ethyl]-4-methylbenzamide 3a) 1,1-Dimethylethyl (1-{8-(2,6-difluorophenyl)-4-[5-({[2-(4-fluorophenyl)ethyl]amino}carbonyl)-2-methylphenyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl}-4-piperidinyl)carbamate

The title compound was prepared from 3-{8-(2,6-Difluorophenyl)-2-[4-({[(1,1-dimethylethyl)oxy]carbonyl}amino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylbenzoic acid by following the procedures in Example 1f except using 4-fluorophenylethylamine for the amide formation. LC-MS m/z 716 (M+H)⁺, 2.47 min (ret. time).

3b) 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-[2-(4-fluorophenyl)ethyl]-4-methylbenzamide

The title compound was prepared from the compound from Example 3a by following the procedures in Example 1g. LC-MS m/z 616 (M+H)⁺, 1.69 min (ret. time).

Example 4 3-[2-[(2-Aminoethyl)(methyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide 4a) N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,78-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide

To a solution of 3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (500 mg) in methylenechloride (100 mL) were added EDC (260 mg), HOBt (160 mg) and cyclopropylmethylamine (260 uL). The reaction mixture was stirred at room temperature overnight and concentrated in vacuo. The residue was purified via column chromatography to provide the title compound as a white solid. LC-MS m/z 496 (M+H)⁺, 2.62 min (ret. time).

4b) N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide

To the solution of the compound from Example 4a (500 mg) in methylenechloride (20 mL) and methanol (10 mL) was added m-CPBA (200 mg) at r.t. The reaction mixture was stirred for 0.5 h and filtered through a silica plug. The solution was dried over MgSO₄ and concentrated to afford the title compound as a yellow solid that was used without further purification. LC-MS m/z 512 (M+H)⁺, 1.77 min (ret time).

4c) 3-[2-[(2-Aminoethyl)(methyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-l]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide

To the solution of the compound from Example 4b (90 mg) in THF (10 mL) was added N-methyl ethylene diamine (70 uL) at r.t. The reaction mixture was stirred at r.t. overnight. The solution was then evaporated in vacuo and the residue was purified by column chromatography to provide the title compound as a white solid. LC-MS m/z 522 (M+H)⁺, 1.55 min (ret. time).

Example 5 N-(Cyclopropylmethyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

To the solution of N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide (90 mg) in THF (10 mL) was added N-methyl ethylene diamine (70 uL) at r.t. The reaction mixture was stirred at r.t. overnight. The solution was then evaporated in vacuo and the residue was purified by column chromatography to provide the title compound as a white solid (in addition to compound 4c). LC-MS m/z 522 (M+H)⁺, 1.47 min (ret. time).

Example 6 N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide 6a) 1,1-Dimethylethyl 4-{[4-(5-{[(cyclopropylmethyl)amino]carbonyl}-2-methylphenyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate

To the solution of N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide (100 mg) in THF (10 mL) was added 1,1-dimethylethyl 4-amino-1-piperidinecarboxylate (195 mg) at r.t. The reaction mixture was heated at reflux for 4 h. The solution was then evaporated in vacuo and the residue was purified by column chromatography to provide the title compound as a white solid. LC-MS m/z 648.4 (M+H)⁺, 2.16 min (ret. time).

6b) N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide

To the solution of the compound from Example 6a (50 mg) in CH₂Cl₂ (5 mL) was added 1 mL of TFA at r.t. The reaction solution was stirred at r.t. for 3 h and concentrated in vacuo. The resultant residue was mixed with EtOAc (5 mL) and NaOH solution (1 M, 5 mL). The organic part was separated, washed with brine, dried over K₂CO₃ and concentrated in vacuo to yield the free base of the title compound as a white solid. LC-MS m/z 548 (M+H)⁺, 1.46 min (ret. time).

Example 7 N-(3-[8-(2,6-Difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl)-3-thiophenecarboxamide 7a) N-(3-iodo-4-methylphenyl)-3-thiophenecarboxamide

3-Thiophenecarboxylic acid (2.0 g, 15.6 mmol) was dissolved in methylene chloride (100 mL) and 2 drops of DMF were added. The mixture was cooled to 0° C. and oxalyl chloride (1.5 mL, 17.1 mmol) was added slowly and allowed to warm to room temperature. Gas evolution was observed during warming. 3-Methyl-4-iodoaniline (5.45 g, 23.5 mmol), 4 drops of pyridine and K₂CO₃ (2.58 g, 18.7 mmol) are dissolved in CH₂Cl₂ (10 mL) and cooled to about 0° C. After about 1 h, the acid chloride mixture is slowly added to the cooled aniline mixture and allowed to warm to room temperature and stirred for about 18 h. The resulting mixture is filtered, washed with ethyl acetate and the filtrate is concentrated to a brown oil. The crude material was purified via flash chromatography (10-30% ethyl acetate in hexanes) to afford the title compound (1.56 g, 29%) as an off-white solid.

7b) N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-thiophenecarboxamide

The iodide from Example 7a (1.56 g, 4.5 mmol), bis(pinacolato)diboran (2.3 g, 9.0 mmol), potassium acetate (2.21 g, 22.5 mmol) and PdCl₂.dppf (0.15 g, 0.225 mmol) are dissolved in DMF (50 mL) and heated to about 85° C. for about 24 h. The mixture was then concentrated to an oil and ethyl acetate and water were added. The organic portion was washed with brine and dried (Na₂SO₄). The concentrated organic layer was purified via flash chromatography to give the title compound (0.212 g, 13%).

7c) N-{3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The title compound was prepared from 5-Chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one by following the procedures in Example 1d except using N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-thiophenecarboxamide for the Suzuki cross-coupling reaction. LC-MS m/z 524 (M+H)⁺, 2.21 min (ret. time).

7d) N-(3-{8-(2,6-Difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-thiophenecarboxamide

To the solution of the compound from Example 7c (83 mg) in methylenechloride (10 mL) was added m-CPBA (41 mg) and MeOH (1 mL). The reaction solution was stirred overnight, diluted with EtOAc, and washed with 5% Na₂CO₃, H₂O and brine. The organic part was separated, dried over MgSO₄, concentrated to afford the mixture of sulfone and sulfoxide as a yellow solid that was used without further purification.

To the solution of the above sulfoxide and sulfone mixture in THF (10 mL) was added 2,2,6,6-tetramethyl-4-piperidinamine (123 uL). The reaction mixture was heated at reflux for 4 h and concentrated in vacuo. Flash chromatography then provided the title compound as a white solid. LC-MS m/z 632.6 (M+H)⁺, 1.68 min (ret. time).

Example 8 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide 8a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (1.2 g, 2.71 mmol) in CH₂Cl₂ (80 mL) were added diisopropyl ethyl amine (0.96 mL, 5.5 mmol), HATU (1.044 g, 2.75 mmol) and 4-fluoroaniline (0.276 mL, 2.92 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (50 mL) and water (50 mL) and shaked. The layers were separated and the organic layer was washed with brine (75 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (load column with DCM, mobile phase EtOAc/Hexane) then provided the title compound as a white solid 1.33 g (92%). LC-MS m/z 536 (M+H)⁺.

8b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of the title compound from Example 8a (100 mg, 0.19 mmol) in CH₂Cl₂ (10 mL) was added mCPBA (45 mg, 0.20 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. CombiFlash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as a white solid 90 mg (87%). LC-MS m/z 552 (M+H)⁺.

8c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (300 mg, 0.54 mmol) in CH₂Cl₂ (30 mL) were added diisopropyl ethyl amine (0.2 mL, 1.14 mmol), N,N-dimethyl-ethylenediamine (0.3 mL, 2.7 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (131 mg, 42%). LC-MS m/z 576 (M+H)⁺; ¹H-NMR (MeOD) δ 2.19 (s, 6H), 2.35 (s, 3H), 2.42 (m, br, 2H), 3.24 (m, br, 2H), 4.16 (s, 2H), 7.12 (m, 4H), 7.52 (m, 2H), 7.72 (m, 2H), 7.83 (s, 1H), 7.99 (d, 1H).

Example 9 3-{3-(2,6-difluorophenyl)-2-[[3-(dimethylamino)-propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide

The title compound was prepared from compound from Example 8b by following the procedures in Example 8c except using N,N,N′-trimethyl-1,3-propanediamine for the displacement reaction. LC-MS m/z 604.2 (M+H)⁺, 1.77 min (ret. time); ¹H-NMR (MeOD) δ 1.60 (m, 2H), 2.10 (m, 2H), 2.19 (s, 6H), 2.35 (s, 3H), 2.98 (m, 3H), 3.33 (m, 2H), 4.18 (s, 2H), 7.17 (m, 4H), 7.53 (m, 2H), 7.77 (m, 2H), 7.83 (s, 1H), 7.98 (d, 1H).

Example 10 N-{3-[8-(2,6-difluorophenyl)-2-(methyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide 10a) 4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-l) aniline

3-Iodo-4-methylaniline (11 g, 47.2 mmol), bis(pinacolato)diboron (24.25 g, 95.5 mmol) and potassium acetate (14.3 g, 145.7 mmol) were stirred under argon in DMF (250 mL) in an oil bath maintained at 80° C. The mixture was degassed by vigorously bubbling argon through the mixture for 5 minutes. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (1.875 g, 2.3 mmol) was added and the mixture heated at 80° C. while stirring under argon for 17 hours. The mixture was allowed to cool to room temperature and 50 g of silica gel were added. Most of the solvent was pumped off in vacuo. The residue was flash chromatographed on 200 grams of silica gel eluted with 0-15% ethyl acetate/hexane to give the title compound as a light yellow solid. LC-MS m/z 233 (M)⁺, 1.53 min (ret. time).

10b) 5-(5-Amino-2-methylphenyl)-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one

To 5-chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (0.342 g, 1 mmol) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.256 g, 1.1 mmol) in dioxane (40 mL), was added a solution of K₂CO₃ (0.417 g, 3 mmol) in water (10 mL). Argon was vigorously bubbled through the mixture for 5 minutes and then tetrakis(triphenyl-phosphine)palladium(0) (0.078 g, 0.05 mmol) was added. The mixture was heated in a 95° C. oil bath for 17 hours. The solvent was pumped off in vacuo, and the residue partitioned between ethyl acetate and water. The phases separated and the organic phase washed with brine, dried over anhydrous Na₂SO₄, filtered and evaporated. The crude product was flash chromatographed on silica gel (20 grams) eluted with 0-10% MeOH/CH₂Cl₂ to give the title product as a white solid. mp 122-125° C. LC-MS m/z 414 (M+H)⁺, 1.58 min (ret. time).

10c) N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compounds 5-(5-amino-2-methylphenyl)-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (0.205 g, 0.5 mmol), 3-thiophenecarboxylic acid (0.0647 g, 0.5 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.107 g, 0.55 mmol), 4-(dimethylamino)pyridine (0.002 g, 0.016 mmol), and triethylamine (0.14 mL, 1 mmol), were dissolved in chloroform (10 mL) and stirred under argon at room temperature for 16 h. The reaction was not complete. An additional 3-thiophenecarboxylic acid (0.13 g, 1.0 mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.107 g, 0.55 mmol) were added and heated to 40° C. for 17 h. The reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water (3×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated. The crude product was flash chromatographed on silica gel (10 g) eluted with 0-5% MeOH/CH₂Cl₂ to give the title compound as a solid. LC-MS m/z 524 (M+H)⁺, 2.2 min (ret. time).

10d) N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide (0.052 g, 0.1 mmol) was dissolved in a mixture of CH₂Cl₂ (10 mL) and DMF (0.5 mL). Then 3-chloroperoxybenzoic acid (50-60%) (0.03 g, 0.1 mmol) was added and the mixture stirred for 45 min at room temperature. Solvent was pumped off in vacuo to give the title compound plus a small amount of the corresponding sulfone. The mixture was used without further purification. LC-MS m/z 540 (M+H)⁺, 1.76 min (ret. time).

10e) N-{3-[8-(2,6-difluorophenyl)-2-(methyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide, (0.027 g, 0.05 mmol) was dissolved in methanol (5 mL) and treated in portions with 60% NaH in mineral oil (0.1 g, 2.5 mmol) while stirring under argon at room temperature. The mixture was stirred for 30 minutes. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (10 g) eluted with 0-3% MeOH/Cl₂Cl₂ to give the title compound as a white solid. mp (dec) 225-228° C.; LC-MS m/z 508 (M+H)⁺, 2.04 min (ret. time).

Example 11 N-{3-[2-(4-amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide, (0.027 g, 0.05 mmol) was dissolved in DMF (4 mL) and 4-aminopiperidine (0.1 g, 1.0 mmol) was added. The mixture was stirred under argon at room temperature for 17 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (10 g) eluted with CH₂Cl₂ followed by 6:0.25:0.025, CH₂Cl₂:isopropanol:NH₄OH and then by 6:0.5:0.025 CH₂Cl₂: isopropanol:NH₄OH to give the title compound as a white amorphous solid. This was crystallized from CH₂Cl₂/hexane to give the title compound as a white crystalline solid. mp (dec) 250-261° C.; LC-MS m/z 576 (M+H)⁺, 1.6 min (ret. time).

Example 12 N-{3-[8-(2,6-difluorophenyl)-2-(dimethylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide, (0.054 g, 0.1 mmol) was dissolved in a mixture of DMF (0.5 mL) and CH₂Cl₂ (10 mL), and 40% dimethylamine in water (1 mL) was added. The mixture was stirred under argon at room temperature for 3 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (10 g) eluted with 10-60% EtOAc/CH₂Cl₂ to give the title compound as a white amorphous solid. The solid was crystallized from CH₂Cl₂/hexane to give the title compound as a white crystalline solid. mp 214-215° C.; LC-MS m/z 521 (M+H)⁺, 2.0 min (ret. time).

Example 13 N-{3-[8-(2,6-difluorophenyl-2-(ethyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide, (0.054 g, 0.1 mmol) was dissolved in ethanol (5 mL) and treated in portions with 95% NaH (0.1 g, 4 mmol) while stirring under argon at room temperature. The mixture was stirred under argon at room temperature for 1 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (10 g) eluted with 0-3% MeOH/CH₂Cl₂ to give the title compound as a white amorphous solid. This solid was crystallized from CH₂Cl₂/hexane to give the title compound as a white crystalline solid. mp (dec) 199-202° C.; LC-MS m/z 522 (M+H)⁺, 2.15 min (ret. time).

Example 14 N-{3-[8-(2,6-difluorophenyl)-2-(methylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide, (0.054 g, 0.1 mmol) was dissolved in THF (20 mL) and a 2M solution of methylamine in THF (1 mL) was added. The mixture was stirred at room temperature for 4 days. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (10 g) eluted with 0-10% MeOH/CH₂Cl₂ to give the title compound as an off-white amorphous solid. mp (dec) 203-207° C.; LC-MS m/z 507 (M+H)⁺, 1.76 min (ret. time).

Example 15 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide 15a) 3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (0.597 g, 1.35 mmol), benzyl amine (0.445 mL, 4.0 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.311 g, 1.62 mmol), 1-hydroxybenzotriazole hydrate (0.219 g, 1.62 mmol), were dissolved in CH₂Cl₂ (50 mL) and stirred under argon at room temperature for 16 h. The solvent was pumped off in vacuo. The reaction mixture was partitioned between ethyl acetate and water. The organic phase washed 3× with water, 1× brine, dried over anhydrous Na₂SO₄, filtered and evaporated. The crude product was flash chromatographed on silica gel (25 g) eluted with a gradient of 6:1:0.1, CH₂Cl₂: isopropanol:NH₄OH to give the title compound. Crystallization from CH₂Cl₂/hexane gave the title compound as a white crystalline solid. m.p. (dec) 154-159° C.; LC-MS m/z 532 (M+H)⁺, 2.24 min (ret. time).

15b) 3-[8-(2,6-Difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide (0.41 g, 0.77 mmol) was dissolved in CH₂Cl₂ (25 mL). 3-Chloroperoxybenzoic acid (50-60%) (0.505 g, ˜1.62 mmol) was added and the mixture stirred for 16 h at room temperature. The solvent was pumped off in vacuo and the residue partitioned between EtOAc and water. The organic phase washed with brine, dried over anhydrous Na₂SO₄, filtered and evaporated. The crude product was flash chromatographed on silica gel eluted with 0-5% MeOH/CH₂Cl₂ to give the title compound. Crystallization from CH₂Cl₂/hexane to give the title compound as a white crystalline solid. m.p. 239-241° C.; LC-MS m/z 564 (M+H)⁺, 2.01 min (ret. time).

15c) 3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.056 g, 0.1 mmol) was dissolved in THF (5 mL) and 4-aminopiperidine (0.2 g, 2.0 mmol) was added. The mixture was stirred under argon at room temperature for 17 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (15 g) eluted with 6:1:0.1, CH₂Cl₂: isopropanol:NH₄OH to give the title compound as a white amorphous solid. m.p. (dec) 210-266° C.; LC-MS m/z 584 (M+H)⁺, 1.68 min (ret. time).

Example 16 3-{8-(2,6-Difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.056 g, 0.1 mmol) was dissolved in THF (5 mL) and 4-amino-2,2,6,6-tetramethylpiperidine (0.032 g, 0.2 mmol) was added. The mixture was stirred under argon at room temperature for 17 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (15 g) eluted with 6:0.5:0.05, to 6:1:0.1, CH₂Cl₂: isopropanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 160-165° C.; LC-MS m/z 640 (M+H)⁺, 1.62 min (ret. time).

Example 17 3-{8-(2,6-Difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.050 g, 0.089 mmol) was dissolved in THF (5 mL) and N,N,N′-trimethyl-1,3-propanediamine (0.054 g, 0.44 mmol) was added. The mixture was stirred under argon at room temperature for 3 h. The reaction was not complete, so additional N,N,N′-trimethyl-1,3-propanediamine (0.108 g, 0.88 mmol) was added and the mixture stirred at room temperature for an additional 17 h, followed by heating to 40° C. for 1 h. The solvents were pumped off in vacuo. The residue was taken up in EtOAc washed with 1M NaOH (2×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated. The residue was flash chromatographed on silica gel (20 g) eluted with 6:1:0.05, CH₂Cl₂: isopropanol:NH₄OH to give the title compound as a white amorphous solid. mp 124-127° C.; LC-MS m/z 600 (M+H)⁺, 1.84 min (ret. time).

Example 18 3-(8-(2,6-Difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-phenylmethyl)benzamide, (0.050 g, 0.089 mmol) was dissolved in THF (5 mL) and N,N-dimethylethylenediamine (0.2 g, 2.2 mmol) was added. The mixture was stirred under argon at room temperature for 4 h. The solvents were pumped off in vacuo. The residue was taken up in EtOAc washed with 1M NaOH (2×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated. The residue was flash chromatographed on silica gel (20 g) eluted with 6:1:0.05, CH₂Cl₂: isopropanol: NH₄OH to give the title compound as a white amorphous solid. mp 148-150° C.; LC-MS m/z 572 (M+H)⁺, 1.68 min (ret. time).

Example 19 3-(8-(2,6-Difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide 19a) 1,1-Dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.065 g, 0.115 mmol) was dissolved in THF (5 mL) and 1,1-dimethylethyl (2-aminoethyl)methylcarbamate (0.082 g, 0.46 mmol) was added. The mixture was stirred under argon at room temperature for 16 h. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (20 g) eluted with 0-50% EtOAc/CH₂Cl₂. This material was dissolved in CH₂Cl₂ and the title compound was precipitated as a white amorphous solid. mp 160-163° C.; LC-MS m/z 658 (M+H)⁺, 2.07 min (ret. time).

19b) 3-(8-(2,6-Difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide

The compound 1,1-dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate, (0.036 g, 0.055 mmol) was dissolved in CH₂Cl₂ (4 mL) and stirred under argon at 0° C. Trifluoroacetic acid (1 mL) was added and the mixture stirred under argon at 0° C. for 2 h. The solvents were pumped off in vacuo, and the residue was partitioned between EtOAc and H₂O. The mixture was made basic by the addition of 1M NaOH. The organic phase was washed with H₂O (2×), with brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated. The residue was flash chromatographed on silica gel (10 g) eluted with 6:1:0.05, CH₂Cl₂: isopropanol:NH₄OH to give the title compound as a white amorphous solid. mp 157-161° C.; LC-MS m/z 558 (M+H)⁺, 1.49 min (ret. time).

Example 20 3-[8-(2,6-Difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.060 g, 0.106 mmol) was dissolved in THF (5 mL) and N-isopropylethylenediamine (0.1 g, 0.98 mmol) was added. The mixture was stirred under argon at room temperature for 3 h. The solvents were pumped off in vacuo. The residue was taken up in EtOAc washed with 1M NaOH (1×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated The residue was flash chromatographed on silica gel (10 g) eluted with 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a off-white amorphous solid. mp 133-137° C.; LC-MS m/z 586 (M+H)⁺, 1.5 min (ret. time).

Example 21 3-[8-(2,6-Difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide 21a) 1,1-Dimethylethyl 4-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide (0.08 g, 0.14 mmol) was dissolved in CH₂Cl₂ (5 mL) and 1,1-dimethylethyl 4-amino-1-piperidinecarboxylate (0.0365 g, 0.175 mmol) and triethylamine (0.0284 g, 0.28 mmol) were added. The mixture was stirred under argon at room temperature overnight with only minor product formation. The reaction mixture was then heated to reflux for 24 h. The reaction still was not complete, so additional 1,1-dimethylethyl 4-amino-1-piperidinecarboxylate (0.146 g, 0 7 mmol) was added and the mixture stirred at reflux for 5 days. The solvents were pumped off in vacuo. The residue was taken up in EtOAc washed with 1M NaOH (2×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated The residue was flash chromatographed on silica gel (20 g) eluted with 0-50% EtOAc/CH₂Cl₂ to give the title compound as a white amorphous solid. mp (dec) 167-172° C.; LC-MS m/z 684 (M+H)⁺, 2.13 min (ret. time).

21b) 3-[8-(2,6-Difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 1,1-dimethylethyl 4-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate, (0.052 g, 0.076 mmol) was dissolved in CH₂Cl₂ (4 mL) and stirred under argon at 0° C. Trifluoroacetic acid (1 mL) was added and the mixture stirred under argon at 0° C. for 2 h. The solvents were pumped off in vacuo, and the residue was partitioned between EtOAc and H₂O. The mixture was made basic by the addition of 1 M NaOH. The organic phase was washed with H₂O (2×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated. The residue was flash chromatographed on silica gel (10 g) eluted with 6:2:0.2, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 172-176° C.; LC-MS m/z 584 (M+H)⁺, 1.49 min (ret time).

Example 22 3-[8-(2,6-Difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4′-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide, (0.06 g, 0.106 mmol) was dissolved in CH₂Cl₂ (5 mL) and 4-amino-1-methylpiperidine (0.031 g, 0.265 mmol) was added. The mixture was stirred under argon at room temperature for 16 h with some product formation. The reaction was not complete, so additional 4-amino-1-methylpiperidine (0.031 g, 0.265 mmol) was added and the mixture stirred for an additional 24 h. The reaction still was not complete, and was then heated to reflux for 24 h. The solvents were pumped off in vacuo. The residue was taken up in EtOAc washed with 1M NaOH (2×), brine (1×), dried over anhydrous Na₂SO₄, filtered and evaporated The residue was flash chromatographed on silica gel (20 g) eluted with 6:2:0.2, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp (dec) 152-154° C.; LC-MS m/z 598 (M+H)⁺, 1.62 min (ret. time).

Example 23 N-(3-{8-(2,6-difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide 23a) 3-Fluoro-N-(3-iodo-4-methylphenyl)-4-methylbenzamide

A stirred suspension of 3-fluoro-4-methyl benzoic acid (1.15 g, 7.44 mmol) in CH₂Cl₂ (50 mL) and DMF (2 drops) was cooled to 0° C. under argon and treated with oxalyl chloride (0.71 mL, 8.18 mmol) dropwise. The mixture was warmed to r.t. and stirred for 1 h. In a separate flask, 3-iodo-4-methyl aniline (2.60 g, 11.16 mmol), K₂CO₃ (1.54 g, 8.93 mmol) and pyridine (4 drops) were suspended in CH₂Cl₂ (10 mL). The mixture was cooled to 0° C. under argon and the acid chloride reaction mixture was slowly added. Upon complete addition, the reaction mixture was allowed to warm to room temperature and stirred for 3 days. The resultant solid was filtered off and the reaction mixture was diluted with EtOAc. The organic phase was washed with water, brine, dried (Na₂SO₄), filtered and concentrated in vacuo. Diethyl ether was added and the impurities were filtered off, affording the title compound as a brown solid. ¹H-NMR (400 MHz, d₆-DMSO) δ: 10.24 (1H, s), 8.32 (1H, d), 7.77 (3H, m), 7.46 (1H, t), 7.32 (1H, t), 2.35 (3H, s), 2.32 (3H, s).

23b) Fluoro-4-methyl-N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzamide

The compound 3-fluoro-N-(3-iodo-4-methylphenyl)-4-methylbenzamide (1.10 g, 2.98 mmol), bis(pinacolato)diboron (1.51 g, 5.96 mmol) and potassium acetate (0.90 g, 9.24 mmol) were suspended in DMF (50 mL) and heated to 80° C. under argon. The reaction mixture was degassed with argon for 5 minutes at this temperature and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (0.109 g, 5 mol %) was added. The reaction was maintained at 80° C. for 17 h. Silica gel (15 g) was added and the DMF removed in vacuo. The dry silica gel was added to the top of a flash chromatography column and eluted with EtOAc/hexane (1:9) to yield a white solid which was recrystallised from hexane to afford the title compound as a white solid. LC-MS m/z 370 (M+H)⁺, 2.59 min (ret. time).

23c) N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide

The compound fluoro-4-methyl-N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzamide (0.323 g, 0.875 mmol) and 5-chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (0.2 g, 0.583 mmol) were dissolved in 1,4-dioxane (5 mL) and potassium carbonate (0.322 g, 2.332 mmol) and water (1.2 mL) were added. The mixture was degassed with argon for 10 min. and tetrakis(triphenylphosphine)palladium(0) (0.034 g, 5 mol %) was added. The mixture was heated to 95° C. and maintained at this temperature for 17 h. Most of the dioxane was removed in vacuo and the residue diluted with CH₂Cl₂. The organic phase was washed with water, brine twice, dried over Na₂SO₄, filtered and evaporated to yield the crude residue. Purification was accomplished by flash chromatography on silica gel, eluting with a CH₂Cl₂-2% MeOH/CH₂Cl₂ gradient. The resultant product was triturated with cold diethyl ether to afford the title compound as a white solid. mp 167-173° C.; LC-MS m/z 550 (M+H)⁺, 2.37 min (ret. time).

23d) N-[3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl]-3-fluoro-4-methylbenzamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide, (0.188 g, 0.343 mmol) was suspended in CH₂Cl₂ (5 mL) and DMF (1 mL) and treated with 3-chloroperoxybenzoic acid (50-60%) (0.192 g, 1.133 mmol) under argon. The reaction was stirred at room temperature for 4 h before the solvent was evaporated. The resultant solid was triturated with diethyl ether, filtered, and washed with ether to yield the title compound as a white solid. mp >270° C.; LC-MS m/z 582 (M+H)⁺, 2.12 min (ret. time).

23e) N-(3-{8-(2,6-difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide (0.070 g, 0.107 mmol) was dissolved in DMF (1.5 mL) and treated with 4-amino-2,2,6,6-tetramethylpiperidine (62 ul, 0.361 mmol). Stirring at room temperature and heating to 70° C. under argon produced no reaction so the mixture was microwaved at 200° C. for 15 min. The solvent was removed in vacuo and the crude product was purified by flash chromatography on silica gel, eluting with CH₂C₂₋₁₀% MeOH/CH₂C₂. The product was repurified by the same method to afford the title compound as a white solid. mp (dec) 220° C.; LC-MS m/z 659 (M+H)⁺, 1.94 min (ret. time).

Example 24 N-{3-[2-(4-amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide (0.080 g, 0.137 mmol) and 4-aminopiperidine (0.055 g, 0.551 mmol) were suspended in THF (3 mL) and stirred under argon for 3 days. The completed reaction mixture was diluted with EtOAc and the organic phase washed with water, brine (twice), dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by flash chromatography on silica gel, eluting with 6:0.5:0.05 CH₂Cl₂: EtOH:NH₄OH to afford the title compound as an off-white solid. mp 240° C.; LC-MS m/z 602 (M+H)⁺, 1.79 min (ret. time).

Example 25 N-{3-[8-(2,6-difluorophenyl)-2-(ethyloxy-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide

Dry ethanol (2 mL) was treated with NaH (0.0056 mg, 0.140 mmol, 60% in mineral oil) under argon and stirred for 10 min. The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide (0.064 g, 0.110 mmol) was added in ethanol (2 mL). The reaction was stirred under argon for 1 h and then warmed to 70° C. for 2 h. The reaction mixture was diluted with EtOAc and the organics washed with water, brine (twice), dried over Na₂SO₄, filtered and evaporated. The crude residue was purified by flash chromatography on silica gel, eluting with a CH₂Cl₂-10% EtOAc/CH₂Cl₂ gradient to afford the title compound as a white solid. mp 257.3-262.5° C.; LC-MS m/z 548 (M+H)⁺, 2.37 min (ret. time).

Example 26 N-(3-{8-(2,6-difluorophenyl)-2-[(1-methylethyl)oxy]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide

Dry iso-propanol (2 mL) was treated with NaH (0.00612 g, 0.153 mmol, 60% in mineral oil) under argon and stirred for 10 min. The product of Example 23d, N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide (0.070 g, 0.120 mmol) was added in iso-propanol (2 mL). The reaction was stirred under argon for 1 hour and then warmed to 80° C. for 3 hours. The reaction mixture was diluted with EtOAc and the organics washed with water, brine (twice), dried over Na₂SO₄, filtered and evaporated. The crude residue was purified by flash chromatography on silica gel, eluting with a CH₂Cl₂-10% EtOAc/CH₂Cl₂ gradient to afford the title compound as a white solid. mp 253.5-255.4° C.; LC-MS m/z 562 (M+H)⁺, 2.44 min (ret. time).

Example 27 N-{3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide 27a) 1,1-dimethylethyl 4-{[8-(2,6-difluorophenyl)-4-(5-{[(3-fluoro-4-methylphenyl)carbonyl]amino}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate

The compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide, (0.1 g, 0.172 mmol), 1,1-dimethylethyl 4-amino-1-piperidinecarboxylate (0.11 g, 0.549 mmol) and triethylamine (0.5 mL) were suspended in stirred THF (4 mL) and heated to 60° C. under argon for 4 days. Dioxane (4 mL) was added and the reaction warmed to 85° C. for 2 days and then 95° C. for 1 day. The reaction mixture was diluted with EtOAc and the organics were washed with water, brine (twice), dried over Na₂SO₄, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography on silica gel, eluting with 10% EtOAc/CH₂Cl₂-50% EtOAc/CH₂Cl₂ to afford the title compound as a white solid. LC-MS m/z 702 (M+H)⁺, 2.41 min (ret. time)

27b) N-{3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide

The product of Example 27a (0.07 g, 0.1 mmol) was suspended in CH₂Cl₂ (3 mL) and treated with TFA (2 mL) on ice under argon. The reaction mixture was stirred at 0° C. for 90 min before most of the solvent and TFA were removed in vacuo. The crude residue was basified with NaOH (1M) and extracted with EtOAc. The organics were washed with water, brine (twice), dried over Na₂SO₄, filtered and evaporated. The crude residue was purified by flash chromatography on silica gel, eluting with 6:0.5:0.025 CH₂Cl₂:EtOH:NH₄OH and then by prep HPLC to afford the title compound as a white solid. mp 218-223.5° C.; LC-MS m/z 602 (M+H)⁺, 1.84 min (ret. time).

Example 28 N-{3-[8-(2,6-difluorophenyl)-2-(dimethylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide

To the compound N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide (0.075 g, 0.129 mmol) in THF (4 mL) was added a 1.0 M solution of dimethylamine in THF (0.322 mL, 0.322 mmol). The mixture was stirred under argon for 3 days. The completed reaction mixture was diluted with EtOAc and the organic phase washed with water, brine (2×), dried over Na₂SO₄, filtered and concentrated. The crude residue was purified by flash chromatography on silica gel, eluting with 1% MeOH/CH₂Cl₂ to afford the title compound as a white solid. mp 257.8-264.3° C.; LC-MS m/z 547 (M+H)⁺, 2.24 min (ret. time).

Example 29 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl]-4-methyl-N-propylbenzamide 29a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (1.2 g, 2.71 mmol) in CH₂Cl₂ (60 mL) was added propylamine (0.7 mL, 8.51 mmol), HATU (1.08 g, 2.84 mmol) and diisopropyl ethyl amine (1.2 mL, 6.9 mmol). The reaction mixture was stirred overnight. The reaction mixture was diluted with CH₂Cl₂ (50 mL) and water (50 mL) and shaken. The layers were separated and the organic layer was washed with brine (75 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (load column with DCM, mobile phase EtOAc/Hexane) then provided the title compound as a white solid 1.10 g (84%). LC-MS m/z 484 (M+H)⁺.

29b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (600 mg, 1.24 mmol) in CH₂Cl₂ (15 mL) was added m-CPBA (293 mg, 1.31 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. CombiFlash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as a white solid 475 mg (77%). LC-MS m/z 500 (M+H)⁺.

29c) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (430 mg, 0.86 mmol) in CH₂Cl₂ (25 mL) was added NAN-diethyl-1,3-propanediamine (0.272 mL, 1.73 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM [90]+MeOH [7]+NH₄OH [3]) provided the title compound as a white solid (452 mg, 93%). LC-MS m/z 566 (M+H)⁺; ¹H-NMR (MeOD) 1.00 (m, 9H), 1.54 (m, 2H), 1.65 (m, 2H), 2.30 (s, 3H), 2.36 (m, 2H), 2.50 (m, 4H), 3.08 (s, 2H), 3.37 (m, 2H), 4.11 (s, 2H), 7.15 (m, 2H), 7.50 (m, 2H), 7.69 (s, 1H), 7.85 (t, 1H).

29d) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

Methyl t-butyl ether (MTBE) (21.2 mL) was added to partially crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free base (0.847 g). The resulting slurry was temperature-cycled with stirring from 10-40° C. overnight. The product was filtered, washed with MTBE, and dried overnight in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 88.8% (0.753 g) of crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free-base with a melting onset at 179° C. (determined by DSC).

29e) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

Acetonitrile (140 mL) was added to partially crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free base (0.867 g). The resulting mixture was temperature-cycled with stirring from 10-40° C. overnight at room temperature. The product was filtered, washed with acetonitrile, and dried overnight in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 89.2% (0.773 g) of crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free base with a melting onset at 176° C. (determined by DSC).

29f) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide hydrochloride salt

Acetone (451 uL) was added to the partially crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free-base (25.2 mg). Hydrochloric acid was added (1.1 equivalents; IM in 1,4-dioxane), and the resulting mixture was temperature-cycled from 0-40° C. for a minimum of 48 hours. The product was filtered and dried in vacuo at room temperature. Yielded 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide HCl salt with a melting onset at 259° C. (determined by DSC).

29g) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide hemi-sulfate salt

Ethanol (3.5 mL) was added to the crystalline 3-[2-{[3-(diethylamino)-propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free-base (229.5 mg), and the resulting mixture was heated to 50° C. Sulfuric acid was added (1.0 equivalents; 1M in THF). The mixture was cooled to room temperature and stirred for several hours. The product was filtered, washed with ethanol, and dried in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 30.7% (82.7 mg) of 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide hemi-sulfate (2 molecules of free base, 1 molecule of H₂SO₄) salt with a melting onset at 218° C. (determined by DSC).

29h) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide fumarate salt

Acetone with 5% water (12.2 mL) was added to the crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide free-base (0.608 g) and solid fumaric acid (1.0 equivalents; 124.8 mg). The resulting mixture was heated to 50° C. for one hour. The mixture was cooled to room temperature and stirred for 30 minutes. The product was filtered, washed with acetone with 5% water, and dried overnight in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 85.4% (0.626 g) of 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide fumarate salt. Examination by PLM showed that the batch may contain amorphous content. Acetone with 10% water (12.9 mL) was added to the fumarate salt, and the resulting mixture stirred several hours at room temperature. The product was filtered, washed with acetone with 10% water, and dried overnight in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 51.3% (0.376 g) of 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide fumarate salt with a melting onset at 192° C. (determined by DSC).

29i) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide phosphate salt

Acetone (845 uL) was added to the crystalline 3-[2-{[3-(diethylamino)propyl]-amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide-free-base (46.9 mg), and the resulting mixture was heated to 50° C. Phosphoric acid was added (1.0 equivalents; IM in methanol). Additional methanol (5 uL) was added to the resulting oily mixture to increase solubility slightly. The mixture was cooled to room temperature and stirred overnight. The product was filtered and dried for at least one hour in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 67.1% (36.9 mg) of partially crystalline 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide phosphate salt.

29j) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide ethanedisulfonate salt

Acetonitrile (450 uL) was added to the crystalline 3-[2-{[3-(diethylamino)propyl]-amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide fee-base (25.0 mg), and the resulting mixture was heated to 50° C. Ethanedisulfonic acid was added (1.1 equivalents; 1M in methanol). The mixture was cooled to room temperature and stirred several hours. The product was filtered and dried for at least one hour in a vacuum oven at 50° C. with a slow nitrogen bleed. The yield was 62.0% (20.7 mg) of 3-[2-{[3-(diethylamino)-propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide ethanedisulfontate salt hydrate with a melting onset at <100° C. (determined by DSC).

Example 30 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 30a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (2.0 g, 4.56 mmol) in CH₂Cl₂ (200 mL) were added 4-fluoroaniline (0.472 mL, 4.99 mmol), HATU (1.82 g, 4.79 mmol) and diisopropyl ethyl amine (2.0 mL, 11.5 mmol). The reaction mixture was stirred over night, diluted with CH₂Cl₂ (50 mL) and water (50 mL). The layers were separated. The organic layer was washed with brine (75 mL), collected, dried over Na₂SO₄, filtered and concentrated. Flash chromatography then provided the title compound as a white solid 2.7 g (89%). LC-MS m/z 536 (M+H)⁺.

30b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of the title compound from Example 30a (850 mg, 1.59 mmol) in CH₂Cl₂ (50 mL) was added m-CPBA (375 mg, 1.67 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. CombiFlash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as a white solid 660 mg (75%). LC-MS m/z 552 (M+H)⁺.

30c) 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of the title compound from Example 30b (30 mg, 0.051 mmol) in THF (3 mL) and DMF (0.5 mL) were added N-(1-methylethyl)-1,2-ethanediamine (0.019 mL, 0.153 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (13 mg, 43%). LC-MS m/z 588 (M+H)⁺; ¹H-NMR (MeOD) a 1.00 (d, 6H), 2.34 (s, 3H), 2.70 (m, 3H), 3.20 (m, 2H), 4.11 (s, 2H), 7.10 (m, 4H), 7.52 (m, 2H), 7.77 (m, 2H), 7.81 (s, 1H), 7.97 (d, 1H).

Example 31 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide 31a) 1,1-dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(5-{[(4-fluorophenyl)amino]carbonyl}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-9-(4-fluorophenyl)-4-methylbenzamide (30 mg, 0.051 mmol) in THF (3 mL) and DMF (1 mL) were added 1,1-dimethylethyl (2-aminoethyl)methylcarbamate (0.046 mL, 0.26 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (20 mg, 59%). LC-MS m/z 662 (M+H)⁺.

31 b) 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of 1,1-dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(5-{[(4-fluorophenyl)amino]carbonyl}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate (20 mg, 0.030 mmol) in DCM (5 mL) was added TFA (0.06 mL). The reaction mixture was stirred at room temperature overnight, quenched with triethylamine (0.2 mL) at −78° C. The residue was mixed with H₂O (5.0 mL). The organic layer was separated and the aqueous layer was extracted with DCM (3×15 mL). The combined organic phases were washed with saturated aq. NaCl, dried over Na₂SO₄, filtered, and concentrated. Purification via a CombiFlash system (90% CH₂Cl₂/7% MeOH/3% NH₄OH) then afforded the title compound (11 mg, 65%). LC-MS (ES) m/z 562 (M+H)⁺; ¹H-NMR (MeOD) δ 2.27 (s, 3H), 2.34 (s, 3H), 2.57 (m, 2H), 3.26 (m, 2H), 4.11 (s, 2H), 7.15 (m, 4H), 7.52 (m, 2H), 7.71 (m, 2H), 7.82 (s, 1H), 7.97 (d, 1H).

Example 32 3-{8-(2,6-difluorophenyl)-2-[[2-(dimethylamino)ethyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (40 mg, 0.073 mmol) in THF (3 mL) and DMF (0.5 mL) were added N,N,N′-trimethyl-1,2-ethanediamine (0.047 mL, 0.364 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (11 mg, 26%). LC-MS m/z 590 (M+H)⁺; ¹H-NMR (MeOD) δ 2.18 (s, 6H), 2.40 (m, 5H), 3.02 (m, 3H), 3.50 (m, 2H), 4.17 (s, 2H), 7.15 (m, 4H), 7.52 (m, 2H), 7.71 (m, 2H), 7.82 (s, 1H), 7.97 (d, 1H).

Example 33 3-{8-(2,6-difluorophenyl)-2-[4-(methylamino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl-4-methylbenzamide 33a) 1,1-dimethylethyl {1-[8-(2,6-difluorophenyl)-4-(5-{[(4-fluorophenyl)amino]carbonyl}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}methylcarbamate

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (40 mg, 0.073 mmol) in THF (3 mL) and DMF (0.5 mL) were added 1,1-dimethylethyl methyl(4-piperidinyl)carbamate (49 mg, 0.229 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Flash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (12 mg, 25%). LC-MS m/z 702 (M+H)⁺.

33b) 3-{8-(2,6-difluorophenyl)-2-[4-(methylamino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of 1,1-dimethylethyl {1-[8-(2,6-difluorophenyl)-4-(5-{[(4-fluorophenyl)amino]carbonyl}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}methylcarbamate (12 mg, 0.017 mmol) in DCM (3 mL) was added TFA (0.04 mL). The reaction mixture was stirred at room temperature overnight, quenched with triethylamine (0.2 mL) at −78° C. The residue was mixed with H₂O (5.0 mL). The organic layer was separated and the aqueous layer was extracted with DCM (3×15 mL). The combined organic phases were washed with saturated aq. NaCl, dried over Na₂SO₄, filtered, and concentrated. Purification via a CombiFlash system (90% CH₂Cl₂/7% MeOH/3% NH₄OH) then afforded the title compound (9 mg, 87%). LC-MS (ES) m/z 602 (M+H)⁺; ¹H-NMR (MeOD) δ 1.18 (m, 2H), 1.81 (d, 2H), 2.34 (s, 3H), 2.37 (s, 3H), 2.58 (m, 1H), 2.78 (t, 2H), 4.11 (s, 2H), 4.40 (m, 2H), 7.15 (m, 4H), 7.52 (m, 2H), 7.70 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 34 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide 34a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (150 mg, 0.34 mmol) in CH₂Cl₂ (10 mL) were added isopropylamine (0.087 mL, 1.02 mmol), HATU (135 mg, 0.355 mmol) and diisopropyl ethyl amine (0.2 mL, 1.15 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (50 mL) and water (50 mL) and shaked. The layers were separated and the organic layer was washed with brine (75 mL), dried over Na₂SO₄, filtered and concentrated. Flash chromatography then provided the title compound as a white solid 160 g (97%). LC-MS m/z 484 (M+H)⁺.

34b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of the title compound from Example 34a (160 mg, 0.33 mmol) in CH₂Cl₂ (15 mL) was added m-CPBA (78 mg, 0.35 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. CombiFlash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as a white solid 150 mg (91%). LC-MS m/z 500 (M+H)⁺.

34c) 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of the title compound from Example 34a (1.33 g, 2.75 mmol) in CH₂Cl₂ (130 mL) was added m-CPBA (678 mg, 3.03 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. Flash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as the minor product as a white solid 270 mg (19%). LC-MS m/z 516 (M+H)⁺.

34d) 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of the title compound from Example 34b (30 mg, 0.06 mmol) in THF (3 mL) were added N,N,N′-trimethyl-1,3-propanediamine (0.044 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (22 mg, 66%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (m, 6H), 1.62 (m, 2H), 2.03 (m, 2H), 2.19 (s, 6H), 2.32 (s, 3H), 3.00 (s, 3H), 3.33 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.17 (t, 2H), 7.44 (d, 1H), 7.54 (m, 1H), 7.69 (s, 1H), 7.86 (d, 1H).

Example 35 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methyl ethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (30 mg, 0.06 mmol) in THF (3 mL) was added N-(1-methylethyl)-1,2-ethanediamine (0.019 mL, 0.15 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH [7]+NH₄OH[3]) provided the title compound as a white solid (23 mg, 71%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (d, 3H), 1.27 (d, 3H), 2.30 (s, 3H), 2.58 (m, 2H), 2.70 (m, 1H), 3.25 (m, 2H), 4.07 (s, 2H), 4.23 (m, 1H), 7.16 (m, 2H), 7.44 (d, 1H), 7.50 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 36 3-{8-(2,6-difluorophenyl)-2-[[2-(dimethylamino)ethyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added N,N,N′-trimethyl-1,2-ethanediamine (0.026 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (21 mg, 97%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.11 (s, 6H), 2.37 (s, 3H), 2.41 (m, 2H), 3.02 (m, 3H), 3.50 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.16 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 37 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added N,N-dimethyl-1,2-ethanediamine (0.022 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH [7]+NH₄OH[3]) provided the title compound as a white solid (20 mg, 95%). LC-MS m/z 524 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.14 (s, 6H), 2.33 (s, 3H), 2.37 (m, 2H), 3.22 (m, 2H), 4.09 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 38 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide 38a) 1,1-dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(1-methylethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added 1,1-dimethylethyl (2-aminoethyl)methylcarbamate (0.036 mL, 0.20 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (118 mg, 74%). LC-MS m/z 610 (M+H)⁺.

38b) 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide

To a solution of 1,1-dimethylethyl (2-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(1-methylethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate (18 mg, 0.030 mmol) in DCM (5 mL) was added TFA (0.05 mL). The reaction mixture was stirred at room temperature overnight, quenched with triethylamine (0.2 mL) at −78° C. The residue was mixed with H₂O (5.0 mL). The organic layer was separated and the aqueous layer was extracted with DCM (3×15 mL). The combined organic phases were washed with saturated aq. NaCl, dried over Na₂SO₄, filtered, and concentrated. Purification via a CombiFlash system (90% CH₂Cl₂/7% MeOH/3% NH₄OH) then afforded the title compound (11 mg, 73%). LC-MS (ES) m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.26 (s, 3H), 2.30 (s, 3H), 2.56 (m, 2H), 3.22 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 39 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (10 mg, 0.018 mmol) in THF (5 mL) were added 1-methyl-4-piperidinamine (10 mg, 0.088 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (9 mg, 83%). LC-MS m/z 602 (M+H)⁺; ¹H-NMR (MeOD) δ 1.47 (m, 2H), 1.84 (m, 4H), 2.24 (s, 3H), 2.33 (s, 3H), 2.79 (m, 2H), 3.20 (m, 1H), 4.13 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 40 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added N,N-dimethyl-1,3-propanediamine (0.023 mL, 0.18 mmol). The resultant solution was stirred at room temperature over night. The result mixture was then concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (21 mg, 97%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.58 (m, 2H), 2.19 (s, 6H), 2.20 (m, 2H), 2.30 (s, 3H), 3.15 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 41 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (18 mg, 0.04 mmol) in THF (3 mL) was added N,N-diethyl-1,3-propanediamine (0.028 mL, 0.18 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (17 mg, 83%). LC-MS m/z 566 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 6H), 1.27 (d, 6H), 1.55 (m, 2H), 2.30 (s, 3H), 2.40 (m, 2H), 2.52 (m, 4H), 3.07 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 42 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (10 mg, 0.018 mmol) in THF (3 mL) was added N,N-dimethyl-1,3-propanediamine (0.012 mL, 0.096 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (9 mg, 84%). LC-MS m/z 590 (M+H)⁺; ¹H-NMR (MeOD) δ 1.58 (m, 2H), 2.19 (s, 6H), 2.24 (m, 2H), 2.34 (s, 3H), 3.10 (m, 2H), 4.11 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 43 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (20 mg, 0.036 mmol) in THF (3 mL) was added N,N-diethyl-1,3-propanediamine (0.030 mL, 0.19 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (14 mg, 62%). LC-MS m/z 619 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 6H), 1.55 (m, 2H), 2.38 (s, 3H), 2.55 (m, 6H), 3.10 (m, 2H), 4.11 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 44 3-{8-(2,6-difluorophenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-4-fluorophenyl)-4-methyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (20 mg, 0.036 mmol) in THF (3 mL)/DMF (3 mL)/DCM (3 mL) were added (1H-imidazol-2-ylmethyl)amine dihydrochloride (50 mg, 0.52 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at 40° C. over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (7 mg, 33%). LC-MS m/z 585 (M+H)⁺; ¹H-NMR (MeOD) δ 2.33 (s, 3H), 4.13 (s, 2H), 4.42 (s, 2H), 6.92 (m, 2H), 7.15 (m, 4H), 7.50 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 45 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (20 mg, 0.036 mmol) in THF (3 mL) was added N,N-dibutyl-1,3-propanediamine (0.041 mL, 0.182 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (16 mg, 66%). LC-MS m/z 674 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 6H), 1.30 (m, 4H), 1.40 (m, 4H), 1.50 (m, 2H), 2.34 (s, 3H), 2.43 (m, 6H), 3.10 (m, 2H), 4.13 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 46 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (20 mg, 0.036 mmol) in THF (3 mL) was added N-(1-methylethyl)-1,3-propanediamine (0.025 mL, 0.179 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (14 mg, 64%). LC-MS m/z 604 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (d, 6H), 1.65 (m, 2H), 2.34 (s, 3H), 2.50 (m, 2H), 2.78 (m, 1H), 3.15 (m, 2H), 4.13 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 47 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-methylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (20 mg, 0.036 mmol) in THF (3 mL) was added N-(1,1-dimethylethyl)-1,3-propanediamine (0.028 mL, 0.177 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (18 mg, 80%). LC-MS m/z 618 (M+H)⁺; ¹H-NMR (MeOD) δ 1.11 (s, 9H), 1.58 (m, 2H), 2.34 (s, 3H), 2.48 (m, 2H), 3.15 (m, 2H), 4.13 (s, 2H), 7.15 (m, 4H), 7.53 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 48 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) were added N,N-dibutyl-1,3-propanediamine (0.041 mL, 0.182 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (24 mg, 96%). LC-MS m/z 622 (M+H)⁺; ¹H-NMR (MeOD) δ 0.98 (t, 6H), 1.30 (m, 10H), 1.46 (m, 4H), 1.52 (m, 2H), 2.30 (s, 3H), 2.41 (m, 6H), 3.07 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 49 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added N-(1-methylethyl)-1,3-propanediamine (0.025 mL, 0.179 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (15 mg, 68%). LC-MS m/z 554 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (d, 6H), 1.27 (d, 6H), 1.60 (m, 2H), 2.31 (s, 3H), 2.50 (m, 2H), 2.75 (m, 1H), 3.15 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 50 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) were added N-(1,1-dimethylethyl)-1,3-propanediamine (0.028 mL, 0.177 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (17 mg, 75%). LC-MS m/z 566 (M+H)⁺; ¹H-NMR (MeOD) δ 1.11 (s, 9H), 1.27 (d, 6H), 1.60 (m, 2H), 2.31 (s, 3H), 2.45 (m, 2H), 3.15 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 51 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) was added 1-methyl-4-piperidinamine (20 mg, 0.176 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (18 mg, 82%). LC-MS m/z 550 (M+H)⁺; ¹H-NMR (MeOD) δ 1.26 (d, 6H), 1.48 (m, 2H), 1.88 (m, 4H), 2.24 (s, 3H), 2.29 (s, 3H), 2.75 (m, 2H), 3.18 (m, 1H), 4.09 (s, 2H), 4.23 (m, 1H), 7.15 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 52 3-{8-(2,6-difluorophenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in THF (3 mL) were added (1H-imidazol-2-ylmethyl)amine dihydrochloride (50 mg, 0.52 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.574 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (7 mg, 33%). LC-MS m/z 533 (M+H)⁺; ¹H-NMR (MeOD) δ 1.26 (d, 6H), 2.26 (s, 3H), 4.12 (s, 2H), 4.23 (m, 1H), 4.36 (s, 2H), 6.88 (s, 2H), 7.10 (t, 2H), 7.48 (m, 2H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 53 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (20 mg, 0.04 mmol) in DCM (5 mL) was added N,N,N′-trimethyl-1,3-propanediamine (0.029 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (16 mg, 72%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.66 (m, 4H), 2.03 (m, 2H), 2.19 (s, 6H), 2.32 (s, 3H), 2.98 (s, 3H), 3.37 (m, 4H), 4.15 (s, 2H), 7.17 (t, 2H), 7.45 (d, 1H), 7.53 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 54 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N,N-dimethyl-1,3-propanediamine (0.036 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (25 mg, 77%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.58 (m, 2H), 1.66 (m, 2H), 2.16 (m, 2H), 2.18 (s, 6H), 2.30 (s, 3H), 3.06 (m, 2H), 3.37 (m, 2H), 4.10 (s, 2H), 7.17 (t, 2H), 7.45 (d, 1H), 7.53 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 55 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N,N-dimethyl-1,3-propanediamine (0.033 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (31 mg, 98%). LC-MS m/z 524 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.66 (m, 2H), 2.13 (s, 6H), 2.38 (s, 3H), 2.83 (m, 2H), 3.20 (m, 2H), 3.37 (m, 2H), 4.11 (s, 2H), 7.15 (t, 2H), 7.45 (d, 1H), 7.53 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 56 3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-phenyl-1-piperazinyl)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(l methylethyl)benzamidetrifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added 1-phenylpiperazine (0.031 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA, then provided the title compound as a white solid (14 mg, 59%). LC-MS m/z 598 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.33 (s, 3H), 3.40 (m, 4H), 3.87 (m, 4H), 4.11 (s, 2H), 4.23 (m, 1H), 7.17 (m, 2H), 7.29 (d, 2H), 7.44 (m, 2H), 7.49 (m, 1H), 7.53 (m, 1H), 7.72 (s, 1H), 7.87 (d, 1H).

Example 57 3-[2-(1,4′-bipiperidin-1′-yl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (150 mg, 0.30 mmol) in DCM (10 mL) was added 1,4′-bipiperidine (152 mg, 0.90 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (35 mg, 19%). LC-MS m/z 604 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.37 (m, 2H), 1.51 (m, 2H), 1.65 (m, 4H), 1.81 (m, 2H), 2.33 (s, 3H), 2.63 (m, 5H), 2.70 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 4.50 (m, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 58 3-[8-(2,6-difluorophenyl)-2-[3-(1-ethylpropyl)-1-imidazolidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamidetrifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (30 mg, 0.06 mmol) in THF (1 mL)/CHCl₃ (1 mL) were added 1-(1-ethylpropyl)imidazolidine (17 mg, 0.12 mmol) and N,N-diisopropylethylamine (0.6 mL, 3.0 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Gilson with TFA provided the title compound as a white solid (18 mg, 52%). LC-MS m/z 578 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.32 (t, 6H), 2.12 (m, 1H), 2.31 (s, 3H), 2.46 (m, 1H), 3.23 (m, 4H), 3.50 (m, 4H), 4.09 (m, 1H), 4.11 (s, 2H), 4.23 (m, 1H), 4.50 (m, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 59 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)-2,2-dimethylpropyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added N,N,2,2-tetramethyl-1,3-propanediamine (0.032 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Gilson with TFA provided the title compound as a white solid (5 mg, 22%). LC-MS m/z 566 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (s, 6H), 1.27 (d, 6H), 2.35 (s, 3H), 2.67 (s, 6H), 2.95 (m, 2H), 3.21 (m, 2H), 4.20 (s, 2H), 4.23 (m, 1H), 7.18 (t, 2H), 7.52 (m, 2H), 7.77 (s, 1H), 7.89 (d, 1H).

Example 60 3-{8-(2,6-difluorophenyl)-7-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (80 mg, 0.16 mmol) in DCM (5 mL) was added 4-(1-pyrrolidinyl)piperidine (74 mg, 0.48 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (75 mg, 79%). LC-MS m/z 590 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.34 (m, 2H), 1.83 (m, 4H), 1.90 (m, 2H), 2.31 (s, 3H), 2.40 (m, 1H), 2.68 (m, 4H), 2.77 (m, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 4.44 (m, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 61 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (60 mg, 0.12 mmol) in DCM (5 mL) was added 1-methylpiperazine (0.04 mL, 0.36 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (58 mg, 90%). LC-MS m/z 536 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.25 (s, 3H), 2.31 (s, 3H), 2.36 (m, 4H), 3.57 (m, 4H), 4.11 (s, 2H), 4.23 (m, 1H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 62 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N-(1-methylethyl)-1,2-ethanediamine (0.037 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (15 mg, 46%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (m, 9H), 1.65 (m, 2H), 2.31 (s, 3H), 2.61 (m, 2H), 2.73 (m, 2H), 3.20 (m, 2H), 3.40 (m, 1H), 4.11 (s, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.86 (d, 1H).

Example 63 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N-(1-methylethyl)-1,3-propanediamine (0.042 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (13 mg, 39%). LC-MS m/z 554 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (m, 9H), 1.65 (m, 4H), 2.31 (s, 3H), 2.50 (m, 2H), 2.78 (m, 2H), 3.16 (m, 2H), 3.43 (m, 1H), 4.11 (s, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.86 (d, 1H).

Example 64 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N,N-dibutyl-1,3-propanediamine (0.06 mL, 0.26 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (30 mg, 83%). LC-MS m/z 622 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (m, 10H), 1.30 (m, 4H), 1.50 (m, 9H), 2.31 (s, 3H), 2.38 (m, 4H), 2.48 (m, 2H), 3.08 (m, 2H), 4.11 (s, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.86 (d, 1H).

Example 65 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (30 mg, 0.06 mmol) in DCM (5 mL) was added N-(1,1-dimethylethyl)-1,3-propanediamine (0.042 mL, 0.26 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (27 mg, 80%). LC-MS m/z 622 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (m, 12H), 1.12 (m, 2H), 1.56 (m, 2H), 1.70 (m, 2H), 2.31 (s, 3H), 2.48 (m, 2H), 3.12 (m, 2H), 4.11 (s, 2H), 7.17 (t, 2H), 7.46 (d, 1H), 7.52 (m, 1H), 7.69 (s, 1H), 7.86 (d, 1H).

Example 66 3-[8-(2,6-difluorophenyl)-2-(hexahydro-1H-azepin-1-yl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (50 mg, 0.10 mmol) in DCM (5 mL) was added hexahydro-1H-azepine (0.034 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (39 mg, 73%). LC-MS m/z 535 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.47 (m, 6H), 1.70 (m, 2H), 2.31 (s, 3H), 3.32 (m, 2H), 3.68 (m, 2H), 4.11 (m, 2H), 4.23 (m, 1H), 7.13 (t, 2H), 7.44 (d, 1H), 7.48 (m, 1H), 7.69 (s, 1H), 7.85 (d, 1H).

Example 67 3-[8-(2,6-difluorophenyl)-7-oxo-2-(1-pyrrolidinyl)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (50 mg, 0.10 mmol) in DCM (5 mL) was added pyrrolidine (0.025 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (34 mg, 67%). LC-MS m/z 507 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.87 (m, 4H), 2.31 (s, 3H), 3.33 (m, 4H), 4.11 (m, 2H), 4.23 (m, 1H), 7.13 (t, 2H), 7.44 (d, 1H), 7.48 (m, 1H), 7.70 (s, 1H), 7.85 (d, 1H).

Example 68 3-[8-(2,6-difluorophenyl)-2-(4-morpholinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (50 mg, 0.10 mmol) in DCM (5 mL) was added morpholine (0.026 mL, 0.30 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Gilson with TFA provided the title compound as a white solid (40 mg, 76%). LC-MS m/z 523 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.30 (s, 3H), 3.33 (m, 4H), 3.52 (m, 4H), 4.18 (s, 2H), 4.23 (m, 1H), 7.16 (t, 2H), 7.46 (d, 1H), 7.50 (m, 1H), 7.71 (s, 1H), 7.85 (d, 1H).

Example 69 3-{8-(2,6-difluorophenyl)-2-[3-(dimethylamino)-1-pyrrolidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)-benzamide (30 mg, 0.06 mmol) in THF (1 mL)/CHCl₃ (1 mL) were added N,N-dimethyl-3-pyrrolidinamine (14 mg, 0.12 mmol) and N,N-diisopropylethylamine (0.6 mL, 3.0 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (25 mg, 76%). LC-MS m/z 550 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.75 (m, 1H), 2.15 (m, 1H), 2.24 (s, 6H), 2.30 (s, 3H), 2.79 (m, 1H), 3.15 (m, 2H), 3.45 (m, 1H), 3.71 (m, 1H), 4.11 (s, 2H), 4.23 (m, 1H), 7.16 (t, 2H), 7.46 (d, 1H), 7.50 (m, 1H), 7.70 (s, 1H), 7.85 (d, 1H).

Example 70 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1,4′-bipiperidin-1′-yl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added 4-methyl-1,4′-bipiperidine (40 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (31 mg, 70%). LC-MS m/z 618 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (d, 3H), 1.22 (m, 2H), 1.27 (d, 6H), 1.38 (m, 3H), 1.68 (d, 2H), 1.81 (d, 2H), 2.19 (t, 2H), 2.30 (s, 3H), 2.50 (t, 1H), 2.71 (t, 2H), 2.93 (d, 2H), 4.11 (s, 2H), 4.23 (m, 1H), 4.45 (m, 2H), 7.16 (t, 2H), 7.46 (d, 1H), 7.50 (m, 1H), 7.68 (s, 1H), 7.85 (d, 1H).

Example 71 3-{8-(2,6-difluorophenyl)-2-[4-(4-morpholinyl)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added 4-(4-piperidinyl)morpholine (37 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (41 mg, 94%). LC-MS m/z 607 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.33 (m, 2H), 1.83 (d, 2H), 2.30 (s, 3H), 2.38 (m, 1H), 2.55 (m, 4H), 2.75 (t, 2H), 3.33 (m, 1H), 3.68 (m, 3H), 4.11 (s, 2H), 4.23 (m, 1H), 4.45 (m, 2H), 7.16 (t, 2H), 7.46 (d, 1H), 7.50 (m, 1H), 7.68 (s, 1H), 7.85 (d, 1H).

Example 72 3-{8-(2,6-difluorophenyl)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added 1-methyl-4-(4-piperidinyl)piperazine (40 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (38 mg, 85%). LC-MS m/z 619 (M+H)⁺; 1H-NMR (MeOD) δ 1.27 (d, 6H), 1.33 (m, 2H), 1.83 (d, 2H), 2.28 (s, 3H), 2.30 (s, 3H), 2.65 (m, 11H), 4.11 (m, 2H), 4.23 (m, 1H), 4.45 (m, 2H), 7.16 (t, 2H), 7.46 (d, 1H), 7.50 (m, 1H), 7.68 (s, 1H), 7.85 (d, 1H).

Example 73 3-[2-[4-(5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added 5-chloro-1-(4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one (51 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. HPLC with TFA separation provided the title compound as a white solid (44 mg, 89%). LC-MS m/z 688 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.75 (d, 2H), 2.00 (m, 2H), 2.86 (m, 2H), 2.36 (s, 3H), 3.00 (d, 2H), 4.18 (m, 2H), 4.23 (m, 1H), 4.46 (m, 1H), 4.54 (m, 2H), 7.06 (m, 2H), 7.16 (m, 3H), 7.50 (m, 2H), 7.74 (s, 1H), 7.88 (d, 1H).

Example 74 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[2-(2-pyridinyl)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamidetrifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added [2-(2-pyridinyl)ethyl]amine (0.026 mL, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. HPLC with TFA, separation then provided the title compound as a white solid (40 mg, 98%). LC-MS m/z 568 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.30 (s, 3H), 3.15 (m, 2H), 3.65 (m, 2H), 4.13 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.51 (m, 2H), 7.68 (m, 2H), 7.90 (m, 2H), 8.46 (m, 1H), 8.67 (m, 1H).

Example 75 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide (26 mg, 0.047 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added 1-methylpiperazine (0.017 mL, 0.15 mmol) and N,N-diisopropylethylamine (0.03 mL, 0.015 mmol). The resultant solution was stirred at 50° C. over night. The result mixture was concentrated. Separation via a HPLC, with TFA then provided the title compound as a white solid (13 mg, 47%). LC-MS m/z 588 (M+H)⁺; ¹H-NMR (MeOD) δ2.34 (s, 3H), 2.91 (s, 3H), 3.11 (m, 2H), 3.15 (m, 2H), 3.45 (m, 2H), 4.23 (m, 2H), 4.54 (m, 2H), 7.15 (m, 4H), 7.55 (m, 2H), 7.71 (m, 2H), 7.82 (s, 1H), 8.00 (d, 1H).

Example 76 3-(8-(2,6-difluorophenyl)-2-{[(1-ethyl-2-pyrrolidinyl)methyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methyl ethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (36 mg, 0.072 mmol) in THF (2 mL)/CHCl₃ (2 mL) were added [(1-ethyl-2-pyrrolidinyl)methyl]amine (27.7 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Purification via a HPLC with TFA then provided the title compound as a white solid (30 mg, 74%). LC-MS m/z 564 (M+H)⁺; ¹H-NMR (MeOD) δ 0.85 (m, 3H), 1.27 (d, 6H), 1.93 (m, 2H), 2.06 (m, 2H), 2.35 (s, 3H), 2.88 (m, 1H), 3.08 (m, 1H), 3.28 (m, 1H), 3.45 (m, 2H), 3.51 (m, 2H), 4.13 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.51 (m, 2H), 7.74 (s, 1H), 7.90 (d, 1H).

Example 77 3-[2-(1,4′-bipiperidin-1′-yl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (17 mg, 0.034 mmol) in DCM (2 mL) was added 1,4′-bipiperidine (16 mg, 0.10 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (13 mg, 63%). LC-MS m/z 604 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.50 (m, 4H), 1.68 (m, 6H), 1.92 (m, 2H), 2.31 (s, 3H), 2.73 (m, 2H), 2.90 (m, 5H), 3.37 (m, 2H), 4.16 (m, 2H), 4.52 (m, 2H), 7.16 (m, 2H), 7.46 (m, 1H), 7.51 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 78 3-{8-(2,6-difluorophenyl)-7-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (17 mg, 0.034 mmol) in DCM (2 mL) was added 4-(1-pyrrolidinyl)piperidine (15 mg, 0.10 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (11 mg, 55%). LC-MS m/z 592 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.34 (m, 2H), 1.68 (m, 3H), 1.90 (m, 5H), 2.31 (s, 3H), 2.36 (m, 1H), 2.68 (m, 6 H), 3.37 (m, 2H), 4.11 (m, 2H), 4.42 (m, 2H), 7.16 (m, 2H), 7.46 (m, 1H), 7.51 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 79 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-l]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (17 mg, 0.034 mmol) in DCM (2 mL) was added 1-methylpiperazine (0.011 mL, 0.10 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (11 mg, 60%). LC-MS m/z 536 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.66 (m, 2H), 2.28 (s, 3H), 2.31 (s, 3H), 2.42 (m, 4H), 3.37 (m, 2H), 3.57 (m, 4H), 4.13 (m, 2H), 7.16 (m, 2H), 7.46 (m, 1H), 7.51 (m, 1H), 7.68 (s, 1H), 7.86 (d, 1H).

Example 80 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[2-(1-pyrrolidinyl)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added [2-(1-pyrrolidinyl)ethyl]amine (0.025 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA provided the title compound as a white solid (10 mg, 45%). LC-MS m/z 550 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.70 (m, 2H), 2.04 (m, 2H), 2.31 (s, 3H), 2.91 (m, 2H), 3.26 (m, 2H), 3.53 (m, 4H), 4.16 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.48 (m, 1H), 7.54 (m, 1H), 7.71 (s, 1H), 7.86 (d, 1H).

Example 81 3-(8-(2,6-difluorophenyl)-2-{[2-(4-morpholinyl)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added [2-(4-morpholinyl)ethyl]amine (0.026 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (11 mg, 49%). LC-MS m/z 566 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.33 (s, 3H), 3.14 (m, 2H), 3.22 (m, 3H), 3.58 (m, 5H), 3.90 (m, 2H), 4.16 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.50 (m, 1H), 7.54 (m, 1H), 7.74 (s, 1H), 7.88 (d, 1H).

Example 82 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[3-(2-oxo-1-pyrrolidinyl)propyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added 1-(3-aminopropyl)-2-pyrrolidinone (0.028 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (10 mg, 43%). LC-MS m/z 578 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.66 (m, 2H), 2.05 (m, 2H), 2.35 (m, 2H), 2.39 (s, 3H), 3.16 (m, 4H), 3.40 (m, 2H), 4.16 (m, 2H), 4.23 (m, 1H), 7.22 (m, 2H), 7.55 (m, 1H), 7.62 (m, 1H), 7.83 (s, 1H), 7.95 (d, 1H).

Example 83 3-(8-(2,6-difluorophenyl)-2-{[3-(4-morpholinyl)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added [3-(4-morpholinyl)propyl]amine (0.029 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (10 mg, 43%). LC-MS m/z 580 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 1.87 (m, 2H), 2.33 (s, 3H), 3.14 (m, 4H), 3.30 (m, 2H), 3.39 (m, 2H), 3.68 (m, 2H), 4.01 (m, 2H), 4.16 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.48 (m, 1H), 7.55 (m, 1H), 7.72 (s, 1H), 7.89 (d, 1H).

Example 84 3-{8-(2,6-difluorophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added 1-(diphenylmethyl)piperazine (50 mg, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (13 mg, 47%). LC-MS m/z 688 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.28 (s, 3H), 3.17 (m, 5H), 3.70 (m, 3H), 4.18 (m, 2H), 4.23 (m, 1H), 5.39 (m, 1H), 7.13 (m, 2H), 7.45 (m, 8H), 7.59 (m, 4H), 7.66 (s, 1H), 7.85 (d, 1H).

Example 85 3-[2-{[4-(diethylamino)-1-methylbutyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To a solution of compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in DCM (2 mL) was added N¹,N¹-diethyl-1,4-pentanediamine (0.039 mL, 0.20 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (7 mg, 29%). LC-MS m/z 594 (M+H)⁺; ¹H-NMR (MeOD) δ 1.10 (d, 3H), 1.27 (m, 12H), 1.51 (m, 2H), 1.65 (m, 2H), 2.34 (s, 3H), 3.02 (m, 2H), 3.17 (m, 4H), 3.38 (m, 1H), 4.16 (m, 2H), 4.23 (m, 1H), 7.18 (m, 2H), 7.48 (m, 1H), 7.54 (m, 1H), 7.72 (s, 1H), 7.89 (d, 1H).

Example 86 3-{8-(2,6-difluorophenyl)-7-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide 86a) 5-chloro-1-(2,6-difluorophenyl)-7-(methylsulfinyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (1.71 g, 5 mmol) in CH₂Cl₂ (60 mL) was added m-CPBA (1.17 g, 5.2 mmol). The mixture was stirred at room temperature for 10 minutes, then directly loaded onto a column. Flash chromatography (mobile phase EtOAc/Hexane) afforded the title compound as a white solid 1.58 g (88%). LC-MS m/z 358 (M+H)⁺.

86b) 5-chloro-1-(2,6-difluorophenyl)-7-[4-(1-pyrrolidinyl)-1-piperidinyl]-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one

To a solution of the title compound from Example 86a (250 mg, 0.70 mmol) in DCM (10 mL) were added 4-(1-pyrrolidinyl)piperidine (323 mg, 2.1 mmol) and N,N-diisopropylethylamine (0.3 mL, 1.7 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (253 mg, 81%). LC-MS m/z 449 (M+H)⁺.

86c) 3-{8-(2,6-difluorophenyl)-7-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of the title compound from Example 86b (18 mg, 0.04 mmol) in dioxane (1.5 mL)/water (0.5 mL) were added potassium carbonate (34 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium(0) (2.3 mg, 0.002 mmol) and N-(4-fluorophenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (22 mg, 0.062 mmol). The reaction mixture was bubbled with N₂ for 5 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (14 mg, 54%). LC-MS m/z 642 (M+H)⁺; ¹H-NMR (MeOD) δ 1.32 (m, 2H), 1.80 (m, 4H), 1.88 (m, 2H), 2.24 (m, 1H), 2.33 (s, 3H), 2.62 (m, 4H), 2.74 (t, 2H), 4.17 (m, 2H), 4.40 (m, 2H), 7.12 (m, 4H), 7.52 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 87 3-[2-(1,4′-bipiperidin-1′-yl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 87a) 7-(1,4′-bipiperidin-1′-yl)-5-chloro-1-(2,6-difluorophenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H-one

To a solution of 5-chloro-1-(2,6-difluorophenyl)-7-(methylsulfinyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (200 mg, 0.56 mmol) in DCM (10 mL) were added 1,4′-bipiperidine (270 mg, 1.61 mmol) and N,N-diisopropylethylamine (0.3 mL, 1.7 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (298 mg, 83%). LC-MS m/z 463 (M+H)⁺.

87b) 3-[2-(1,4′-bipiperidin-1′-yl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide

To a solution of compound 7-(1,4′-bipiperidin-1′-yl)-5-chloro-1-(2,6-difluorophenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (18 mg, 0.04 mmol) in dioxane (1.5 mL)/water (0.5 mL) were added potassium carbonate (34 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium(0) (2.3 mg, 0.002 mmol) and N-(4-fluorophenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (22 mg, 0.062 mmol). The reaction mixture was bubbled with N₂ for 5 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH [7]+NH₄OH[3]) provided the title compound as a white solid (13 mg, 51%). LC-MS m/z 656 (M+H)⁺; ¹H-NMR (MeOD) δ 1.37 (m, 2H), 1.48 (m, 2H), 1.60 (m, 4H), 1.80 (m, 2H), 2.33 (s, 3H), 2.56 (m, 5H), 2.72 (t, 2H), 4.17 (m, 2H), 4.46 (m, 2H), 7.12 (m, 4H), 7.52 (m, 2H), 7.72 (m, 2H), 7.82 (s, 1H), 7.98 (d, 1H).

Example 88 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(1-methylethyl)benzamide 88a) 5-chloro-1-(2,6-difluorophenyl)-7-{[2-(dimethylamino)ethyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one

To a solution of 5-chloro-1-(2,6-difluorophenyl)-7-(methylsulfinyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (800 mg, 2.23 mmol) in DCM (45 mL) were added N,N-dimethylethylenediamine (0.36 mL, 3.23 mmol) and triethylamine (0.63 mL, 4.5 mmol). The resultant solution was stirred at room temperature over night. The result mixture was concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) provided the title compound as a white solid (730 mg, 85%). LC-MS m/z 383 (M+H)⁺.

88b) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid

To a solution of the title compound from Example 88a (100 mg, 0.26 mmol) in dioxane (9 mL)/water (3 mL) were added potassium carbonate (217 mg, 1.57 mmol), tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.013 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (65 mg, 0.39 mmol). The reaction mixture was bubbled with N₂ for 5 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. To the concentrated mixture were added DMSO (2 mL), H₂O (0.5 mL) and AcOH (0.05 mL). Separation via a HPLC then provided the title compound as a white solid (120 mg, 98%). LC-MS m/z 469 (M+H)⁺.

88c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(1-methylethyl)benzamide

To the solution of the title compound from Example 88b (23 mg, 0.05 mmol) in CH₂Cl₂ (3 mL) were added isopropylamine (0.005 mL, 0.055 mmol), HATU (20 mg, 0.052 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol), The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (20 mg, 80%). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.16 (s, 6H), 2.36 (m, 2H), 3.28 (m, 2H), 4.23 (m, 1H), 4.46 (m, 2H), 7.14 (m, 2H), 7.49 (m, 1H), 7.61 (m, 1H), 7.72 (m, 1H), 7.96 (d, 1H), 8.00 (s, 1H).

Example 89 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (23 mg, 0.05 mmol) in CH₂Cl₂ (3 mL) were added ammonia (2.0 M soln. in isopropanol, 0.0275 mL, 0.055 mmol), HATU (20 mg, 0.052 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (6 mg, 26%). LC-MS m/z 468 (M+H)⁺; ¹H-NMR (MeOD) δ 2.16 (s, 6H), 2.36 (m, 2H), 3.20 (m, 2H), 4.46 (s, 2H), 7.14 (m, 2H), 7.49 (m, 1H), 7.61 (m, 1H), 7.75 (m, 1H), 8.00 (d, 1H), 8.07 (s, 1H).

Example 90 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-dimethylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (23 mg, 0.05 mmol) in CH₂Cl₂ (3 mL) were added dimethylamine (2.0 M soln. in THF, 0.0275 mL, 0.055 mmol), HATU (20 mg, 0.052 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (10 mg, 41%). LC-MS m/z 496 (M+H)⁺; ¹H-NMR (MeOD) δ 2.15 (s, 6H), 2.36 (m, 2H), 3.15 (s, 3H), 3.06 (s, 3H), 3.23 (m, 2H), 4.46 (s, 2H), 7.14 (m, 2H), 7.12 (m, 1H), 7.56 (m, 4H).

Example 91 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl-N-phenylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (23 mg, 0.05 mmol) in CH₂Cl₂ (3 mL) were added aniline (0.005 mL, 0.055 mmol), HATU (20 mg, 0.052 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (15 mg, 56%). LC-MS m/z 544 (M+H)⁺; ¹H-NMR (MeOD) δ 2.43 (s, 6H), 2.70 (m, 2H), 3.48 (m, 2H), 4.52 (s, 2H), 7.17 (m, 3H), 7.39 (m, 2H), 7.52 (m, 1H), 7.69 (m, 3H), 7.79 (d, 1H), 8.08 (d, 1H), 8.15 (s, 1H).

Example 92 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-1,3-thiazol-2-ylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added 1,3-thiazol-2-amine (3.5 mg, 0.035 mmol), HATU (13 mg, 0.034 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (7 mg, 40%). LC-MS m/z 551 (M+H)⁺; ¹H-NMR (MeOD) δ 2.22 (s, 6H), 2.46 (m, 2H), 3.16 (m, 2H), 4.51 (s, 2H), 7.17 (m, 3H), 7.51 (m, 2H), 7.69 (m, 1H), 7.83 (d, 1H), 8.16 (d, 1H), 8.23 (s, 1H).

Example 93 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl benzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added 4-fluoroaniline (0.003 mL, 0.035 mmol), HATU (13 mg, 0.034 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (13 mg, 72%). LC-MS m/z 562 (M+H)⁺; ¹H-NMR (MeOD) δ 2.81 (s, 6H), 3.21 (m, 2H), 3.59 (m, 2H), 4.53 (s, 2H), 7.17 (m, 4H), 7.53 (m, 1H), 7.72 (m, 3H), 7.80 (d, 1H), 8.10 (d, 1H), 8.16 (s, 1H).

Example 94 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-methylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added methylamine (2.0 M soln. in THF, 0.018 mL, 0.036 mmol), HATU (13 mg, 0.034 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (10 mg, 65%). LC-MS m/z 482 (M+H)⁺; ¹H-NMR (MeOD) δ 2.16 (s, 6H), 2.38 (m, 2H), 2.96 (s, 3H), 3.22 (m, 2H), 4.45 (s, 2H), 7.16 (m, 2H), 7.50 (m, 1H), 7.64 (m, 1H), 7.74 (d, 1H), 7.95 (d, 1H), 8.00 (s, 1H).

Example 95 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-propylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added propylamine (0.003 mL, 0.035 mmol), HATU (13 mg, 0.034 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (5 mg, 31%). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 1.00 (t, 3H), 1.67 (m, 2H), 2.80 (s, 6H), 3.25 (m, 2H), 3.40 (m, 2H), 3.62 (m, 2H), 4.52 (s, 2H), 7.19 (m, 1H), 7.53 (m, 1H), 7.65 (m, 1H), 7.76 (d, 1H), 7.98 (d, 1H), 8.05 (s, 1H).

Example 96 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-1,3-thiazol-2-ylbenzamide 96a) 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid

To a solution of 5-chloro-1-(2,6-difluorophenyl)-7-{[2-(dimethylamino)ethyl]-amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (150 mg, 0.39 mmol) in dioxane (12 mL)/water (4 mL) were added potassium carbonate (325 mg, 2.36 mmol), tetrakis(triphenylphosphine)palladium(0) (23 mg, 0.019 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (146 mg, 0.59 mmol). The reaction mixture was bubbled with N₂ for 5 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. To the concentrated mixture were added DMSO (2 mL), H₂O (0.5 mL) and AcOH (0.05 mL). Separation via a HPLC then provided the title compound as a white solid (142 mg, 77%). LC-MS m/z 469 (M+H)⁺.

96b) 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-1,3-thiazol-2-ylbenzamide

To the solution of the title compound from Example 96a (15 mg, 0.03 mmol) in DMF (3 mL) were added 1,3-thiazol-2-amine (3.5 mg, 0.035 mmol), HATU (13 mg, 0.035 mmol) and diisopropyl ethyl amine (0.05 mL, 0.3 mmol). The reaction mixture was stirred over night. The reaction mixture was diluted with CH₂Cl₂ (5 mL) and water (5 mL) and shaked. The layers were separated and the organic layer was washed with brine (8 mL), dried over Na₂SO₄, filtered and concentrated. CombiFlash chromatography (mobile phase DCM/DCM[90]+MeOH[7]+NH₄OH[3]) then provided the title compound as a white solid (7 mg, 40%). LC-MS m/z 551 (M+H)⁺; ¹H-NMR (MeOD) δ 2.83 (s, 6H), 3.15 (m, 2H), 3.51 (m, 2H), 4.52 (s, 2H), 7.17 (m, 3H), 7.53 (m, 2H), 7.77 (m, 2H), 8.19 (m, 2H).

Example 97 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(1-methylethyl)benzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added isopropylamine (0.0085 mL, 0.1 mmol) and HATU (13 mg, 0.035 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (5 mg, 31%). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 1.29 (d, 6H), 2.79 (s, 6H), 3.22 (m, 2H), 3.59 (m, 2H), 4.26 (m, 1H), 4.50 (s, 2H), 7.17 (m, 2H), 7.54 (m, 1H), 7.67 (m, 2H), 7.99 (m, 2H).

Example 98 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-propylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added propylamine (0.0082 mL, 0.1 mmol) and HATU (13 mg, 0.035 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (5 mg, 31%). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 1.02 (t, 3H), 1.68 (m, 2H), 2.79 (s, 6H), 3.22 (m, 2H), 3.59 (m, 2H), 4.50 (s, 2H), 7.17 (m, 2H), 7.54 (m, 1H), 7.68 (m, 2H), 7.99 (m, 2H).

Example 99 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl)-N-phenylbenzamide trifluoroacetate

To the solution of -(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added aniline (0.0091 mL, 0.1 mmol) and HATU (13 mg, 0.035 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (7 mg, 40%). LC-MS m/z 544 (M+H)⁺; ¹H-NMR (MeOD) δ 2.80 (s, 6H), 3.21 (m, 2H), 3.59 (m, 2H), 4.53 (s, 2H), 7.18 (m, 3H), 7.40 (m, 2H), 7.52 (m, 1H), 7.72 (m, 4H), 8.12 (m, 2H).

Example 100 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)benzamide trifluoroacetate

To the solution of -(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (15 mg, 0.03 mmol) in CH₂Cl₂ (3 mL) were added 4-fluoroaniline (0.0096 mL, 0.1 mmol) and HATU (13 mg, 0.035 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (7 mg, 39%). LC-MS m/z 562 (M+H)⁺; ¹H-NMR (MeOD) δ 2.80 (s, 6H), 3.19 (m, 2H), 3.59 (m, 2H), 4.53 (s, 2H), 7.17 (m, 4H), 7.52 (m, 1H), 7.72 (m, 4H), 8.12 (m, 2H).

Example 101 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-dimethylbenzamide trifluoroacetate

To the solution of -(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (20 mg, 0.043 mmol) in CH₂Cl₂ (2 mL) were added dimethylamine (2.0 M soln. in THF, 0.064 mL, 0.13 mmol) and HATU (17.2 mg, 0.045 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (18 mg, 85%). LC-MS m/z 496 (M+H)⁺; ¹H-NMR (MeOD) δ 2.79 (s, 6H), 3.06 (s, 3H), 3.16 (s, 3H), 3.22 (m, 2H), 3.58 (m, 2H), 4.50 (s, 2H), 7.17 (m, 2H), 7.54 (m, 1H), 7.61 (m, 2H), 7.71 (m, 2H).

Example 102 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-methylbenzamide trifluoroacetate

To the solution of -(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (20 mg, 0.043 mmol) in CH₂Cl₂ (2 mL) were added methylamine (2.0 M soln. in THF, 0.064 mL, 0.13 mmol) and HATU (17.2 mg, 0.045 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (3 mg, 15%). LC-MS m/z 482 (M+H)⁺; ¹H-NMR (MeOD) δ 2.79 (s, 6H), 2.98 (s, 3H), 3.26 (m, 2H), 3.59 (m, 2H), 4.50 (s, 2H), 7.17 (m, 2H), 7.53 (m, 1H), 7.68 (m, 2H), 7.99 (m, 2H).

Example 103 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzamide trifluoroacetate

To the solution of -(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid (20 mg, 0.043 mmol) in CH₂Cl₂ (2 mL) were added ammonia (2.0 M soln. in propanol, 0.064 mL, 0.13 mmol) and HATU (17.2 mg, 0.045 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (18 mg, 90%). LC-MS m/z 468 (M+H)⁺; ¹H-NMR (MeOD) δ 2.79 (s, 6H), 3.18 (m, 2H), 3.58 (m, 2H), 4.50 (s, 2H), 7.17 (m, 2H), 7.53 (m, 1H), 7.71 (m, 2H), 8.05 (m, 2H).

Example 104 4-(8-(2,6-difluorophenyl-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-(1-methyl ethyl)benzamide trifluoroacetate 104a) 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid

To a solution of 4-iodo-3-methylbenzoic acid (520 mg, 2.0 mmol) in DMF (8 mL) were added palladium acetate (23 mg, 0.10 mmol), potassium acetate (590 mg, 6.0 mmol) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane (560 mg, 2.2 mmol). The reaction mixture was microwaved at 150° C. for 30 mins. The reaction mixture was poured into water (25 mL), extracted with ethylacetate (100 mL) while acetic acid (1 mL) was added. The organic layer was washed with water (50 mL), brine (50 mL), dried with sodium sulfate, filtered and concentrated. The residue was separated by combiflash which provided the title compound as a white solid (460 mg, 88%). LC-MS m/z 263 (M+H)⁺.

104b) 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid

To a solution of 5-chloro-1-(2,6-difluorophenyl)-7-{[2-(dimethylamino)ethyl]-amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (200 mg, 0.52 mmol) in dioxane (15 mL)/water (5 mL) were added potassium carbonate (433 mg, 3.14 mmol), tetrakis(triphenylphosphine)palladium(0) (31 mg, 0.027 mmol) and 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (205 mg, 0.78 mmol). The reaction mixture was bubbled with N₂ for 10 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. To the concentrated mixture were added DMSO (2 mL), H₂O (0.5 mL) and AcOH (0.05 mL). Gilson with TFA provided the title compound as a white solid (310 mg, 99%). LC-MS m/z 483 (M+H)⁺.

104c) 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-(1-methylethyl)benzamide trifluoroacetate

To the solution of the title compound from Example 104b (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added isopropylamine (0.022 mL, 0.25 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (17 mg, 63%). LC-MS m/z 524 (M+H)⁺; ¹H-NMR (MeOD) δ 1.29 (d, 6H), 2.34 (s, 3H), 2.76 (s, 6H), 3.16 (m, 2H), 3.55 (m, 2H), 4.15 (s, 2H), 4.25 (m, 1H), 7.21 (m, 2H), 7.36 (m, 1H), 7.55 (m, 1H), 7.78 (d, 1H), 7.84 (s, 1H).

Example 105 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-propylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added propylamine (0.021 mL, 0.25 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (7 mg, 26%). LC-MS m/z 524 (M+H)⁺; ¹H-NMR (MeOD) δ 1.01 (t, 3H), 1.67 (m, 2H), 2.33 (s, 3H), 2.76 (s, 6H), 3.16 (m, 2H), 3.55 (m, 2H), 4.15 (s, 2H), 7.18 (m, 2H), 7.36 (m, 1H), 7.55 (m, 1H), 7.78 (d, 1H), 7.84 (s, 1H).

Example 106 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-l]pyrimidin-4-yl)-3-methyl-N-phenylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added aniline (0.024 mL, 0.25 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (23 mg, 79%). LC-MS m/z 558 (M+H)⁺; ¹H-NMR (MeOD) δ 2.38 (s, 3H), 2.77 (s, 6H), 3.16 (m, 2H), 3.55 (m, 2H), 4.17 (s, 2H), 7.21 (m, 3H), 7.42 (m, 3H), 7.55 (m, 1H), 7.72 (m, 2H), 7.89 (m, 1H), 7.97 (s, 1H).

Example 107 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-3-methylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino-}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added 4-fluoroaniline (0.025 mL, 0.25 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (22 mg, 74%). LC-MS m/z 576 (M+H)⁺; ¹H-NMR (MeOD) δ 2.37 (s, 3H), 2.77 (s, 6H), 3.16 (m, 2H), 3.55 (m, 2H), 4.17 (s, 2H), 7.16 (m, 4H), 7.42 (m, 1H), 7.55 (m, 1H), 7.72 (m, 2H), 7.89 (m, 1H), 7.97 (s, 1H).

Example 108 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N,3-trimethylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added dimethylamine (2.0 M soln. in THF, 0.13 mL, 0.26 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (19 mg, 72%). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 2.32 (s, 3H), 2.77 (s, 6H), 3.06 (s, 3H), 3.15 (m, 5H), 3.55 (m, 2H), 4.17 (s, 2H), 7.19 (m, 2H), 7.37 (m, 2H), 7.46 (s, 1H), 7.55 (m, 1H).

Example 109 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,3-dimethylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added methylamine (2.0 M soln. in THF, 0.13 mL, 0.26 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (3 mg, 12%). LC-MS m/z 496 (M+H)⁺; ¹H-NMR (MeOD) δ 2.33 (s, 3H), 2.76 (s, 6H), 2.96 (s, 3H), 3.15 (m, 2H), 3.55 (m, 2H), 4.15 (s, 2H), 7.18 (m, 2H), 7.36 (m, 1H), 7.55 (m, 1H), 7.76 (m, 1H), 7.83 (s, 1H).

Example 110 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzamide trifluoroacetate

To the solution of 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid (25 mg, 0.052 mmol) in CH₂Cl₂ (2 mL) were added ammonia (2.0 M soln. in propanol, 0.13 mL, 0.26 mmol) and HBTU (21 mg, 0.055 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA then provided the title compound as a white solid (15 mg, 60%). LC-MS m/z 482 (M+H)⁺; ¹H-NMR (MeOD) δ 2.33 (s, 3H), 2.76 (s, 6H), 3.15 (m, 2H), 3.55 (m, 2H), 4.15 (s, 2H), 7.19 (m, 2H), 7.36 (m, 1H), 7.55 (m, 1H), 7.84 (m, 1H), 7.91 (s, 1H).

Example 111 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methyl-N-(1-methylethyl)benzamide 111a) 1,1-dimethylethyl 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoate

To a solution of 5-chloro-1-(2,6-difluorophenyl)-7-{[2-(dimethylamino)ethyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (200 mg, 0.52 mmol) in dioxane (15 mL)/water (5 mL) were added potassium carbonate (433 mg, 3.14 mmol), tetrakis(triphenylphosphine)palladium(0) (31 mg, 0.027 mmol) and (5-{[(1,1-dimethylethyl)oxy]carbonyl}-3-fluoro-2-methylphenyl)boronic acid (159 mg, 0.63 mmol). The reaction mixture was bubbled with N₂ for 10 mins, then microwaved at 150° C. for 30 mins. The reaction mixture was concentrated. To the concentrated mixture were added DMSO (2 mL), H₂O (0.5 mL) and AcOH (0.05 mL). Separation via a HPLC then provided the title compound as a white solid (270 mg, 88%). LC-MS m/z 587 (M+H)⁺.

111b) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,78-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoic acid

To a solution of the title compound from Example 111a (260 mg, 0.45 mmol) in CH₂Cl₂ (1 mL) were added TFA (0.45 mL, 5.84 mmol) and triethylsilane (0.18 mL, 1.12 mmol). The reaction mixture was stirred overnight. The reaction mixture was concentrated. Separation via a HPLC then provided the title compound as a white solid (260 mg, 96%). LC-MS m/z 501 (M+H)⁺.

111c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methyl-N-(1-methylethyl)benzamide

To the solution of the title compound from Example 111b (25 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) were added isopropylamine (0.021 mL, 0.25 mmol) and HBTU (20 mg, 0.053 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (9 mg, 33%). LC-MS m/z 542 (M+H)⁺; ¹H-NMR (MeOD) δ 1.27 (d, 6H), 2.40 (s, 3H), 2.78 (s, 6H), 3.15 (m, 2H), 3.55 (m, 2H), 4.22 (m, 3H), 7.18 (m, 2H), 7.57 (m, 2H), 7.71 (m, 1H).

Example 112 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methyl-N-phenylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoic acid (25 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) were added aniline (0.025 mL, 0.25 mmol) and HBTU (20 mg, 0.053 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (10 mg, 35%). LC-MS m/z 576 (M+H)⁺; ¹H-NMR (MeOD) δ 2.27 (s, 3H), 2.79 (s, 6H), 3.15 (m, 2H), 3.55 (m, 2H), 4.21 (s, 2H), 7.19 (m, 3H), 7.39 (m, 2H), 7.54 (m, 1H), 7.71 (m, 3H), 7.86 (m, 1H).

Example 113 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-N,N,4-trimethylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoic acid (25 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) were added dimethylamine (2.0 M soln. in THF, 0.13 mL, 0.26 mmol), triethylamine (0.05 mL, 0.36 mmol) and HBTU (20 mg, 0.053 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (15 mg, 57%). LC-MS m/z 528 (M+H)⁺; ¹H-NMR (MeOD) δ 2.23 (s, 3H), 2.78 (s, 6H), 3.06 (s, 3H), 3.15 (m, 5H), 3.55 (m, 2H), 4.22 (s, 2H), 7.19 (m, 3H), 7.34 (m, 1H), 7.56 (m, 1H).

Example 114 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-N,4-dimethylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoic acid (25 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) were added methylamine (2.0 M soln. in THF, 0.13 mL, 0.26 mmol), triethylamine (0.05 mL, 0.36 mmol) and HBTU (20 mg, 0.053 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (14 mg, 54%). LC-MS m/z 514 (M+H)⁺; ¹H-NMR (MeOD) δ 2.24 (s, 3H), 2.78 (s, 6H), 2.94 (s, 3H), 3.15 (m, 2H), 3.55 (m, 2H), 4.22 (s, 2H), 7.18 (m, 2H), 7.56 (m, 2H), 7.39 (m, 1H).

Example 115 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-N-(4-fluorophenyl)-4-methylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-5-fluoro-4-methylbenzoic acid (25 mg, 0.05 mmol) in CH₂Cl₂ (2 mL) were added 4-fluoroaniline (0.025 mL, 0.25 mmol), triethylamine (0.05 mL, 0.36 mmol) and HBTU (20 mg, 0.053 mmol). The reaction mixture was stirred over night. The reaction mixture was concentrated. Separation via a HPLC with TFA followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (26 mg, 88%). LC-MS m/z 594 (M+H)⁺; ¹H-NMR (MeOD) δ 2.27 (s, 3H), 2.79 (s, 6H), 3.16 (m, 2H), 3.55 (m, 2H), 4.21 (s, 2H), 7.15 (m, 4H), 7.54 (m, 1H), 7.71 (m, 3H), 7.85 (m, 1H).

Example 116 3-{8-(2,6-difluorophenyl)-2-[{3-[[3-(dimethylamino)propyl]-(methyl)amino]propyl}(methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide

To a solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide (20 mg, 0.04 mmol) in CH₂Cl₂ (1 mL) were added N-[3-(dimethylamino)propyl]N,N′-dimethyl-1,3-propanediamine (0.004 mL, 0.02 mmol) and triethylamine (0.05 mL, 0.36 mmol). The resultant solution was stirred at room temperature over night. The reaction mixture was concentrated. Separation via a HPLC followed by treatment with t-amino SPE cartridge then provided the title compound as a white solid (7 mg, 29%). LC-MS m/z 609 (M+H)⁺; ¹H-NMR (MeOD) δ 1.29 (d, 6H), 1.95 (m, 4H), 2.33 (s, 3H), 2.75 (s, 3H), 2.78 (s, 3H), 2.92 (s, 3H), 3.17 (m, 6H), 3.50 (m, 2H), 4.15 (s, 2H), 4.23 (m, 1H), 7.19 (m, 2H), 7.48 (d, 1H), 7.55 (m, 1H), 7.71 (s, 1H), 7.86 (d, 1H).

Example 117 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzoic acid

To the solution of 5-chloro-1-(2,6-difluorophenyl)-7-{[2-(dimethylamino)ethyl]amino}-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (191 mg, 0.50 mmol) in dioxane (15 mL) and water (5 mL) were added 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (197 mg, 0.75 mmol), K₂CO₃ (415 mg, 3.0 mmol) and tetrakis(triphenyl-phosphine)palladium(0) (23 mg, 0.025 mmol). The reaction mixture was heated to 150° C. for 15 minutes with microwave. The reaction mixture was concentrated to dry then was added DMSO (2 mL), water (0.5 mL) and HOAc (1 drop). The solution was filtered and applied to the reverse phase HPLC to afford the titled compound 0.24 g (quantitative). LC-MS m/z 483 (M+H)⁺; ¹H-NMR (MeOD) 2.36 (s, 3H), 2.76 (s, 6H), 3.16 (s, 2H), 3.56 (s, 2H), 4.13 (s, 2H), 7.21 (m, 1H), 7.53 (m, 2H), 7.95 (s, 1H), 8.09 (d, J=7.6 Hz, 1H).

Example 118 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide 118a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (1.41 g, 3.19 mmol) in DMF (50 mL) was added 2-aminothiazole (479 mg, 4.78 mmol), HBTU (1.33 g, 3.51 mmol) and Et₃N (0.90 mL, 6.38 mmol). The reaction mixture was stirred at room temperature for 18 hours before was concentrated and applied to flash chromatography to afford the titled compound 0.99 g (60%). LC-MS m/z 525 (M+H)⁺.

118) 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide (262 mg, 0.50 mmol) in dichloromethane (10 mL) was added mCPBA (116 mg, 0.75 mmol). The reaction mixture was stirred at room temperature for 10 minutes. Then the reaction mixture was applied to flash chromatography to afford the titled compound 256 mg (95%). LC-MS m/z 541 (M+H)⁺.

118c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide

To the solution of 3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide (30 mg, 0.055 mmol) in dichloromethane (3.0 mL) were added NAN-dimethyl-1,2-ethanediamine (12.2 μL, 0.11 mmol) and triethylamine (15.6 μL, 0.11 mmol). The reaction mixture was stirred at room temperature for 16 hours then was concentrated, redissolved in DMSO (0.5 mL), filtered and applied to the reverse phase HPLC to afford the titled compound 16.9 mg (54%). LC-MS m/z 565 (M+H)⁺; ¹H-NMR (MeOD) 2.20 (s, 3H), 2.33 (m, 7H), 2.81 (s, 2H), 3.26 (m, 1H), 4.13 (m, 1H), 4.43 (s, 1H), 7.17 (m, 3H), 7.50 (m, 3H), 8.01 (m, 2H).

Example 119 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N,N,N′-trimethyl-1,3-propanediamine was used in the displacement (yield: 86%). LC-MS m/z 579 (M+H)⁺; ¹H-NMR (MeOD) 1.83 (m, 2H), 2.37 (s, 3H), 2.78 (s, 6H), 3.02 (s, br, 2H), 3.27 (m, 2H), 4.17 (m, 2H), 7.19 (m, 3H), 7.55 (m, 3H), 7.92 (s, 1H), 8.08 (m, 1H).

Example 120 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N,N-diethyl-1,3-propanediamine was used in the displacement (yield: 64%). LC-MS m/z 607 (M+H)⁺; ¹H-NMR (MeOD) 1.14 (t, J=7.6 Hz, 6H), 1.70 (m, 2H), 2.34 (s, 3H), 2.76 (m, 2H), 2.90 (m, 4H), 3.18 (m, 2H), 4.11 (m, 2H), 7.18 (m, 3H), 7.53 (m, 3H), 7.89 (s, 1H), 8.04 (d, J=7.2 Hz, 1H).

Example 121 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N,N-dibutyl-1,3-propanediamine was used in the displacement (yield: 99%). LC-MS m/z 663 (M+H)⁺; ¹H-NMR (MeOD) 0.97 (m, 6H), 1.38 (m, 4H), 1.59 (m, 4H), 1.81 (m, 2H), 2.35 (s, 3H), 3.05 (m, 6H), 3.23 (m, 2H), 4.11 (m, 2H), 7.18 (m, 3H), 7.53 (m, 3H), 7.89 (s, 1H), 8.05 (d, J=7.6 Hz, 1H).

Example 122 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N-(1-methylethyl)-1,2-ethanediamine was used in the displacement (yield: 31%). LC-MS m/z 579 (M+H)⁺; ¹H-NMR (MeOD) 1.16 (d, J=6.4 Hz, 6H), 2.37 (s, 3H), 3.02 (s, 2H), 3.21 (m, 1H), 3.46 (m, 2H), 4.19 (m, 2H), 7.18 (m, 3H), 7.53 (d, J=3.6 Hz, 2H), 7.59 (d, J=8.4 Hz, 1H), 7.92 (s, 1H), 8.08 (m, 1H).

Example 123 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N-(1-methylethyl)-1,3-propanediamine was used in the displacement (yield: 71%). LC-MS m/z 593 (M+H)⁺; ¹H-NMR (MeOD) 1.23 (m, 6H), 1.78 (m, 2H), 2.36 (s, 3H), 2.91 (s, 2H), 3.27 (m, 3H), 4.15 (m, 2H), 7.18 (m, 3H), 7.53 (d, J=3.6 Hz, 2H), 7.56 (d, J=8.4 Hz, 1H), 7.91 (s, 1H), 8.08 (m, 1H).

Example 124 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except N,N,N′-trimethyl-1,3-propanediamine was used in the displacement (yield: 35%). LC-MS m/z 593 (M+H)⁺; ¹H-NMR (MeOD) 1.62 (m, 2H), 2.09 (m, 3H), 2.20 (s, 6H), 2.36 (s, 3H), 2.98 (m, 3H), 3.38 (m, 1H), 4.17 (m, 2H), 7.17 (m, 3H), 7.53 (m, 3H), 7.92 (s, 1H), 8.05 (d, J=8.0 Hz, 1H).

Example 125 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(2,2-dimethylpropyl)-4-methylbenzamide

To the solution of 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzoic acid (30 mg, 0.062 mmol) in dichloromethane (2.0 mL) and DMF (0.5 mL) were added (2,2-dimethylpropyl)amine (10.9 μL, 0.093 mmol), HBTU (25.6 mg, 0.068 mmol) and triethylamine (35.0 μL, 0.25 mmol). The reaction mixture was stirred at room temperature for 16 hours then was applied to HPLC to afford the titled compound 14.9 mg (44%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) 0.99 (s, 9H), 2.33 (s, 3H), 2.76 (s, 6H), 3.15 (s, 2H), 3.24 (s, 2H), 3.54 (m, 2H), 4.16 (m, 2H), 7.18 (m, 2H), 7.51 (m, 2H), 7.72 (s, 1H), 7.89 (m, 1H).

Example 126 Methyl 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzoate

The title compound was prepared by following the procedure in Example 125 except methanol was used in the coupling reaction (yield: 44%). LC-MS m/z 497 (M+H)⁺; ¹H-NMR (MeOD) 2.34 (s, 3H), 2.76 (s, 6H), 3.15 (s, 2H), 3.54 (m, 2H), 3.93 (s, 3H), 4.12 (m, 2H), 7.18 (m, 2H), 7.52 (m, 2H), 7.89 (s, 1H), 8.04 (m, 1H).

Example 127 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(methylthio)-phenyl]benzamide

The title compound was prepared by following the procedure in Example 125 except [4-(methylthio)phenyl]amine was used in the coupling reaction (yield: 36%). LC-MS m/z 604 (M+H)⁺; ¹H-NMR (MeOD) 2.24 (s, 6H), 2.35 (s, 3H), 2.49 (m, 5H), 3.26 (m, 1H), 3.37 (m, 1H), 4.16 (m, 2H), 7.15 (t, J=8.4 Hz, 2H), 7.30 (d, J=8.8 Hz, 2H), 7.53 (m, 2H), 7.66 (d, J=8.8 Hz, 2H), 7.82 (s, 1H), 7.98 (m, 1H).

Example 128 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide

The title compound was prepared by following the procedure in Example 125 except (2R)-1-amino-2-propanol was used in the coupling reaction (yield: 15%). LC-MS m/z 540 (M+H)⁺; ¹H-NMR (MeOD) 1.22 (d, J=6.4 Hz, 3H), 2.32 (s, 3H), 2.51 (m, 6H), 2.83 (s, 2H), 3.43 (m, 4H), 3.97 (m, 1H), 4.14 (m, 2H), 7.15 (t, J=8.4 Hz, 2H), 7.53 (m, 2H), 7.72 (s, 1H), 7.88 (m, 1H).

Example 129 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide

The title compound was prepared by following the procedure in Example 125 except (2S)-1-amino-2-propanol was used in the coupling reaction (yield: 37%). LC-MS m/z 540 (M+H)⁺; ¹H-NMR (MeOD) 1.22 (d, J=6.4 Hz, 3H), 2.32 (s, 3H), 2.71 (s, 6H), 3.08 (s, 2H), 3.43 (m, 4H), 3.98 (m, 1H), 4.13 (m, 2H), 7.17 (t, J=8.4 Hz, 2H), 7.49 (m, 2H), 7.72 (s, 1H), 7.88 (m, 1H).

Example 130 3-{8-(2,6-difluorophenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 118c except (1H-imidazol-2-ylmethyl)amine dihydrochloride was used in the displacement and HPLC with TFA (yield: 18%). LC-MS m/z 574 (M+H)⁺; ¹H-NMR (MeOD) 2.29 (m, 5H), 4.20 (m, 3H), 4.57 (m, 3H), 7.09 (m, 2H), 7.22 (m, 1H), 7.48 (m, 5H), 7.90 (s, 1H), 8.08 (d, J=8.0 Hz, 1H).

Example 131 3-{8-(2,6-difluorophenyl)-2-[[2-(dimethylamino)ethyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 118c except N,N′-trimethyl-1,2-ethanediamine was used in the displacement and HPLC with TFA (yield: 49%). LC-MS m/z 579 (M+H)⁺; ¹H-NMR (MeOD) 2.37 (s, 3H), 2.75 (s, 6H), 2.97 (s, 3H), 3.28 (s, 2H), 3.82 (m, 2H), 4.23 (m, 2H), 7.23 (m, 3H), 7.58 (m, 3H), 7.94 (s, 1H), 8.11 (m, 1H).

Example 132 3-{8-(2,6-difluorophenyl)-2-[(2,2-dimethylpropyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 118c except (2,2-dimethylpropyl)amine was used in the displacement and HPLC with TFA (yield: 32%). LC-MS m/z 564 (M+H)⁺; ¹H-NMR (MeOD) 0.76 (s, 9H), 2.42 (s, 3H), 3.00 (s, 2H), 4.21 (m, 2H), 7.23 (m, 3H), 7.55 (d, J=3.8 Hz, 1H), 7.64 (m, 2H), 8.07 (s, 1H), 8.16 (d, J=8.0 Hz, 1H).

Example 133 3-(8-(2,6-difluorophenyl)-2-{[(2R)-2-hydroxypropyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 118c except (2R)-1-amino-2-propanol was used in the displacement and HPLC with TFA (yield: 49%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) 0.97 (m, 3H), 2.43 (s, 3H), 3.00 (s, br, 2H), 3.19 (s, br, 2H), 3.76 (m, 1H), 4.23 (m, 2H), 7.22 (m, 3H), 7.56 (m, 2H), 7.66 (d, J=8.0 Hz, 1H), 8.06 (s, 1H), 8.18 (d, J=8.0 Hz, 1H).

Example 134 3-(8-(2,6-difluorophenyl)-2-{[(2S)-2-hydroxypropyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except (2S)-1-amino-2-propanol was used in the displacement (yield: 27%). LC-MS m/z 552 (M+H)⁺; ¹H-NMR (MeOD) 0.97 (m, 3H), 2.43 (s, 3H), 2.99 (s, br, 2H), 3.18 (s, br, 2H), 3.76 (m, 1H), 4.22 (m, 2H), 7.22 (m, 3H), 7.55 (m, 2H), 7.66 (d, J=8.0 Hz, 1H), 8.05 (s, 1H), 8.18 (d, J=7.4 Hz, 1H).

Example 135 3-[8-(2,6-difluorophenyl)-2-({2-[2-(methyloxy phenyl]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 118c except 2-[2-(methyloxy)phenyl]ethanamine was used in the displacement and HPLC with TFA (yield: 33%). LC-MS m/z 628 (M+H)⁺; ¹H-NMR (MeOD) 2.38 (s, 3H), 2.70 (s, br, 2H), 3.30 (m, 2H), 3.77 (s, 3H), 4.16 (m, 2H), 6.89 (m, 3H), 7.18 (m, 4H), 7.57 (m, 3H), 7.98 (s, 1H), 8.12 (d, J=8.0 Hz, 1H).

Example 136 3-[8-(2,6-difluorophenyl)-7-oxo-2-(propylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide

The title compound was prepared by following the procedure in Example 118c except propyl amine was used in the displacement (yield: 29%). LC-MS m/z 536 (M+H)⁺; ¹H-NMR (MeOD) 0.77 (s, 3H), 1.45 (m, 2H), 2.44 (s, 3H), 3.09 (s, 2H), 4.23 (m, 2H), 7.23 (m, 3H), 7.60 (m, 2H), 7.68 (m, 1H), 8.08 (s, 1H), 8.20 (d, J=8.0 Hz, 1H).

Example 137 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-phenylbenzamide

The title compound was prepared by following the procedure in Example 125 except aniline was used in the amide coupling reaction (yield: 45%). LC-MS m/z 558 (M+H)⁺; ¹H-NMR (MeOD) 2.36 (s, 3H), 2.77 (s, 6H), 3.15 (s, 2H), 3.55 (m, 2H), 4.20 (m, 2H), 7.18 (m, 3H), 7.38 (m, 2H), 7.56 (m, 2H), 7.71 (m, 2H), 7.84 (s, 1H), 8.01 (d, J=8.0 Hz, 1H).

Example 138 N-(3,4-difluorophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)-ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

The title compound was prepared by following the procedure in Example 125 except 3,4-difluoro aniline was used in the amide coupling reaction (yield: 15%). LC-MS m/z 594 (M+H)⁺; ¹H-NMR (MeOD) 2.36 (s, 3H), 2.77 (s, 6H), 3.16 (s, 2H), 3.55 (m, 2H), 4.19 (m, 2H), 7.24 (m, 3H), 7.50 (m, 3H), 7.86 (m, 2H), 8.00 (m, 1H).

Example 139 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-3-pyridinylbenzamide

The title compound was prepared by following the procedure in Example 125 except 3-pyridinamine was used in the amide coupling reaction (yield: 6%). LC-MS m/z 559 (M+H)⁺; ¹H-NMR (MeOD) 2.14 (s, 6H), 2.35 (m, 5H), 3.24 (m, 2H), 4.14 (m, 2H), 7.15 (m, 2H), 7.50 (m, 3H), 7.87 (s, 1H), 8.01 (m, 1H), 8.30 (m, 2H), 8.92 (s, 1H).

Example 140 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[6-(methyloxy)-3-pyridinyl]benzamide

The title compound was prepared by following the procedure in Example 125 except 6-(methyloxy)-3-pyridinamine was used in the amide coupling reaction (yield: 65%). LC-MS m/z 589 (M+H)⁺; ¹H-NMR (MeOD) 2.12 (s, 6H), 2.33 (m, 5H), 3.21 (m, 2H), 3.92 (s, 3H), 4.11 (m, 2H), 6.83 (d, J=8.8 Hz, 1H), 7.14 (m, 2H), 7.50 (d, J=8.0 Hz, 2H), 7.82 (s, 1H), 7.98 (m, 2H), 8.44 (s, 1H).

Example 141 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethylbenzoic acid

The title compound was prepared by following the procedure in Example 117 except 3-(dihydroxyboranyl)-4-ethylbenzoic acid was used in the coupling reaction (yield: 38%). LC-MS m/z 497 (M+H)⁺; ¹H-NMR (MeOD) 1.22 (t, J=7.6 Hz, 3H), 2.68 (s, 2H), 2.77 (s, 6H), 3.16 (m, 2H), 3.53 (m, 2H), 4.13 (m, 2H), 7.18 (m, 2H), 7.55 (m, 2H), 7.86 (s, 1H), 8.10 (m 1H).

Example 142 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethyl-N-(4-fluorophenyl)benzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 125 except 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethylbenzoic acid was used as the acid and 4-fluoroaniline was used as the amine for amide coupling and HPLC with TFA (yield: 56%). LC-MS m/z 590 (M+H)⁺; ¹H-NMR (MeOD) 1.22 (t, J=7.6 Hz, 3H), 2.69 (s, 2H), 2.77 (s, 6H), 3.15 (m, 2H), 3.54 (m, 2H), 4.13 (m, 2H), 7.15 (m, 4H), 7.53 (m, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.72 (m, 2H), 7.80 (s, 1H), 8.05 (m 1H).

Example 143 N-(3,4-difluorophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)-ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 142 except 3,4-difluoroaniline was used in the amide coupling reaction and HPLC with TFA (yield: 54%). LC-MS m/z 608 (M+H)⁺; ¹H-NMR (MeOD) 1.24 (t, J=7.6 Hz, 3H), 2.69 (s, 2H), 2.77 (s, 6H), 3.15 (m, 2H), 3.54 (m, 2H), 4.18 (m, 2H), 7.24 (m, 3H), 7.54 (m, 3H), 7.85 (m, 2H), 8.05 (ml H).

Example 144 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethyl-N-1,3-thiazol-2-ylbenzamide trifluoroacetate

The title compound was prepared by following the procedure in Example 142 except 1,3-thiazol-2-amine was used in the amide coupling reaction and HPLC with TFA (yield: 43%). LC-MS m/z 579 (M+H)⁺; ¹H-NMR (MeOD) 1.25 (t, J=7.6 Hz, 3H), 2.71 (s, 2H), 2.77 (s, 6H), 3.16 (m, 2H), 3.56 (m, 2H), 4.18 (m, 2H), 7.20 (m, 3H), 7.55 (m, 2H), 7.66 (m, 1H), 7.90 (s, 1H), 8.14 (m 1H).

Example 145 N-1,3-benzodioxol-5-yl-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)-ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide trifluoroacetate

Prepared following General Procedure for HATU Couplings. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 4.9 mg (23%). LC-MS m/z 602 (M+H)⁺.

Example 146 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-ethylbenzamide

The title compound was prepared by following the procedure in Example 142 except ammonia was used in the amide coupling reaction and HPLC without TFA (yield: 64%). LC-MS m/z 496 (M+H)⁺; ¹H-NMR (MeOD) 1.23 (m, 3H), δ 2.13 (s, 6H), 2.35 (m, 2H), 2.66 (m, 2H), 3.26 (m, 2H), 4.12 (m, 2H), 7.15 (m, 2H), 7.51 (m, 2H), 7.73 (s, 1H), 7.94 (m 1H).

Example 147 1,1-dimethylethyl {1-[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}methylcarbamate

Compound 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide (0.0811 g, 0.144 mmol) was dissolved in CH₂Cl₂ (5 mL) and 1,1-dimethylethyl methyl(4-piperidinyl)carbamate (0.0394 g, 0.18 mmol) and triethylamine (0.029 g, 0.288 mmol) were added. The reaction mixture was stirred for 4 days. Additional 1,1-dimethylethyl methyl(4-piperidinyl)carbamate (0.0788 g, 0.36 mmol) and triethylamine (0.058 g, 0.576 mmol) were added and the mixture was stirred under argon at room temperature for an additional 7 days. The solvents were pumped off in vacuo, and the residue taken up in EtOAc and washed with 1 N NaOH, brine, dried over anhydrous Na₂SO₄ filtered and evaporated. The residue was flash chromatographed on silica gel (20 g) eluted with 0-70% EtOAc/hexane. Some impurities remained, so the material was rechromatographed on silica gel (20 g) eluted with 0-50% EtOAc/hexane to give the title compound as a white amorphous solid. mp (dec) 146-150° C. LC-MS m/z 698 (M+H)⁺, 2.66 min (ret time).

Example 148 3-[8-(2,6-difluorophenyl-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide

The 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide (0.056 g, 0.1 mmol) was dissolved in THF (5 mL) and 1-methylpiperazine (0.0303 g, 0.3 mmol) was added. The reaction was stirred for 72 h. The solvents were pumped off in vacuo, and the residue taken up in EtOAc and washed with 1 N NaOH, brine, dried over anhydrous Na₂SO₄ filtered and evaporated. The residue was flash chromatographed on silica gel (20 g) eluted with 6:0.1:0.01 to 6:0.3:0.03, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp 164-168° C. LC-MS m/z 584 (M+H)⁺, 1.85 min (ret time).

Example 149 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide 149a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide

4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1 g, 3.8 mmoles) was taken up in CH₂Cl₂ (200 mL) and was treated with oxalyl chloride (0.44 mL, 5 mmol) and DMF (1 drop). One hour after gas evolution had ceased, the solvents were pumped off in vacuo, and the residue stripped from toluene. This was again taken up in CH₂Cl₂ (200 mL), and excess dimethyl amine was bubbled into the mixture, which was then sealed off and stirred overnight at room temperature. The solvents were pumped off to give the crude N,N,4-trimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, which was used without further purification in the next step.

5-chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (0.102 g, 0.298 mmol), N,N,4-trimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide from above, (0.129 g, 0.447 mmol), and K₂CO₃ (0.123 g, 0.894 mmol), were taken up in dioxane (6 mL) and water (1.2 mL). The mixture was degassed with argon for 30 min and tetrakis(triphenyl-phosphine)palladium(0) (0.026 g, 0.022 mmol) was added. The mixture was then heated under argon at 95° C. for 18 h. The solvents were pumped off, and after aqueous workup, the crude material was flashed on silica gel (15 g), eluted with a EtOAc/CH₂Cl₂ gradient to give the title compound as a white amorphous solid. mp 144-147° C. LC-MS m/z 470 (M+H)⁺, 2.02 min (ret time).

149b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide (0.089 g, 0.19 mmol) was dissolved in CH₂Cl₂ (10 mL) and 50-60% 3-chloroperoxybenzoic acid (0.118 g, 0.38 mmol) was added and the mixture stirred overnight. The solvents were pumped off, and the residue flashed on silica gel eluted with CH₂Cl₂-90% EtOAc/CH₂Cl₂ to give 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide. LC-MS m/z 502 (M+H)⁺, 1.78 min (ret time).

149c) 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide (0.050 g, 0.1 mmol) was dissolved in THF (5 mL) and 1-methylpiperazine (0.050 g, 0.5 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo. The residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp 159-162° C. LC-MS m/z 522 (M+H)⁺, 1.59 min (ret time).

Example 150 N-4-biphenylyl-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide trifluoroacetate

Prepared following General Procedure for HATU Couplings. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 4.4 mg (19%). LC-MS m/z 634 (M+H)⁺.

Example 151 3-(8-(2,6-difluorophenyl-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide (0.056 g, 0.1 mmol) was dissolved in THF (5 mL) and N,N-dimethyl-1,3-propanediamine (0.035 g, 0.3 mmol) was added. The reaction was carried out and worked up as in Example 148 to give the title compound as a white amorphous solid. mp 141-144° C. LC-MS m/z 586 (M+H)⁺, 1.52 min (ret time).

Example 152 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-N,N,4-trimethylbenzamide

The reaction was carried out and worked up as in Example 149c except substituting dimethylaminoethylamine (0.044 g, 0.5 mmol) for 1-methylpiperazine to give the title compound as a white amorphous solid. mp 138-142° C. LC-MS m/z 510 (M+H)⁺, 1.31 min (ret time).

Example 153 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide

The reaction was carried out and worked up as in Example 149c except substituting (2-aminoethyl)(1-methylethyl)amine (0.051 g, 0.5 mmol) for 1-methylpiperazine to give the title compound as a white amorphous solid. mp 130-133° C. LC-MS m/z 524 (M+H)⁺, 1.36 min (ret time).

Example 154 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N,N,4-trimethylbenzamide

The reaction was carried out and worked up as in Example 149c except substituting [3-(dimethylamino)propyl]methylamine (0.058 g, 0.5 mmol) for 1-methylpiperazine to give the title compound as a white amorphous solid. mp 114-118° C. LC-MS m/z 538 (M+H)⁺, 1.49 min (ret time).

Example 155 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl}N,N,4-trimethylbenzamide

The reaction was carried out and worked up as in Example 149c except substituting 1-methyl-4-piperidinamine (0.057 g, 0.5 mmol) for 1-methylpiperazine to give the title compound as a white amorphous solid. mp 163-165° C. LC-MS m/z 536 (M+H)⁺, 1.25 min (ret time).

Example 156 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-diethyl-4-methylbenzamide 156a) 3-[8-(2,6-difluorophenyl-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide

The reaction was carried out and worked up as in example 149a except adding excess diethylamine instead of dimethylamine to give the crude N,N-diethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. This was chromatographed on silica gel (100 g) eluted with a methylene chloride ethyl acetate gradient to give clean N,N-diethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide. LC-MS m/z 470 (M+H)⁺, 2.40 min (ret time).

5-chloro-1-(2,6-difluorophenyl)-7-(methylthio)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (0.720 g, 2.1 mmol), N,N-diethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide from above (1.09 g, 3.15 mmol), and K₂CO₃ (0.868 g, 6.3 mmol), were taken up in dioxane (42 mL) and water (8.5 mL). The mixture was degassed with argon for 30 min and tetrakis-(triphenylphosphine)palladium(0) (0.183 g, 0.15 mmol) was added. The mixture was then heated under argon at 950 C for 18 h. The solvents were pumped off and after aqueous workup, the crude material was flashed on silica gel (150 g) eluted with a EtOAc/CH₂Cl₂ gradient to give the title compound as a white amorphous solid. mp 127-129° C. LC-MS m/z 498 (M+H)⁺, 2.11 min (ret time).

156b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide (0.63 g, 1.26 mmol) was dissolved in CH₂Cl₂ (100 mL) and 50-60% 3-chloroperoxybenzoic acid (0.786 g, 2.52 mmol) was added and the mixture stirred overnight. The solvents were pumped off, and the residue flashed on silica gel eluted with CH₂Cl₂-90% EtOAc/CH₂Cl₂ to give the title compound as a white amorphous solid. mp 132-135° C. LC-MS m/z 530 (M+H)⁺, 1.81 min (ret time).

156c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-diethyl-4-methylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide-(0.053 g, 0.1 mmol) was dissolved in THF (5 mL) and dimethylaminoethylamine (0.044 g, 0.5 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp 125-127° C. LC-MS m/z 538 (M+H)⁺, 1.57 min (ret time).

Example 157 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-[4-(ethyloxy)phenyl]-4-methylbenzamide trifluoroacetate

Prepared following General Procedure for HATU Couplings. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 5.1 mg (24%). LC-MS m/z 602 (M+H)⁺.

Example 158 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(methyloxy)phenyl]benzamide trifluoroacetate

Prepared following General Procedure for HATU Couplings. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 3.4 mg (16%). LC-MS m/z 588 (M+H)⁺.

Example 159 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-dl-pyrimidin-4-yl}-N,N-diethyl-4-methylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide (0.053 g, 0.1 mmol) was dissolved in THF (5 mL) and 1-methyl-4-piperidinamine (0.044 g, 0.5 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo, and the residue was purified by mass directed auto prep. The fractions were evaporated, and aqueous basic workup gave the title compound as a white amorphous solid. mp 165-169° C. LC-MS m/z 564 (M+H)⁺, 1.44 min (ret time).

Example 160 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide

The reaction was carried out and worked up as in Example 156c except substituting (2-aminoethyl)(1-methylethyl)amine (0.051 g, 0.5 mmol) for dimethylaminoethylamine to give the title compound as a white amorphous solid. mp 89-91° C. LC-MS m/z 552 (M+H)⁺, 1.32 min (ret time).

Example 161 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N,N-diethyl-4-methylbenzamide

The reaction was carried out and worked up as in Example 156c except substituting [3-(dimethylamino)propyl]methylamine (0.058 g, 0.5 mmol) for dimethylaminoethyl-amine to give the title compound as a white amorphous solid. mp 106-108° C. LC-MS m/z 566 (M+H)⁺, 1.69 min (ret time).

Example 162 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,N-diethyl-4-methylbenzamide

The reaction was carried out and worked up as in Example 156c except substituting 1-methylpiperazine (0.05 g, 0.5 mmol) for dimethylaminoethylamine to give the title compound as a white amorphous solid. mp (dec) 201-205° C. LC-MS m/z 550 (M+H)⁺, 1.35 min (ret time).

Example 163 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,4-dimethylbenzamide 163a) 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid (0.59 g, 1.33 mmol) was taken up in CH₂Cl₂ (75 mL), and diisopropylethylamine (0.7mL, 4 mmol) was added followed by HATU (0.556 g, 1.46 mmol). Gaseous methyl amine was then bubbled in very slowly until reaction was complete. Aqueous workup followed by chromatography on silica gel (100 g) eluted with CH₂Cl₂-90% EtOAc/CH₂Cl₂ gave the title compound as a white amorphous solid. mp 273-275° C. LC-MS m/z 456 (M+H)⁺, 1.85 min (ret time). 163b) 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide, (0.592 g, 1.3 mmol) was taken up in CH₂Cl₂ (75 mL), and 50-60% 3-chloroperoxybenzoic acid (0.84 g, 2.7 mmol) was added. The mixture was stirred overnight under argon. The solvent was pumped off in vacuo, and the residue was chromatographed on silica gel (80 g) eluted with 0-10% MeOH/CH₂Cl₂. Crystallization from MeOH gave the title compound as a white crystalline solid. mp 275-278° C. LC-MS m/z 488 (M+H)⁺, 1.58 min (ret time).

163c) 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl)-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.03 g, 0.06 mmol) was dissolved in THF (5 mL) and dimethylaminoethylamine (0.026 g, 0.3 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp (dec) 155-158° C. LC-MS m/z 496 (M+H)⁺, 1.29 min (ret time).

Example 164 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(3-methylphenyl)benzamide trifluoroacetate

Prepared following General Procedure for HATU Couplings. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 4.5 mg (21%). LC-MS m/z 583 (M+H)⁺.

Example 165 N-(2,4-difluorophenyl)-3-(8-(2,6-difluorophenyl-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound 5 mg (23%). LC-MS m/z 594 (M+H)⁺.

Example 166 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.032 g, 0.031 mmol) was dissolved in THF (5 mL) and N,N-dimethyl-1,3-propanediamine (0.032 g, 0.31 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂:ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 164-167° C. LC-MS m/z 510 (M+H)⁺, 1.31 min (ret time).

Example 167 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.031 g, 0.064 mmol) was dissolved in THF (5 mL) and (2-aminoethyl)(1-methylethyl)amine (0.032 g, 0.31 mmol) was added. The reaction was stirred under argon for ten days. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂:ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 136-139° C. LC-MS m/z 510 (M+H)⁺, 1.35 min (ret time).

Example 168 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.036 g, 0.074 mmol) was dissolved in THF (5 mL) and (3-aminopropyl)(1-methylethyl)amine (0.045 g, 0.37 mmol) was added. The reaction was stirred under argon overnight. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂:ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 153-157° C. LC-MS m/z 524.6 (M+H)⁺, 1.31 min (ret time).

Example 169 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.033 g, 0.0678 mmol) was dissolved in THF (5 mL) and 1-methylpiperazine (0.034 g, 0.34 mmol) was added. The reaction was heated to 45° C. for 4 h and then cooled to room temperature overnight. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 164-168° C. LC-MS m/z 508 (M+H)⁺, 1.34 min (ret time).

Example 170 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.036 g, 0.074 mmol) was dissolved in THF (5 mL) and (3-aminopropyl)(1,1-dimethylethyl)amine (0.045 g, 0.37 mmol) was added. The reaction was stirred under argon for 2 days. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 166-170° C. LC-MS m/z 538 (M+H)⁺, 1.38 min (ret time).

Example 171 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.03 g, 0.062 mmol) was dissolved in THF (5 mL) and (3-aminopropyl)dibutylamine (0.058 g, 0.31 mmol) was added. The reaction was stirred under argon for 24 h. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp 112-115° C. LC-MS m/z 594.6 (M+H)⁺, 1.59 min (ret time).

Example 172 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.03 g, 0.062 mmol) was dissolved in THF (5 mL) and (3-aminopropyl)diethylamine (0.041 g, 0.31 mmol) was added. The reaction was stirred under argon for 24 h. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (15 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp 133-136° C. LC-MS m/z 538 (M+H)⁺, 1.34 min (ret time).

Example 173 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide, (0.02 g, 0.041 mmol) was dissolved in THF (5 mL) and 1-methyl-4-piperidinamine (0.024 g, 0.21 mmol) was added. The reaction mixture was stirred at room temperature for 24 hours, but the reaction had not gone to completion. The reaction was heated to 45° C. for 24 h and then cooled to room temperature. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (10 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 205-209° C. LC-MS m/z 522 (M+H)⁺, 1.29 min (ret time).

Example 174 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide, (0.02 g, 0.041 mmol) was dissolved in THF (5 mL) and [3-(dimethylamino)propyl]methylamine (0.024 g, 0.205 mmol) was added. The reaction mixture was stirred at room temperature for 6 days, but the reaction had not gone to completion. The reaction was heated to 45° C. overnight and then cooled to room temperature. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (10 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂:ethanol:NH₄OH to give the title compound as a white amorphous solid. mp 163-165° C. LC-MS m/z 524.6 (M+H)⁺, 1.47 min (ret time).

Example 175 3-{8-(2,6-difluorophenyl)-7-oxo-2-[4-(1-pyrrolidinyl)-1-piperidinyl]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.015 g, 0.031 mmol) was dissolved in THF (5 mL) and 4-(1-pyrrolidinyl)piperidine (0.024 g, 0.155 mmol) was added. The reaction mixture was stirred at room temperature for 4 days. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (10 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol:NH₄OH to give the title compound as a white amorphous solid. mp (dec) 189-194° C. LC-MS m/z 562 (M+H)⁺, 1.62 min (ret time).

Example 176 3-[2-(1,4′-bipiperidin-1′-yl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide

3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide (0.015 g, 0.031 mmol) was dissolved in THF (5 mL) and 1,4′-bipiperidine (0.026 g, 0.155 mmol) was added. The reaction mixture was stirred at room temperature for 4 days. The solvents were pumped off in vacuo, and the residue was flash chromatographed on silica gel (10 g) eluted with CH₂Cl₂ to 6:0.5:0.05, CH₂Cl₂: ethanol: NH₄OH to give the title compound as a white amorphous solid. mp (dec) 179-184° C. LC-MS m/z 576 (M+H)⁺, 1.54 min (ret time).

Example 177 3-[8-(2,6-difluorophenyl)-2-({3-[methyl(phenyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 5 mg (19%). LC-MS m/z 600 (M+H)⁺.

Example 178 3-(8-(2,6-difluorophenyl)-2-{[2-(methyloxy)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 6.2 mg (28%). LC-MS m/z 511 (M+H)⁺.

Example 179 3-[8-(2,6-difluorophenyl)-2-(4-methylhexahydro-1H-1,4-diazepin-1-yl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 8.5 mg (35%). LC-MS m/z 550 (M+H)⁺.

Example 180 3-[8-(2,6-difluorophenyl)-2-(4-ethyl-1-piperazinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 8.5 mg (35%). LC-MS m/z 550 (M+H)⁺.

Example 181 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(2-fluorophenyl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound 4.6 mg (22%). LC-MS m/z 576 (M+H)⁺.

Example 182 3-(8-(2,6-difluorophenyl)-2-{[3-(hexahydro-1H-azepin-1-yl)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 12 mg (46%). LC-MS m/z 592 (M+H)⁺.

Example 183 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[3-(1-pyrrolidinyl)propyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 11 mg (44%). LC-MS m/z 564 (M+H)⁺.

Example 184 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 11.4 mg (42%). LC-MS m/z 612 (M+H)⁺.

Example 185 3-[8-(2,6-difluorophenyl)-2-({[(2S)-1-ethyl-2-pyrrolidinyl]methyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 9.1 mg (37%). LC-MS m/z 564 (M+H)⁺.

Example 186 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)-1-methylethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 11.1 mg (47%). LC-MS m/z 538 (M+H)⁺.

Example 187 3-(8-(2,6-difluorophenyl)-2-{[2-(1-methyl-2-pyrrolidinyl)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 12.2 mg (49%). LC-MS m/z 564 (M+H)⁺.

Example 188 3-(8-(2,6-difluorophenyl-7-oxo-2-{[2-(1-piperidinyl)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 13.8 mg (56%). LC-MS m/z 564 (M+H)⁺.

Example 189 3-(8-(2,6-difluorophenyl)-2-{[3-(1H-imidazol-1-yl)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 12.3 mg (50%). LC-MS m/z 561 (M+H)⁺.

Example 190 3-(8-(2,6-difluorophenyl)-2-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound 3.4 mg (15%). LC-MS m/z 527 (M+H)⁺.

Example 191 3-[2-({2-[bis(1-methylethyl)amino]ethyl}amino)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 6.5 mg (25%). LC-MS m/z 580 (M+H)⁺.

Example 192 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(5-methyl-1,3-thiazol-2-yl)benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 4.1 mg (20%). LC-MS m/z 579 (M+H)⁺.

Example 193 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-4-pyridinylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound. 2.6 mg (13%). LC-MS m/z 559 (M+H)⁺.

Example 194 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[2-(phenylamino)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 14 mg (56%). LC-MS m/z 572 (M+H)⁺.

Example 195 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[1-phenyl-2-(1-pyrrolidinyl)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 9.2 mg (33%). LC-MS m/z 626 (M+H)⁺.

Example 196 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[2-phenyl-2-(1-pyrrolidinyl)ethyl]amino}-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 6.1 mg (22%). LC-MS m/z 626 (M+H)⁺.

Example 197 3-[8-(2,6-difluorophenyl)-7-oxo-2-({2-[4-(phenylmethyl)-1-piperazinyl]ethyl}amino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 12.5 mg (43%). LC-MS m/z 655 (M+H)⁺.

Example 198 3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-propyl-1-piperazinyl)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 3.4 mg (14%). LC-MS m/z 564 (M+H)⁺.

Example 199 3-[2-(4-butyl-1-piperazinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 9 mg (35%). LC-MS m/z 578 (M+H)⁺.

Example 200 3-(8-(2,6-difluorophenyl)-7-oxo-2-{[1-(phenylmethyl)-4-piperidinyl]amino}-5,6,718-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC without TFA provided the title compound 6.7 mg (24%). LC-MS m/z 626 (M+H)⁺.

Example 201 3-[8-(2,6-difluorophenyl)-7-oxo-2-(2-propen-1-ylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC without TFA provided the title compound, 3 mg (14%). LC-MS m/z 493 (M+H)⁺.

Example 202 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-3-isoquinolinyl-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 4.7 mg (21%). LC-MS m/z 609 (M+H)⁺.

Example 203 3-[8-(2,6-difluorophenyl)-2-({2-[ethyl(3-methylphenyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 9.8 mg (36%). LC-MS m/z 614 (M+H)⁺.

Example 204 3-[2-[[2-(diethylamino)ethyl](methyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide trifluoroacetate

Prepared following General Procedure for sulfoxide displacement. Reversed-phase HPLC (10-90% gradient of acetonitrile in water with 0.1% TFA) provided the title compound, 5.5 mg (22%). LC-MS m/z 566 (M+H)⁺.

Example 205 N-(4-cyanophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound 2.4 mg (11%). LC-MS m/z 583 (M+H)⁺.

Example 206 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[3-(methylthio)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 3.6 mg (17%). LC-MS m/z 604 (M+H)⁺.

Example 207 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(phenylcarbonyl)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound 3.2 mg (13%). LC-MS m/z 662 (M+H)⁺.

Example 208 Butyl 4-({[3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylphenyl]carbonyl}amino)benzoate

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 4 mg (17%). LC-MS m/z 658 (M+H)⁺.

Example 209 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(1-piperidinylsulfonyl)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 2.3 mg (9%). LC-MS m/z 704 (M+H)⁺.

Example 210 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(phenyloxy)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 3.2 mg (14%). LC-MS m/z 650 (M+H)⁺.

Example 211 N-[3-(aminocarbonyl)phenyl]-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.5 mg (25%). LC-MS m/z 601 (M+H)⁺.

Example 212 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 8 mg (36%). LC-MS m/z 616 (M+H)⁺.

Example 213 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl)-4-methyl-N-(2-methylphenyl)benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 7.1 mg (35%). LC-MS m/z 571 (M+H)⁺.

Example 214 N-(3-cyanophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.4 mg (26%). LC-MS m/z 583 (M+H)⁺.

Example 215 N-(3,5-difluorophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]-amino}-7-oxo-5,6,718-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 3.6 mg (17%). LC-MS m/z 594 (M+H)⁺.

Example 216 N-(3-chlorophenyl-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5 mg (23%). LC-MS m/z 592 (M+H)⁺.

Example 217 N-(3-chloro-4-fluorophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 6.8 mg (31%). LC-MS m/z 610 (M+H)⁺.

Example 218 N-(4-chlorophenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 6.8 mg (32%). LC-MS m/z 592 (M+H)⁺.

Example 219 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-[4-(dimethylamino)phenyl]-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 9 mg (42%). LC-MS m/z 601 (M+H)⁺.

Example 220 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[4-(trifluoromethyl)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.8 mg (26%). LC-MS m/z 626 (M+H)⁺.

Example 221 N-(4-acetylphenyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 4.4 mg (20%). LC-MS m/z 600 (M+H)⁺.

Example 222 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-[3-(phenyloxy)phenyl]benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.7 mg (24%). LC-MS m/z 650 (M+H)⁺.

Example 223 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]-pyrimidin-4-yl)-N-1H-indazol-6-yl-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 9.3 mg (43%). LC-MS m/z 598 (M+H)⁺.

Example 224 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(2-methyl-1,3-benzothiazol-5-yl)benzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.3 mg (23%). LC-MS m/z 629 (M+H)⁺.

Example 225 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4′-fluoro-3-biphenylyl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 4 mg (17%). LC-MS m/z 652 (M+H)⁺.

Example 226 N-[3-(aminosulfonyl)phenyl]-3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)-ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide

Prepared following General Procedure for HATU Couplings. Solid phase extraction (SPE, aminopropyl, 500 mg) by elution with chloroform followed by ethyl acetate, 20% methanol/ethyl acetate and finally methanol provided the title compound, 5.5 mg (24%). LC-MS m/z 637 (M+H)⁺.

Example 227 3-[2-[(3-aminopropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide 227a) 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To a stirring suspension of Oxone (817.96 g, 1.33 mole, 3 eq) in water (2142 mL, 10 vol) was added 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (214.21 g 0.443 mole, 1 eq) suspended in acetonitrile (4284 mL). The resulting mixture was stirred at ambient temperature overnight. The mixture was then filtered and the residue stirred sequentially with 5% sodium metabisulfite (2×3000 mL) and water (1×300 mL). The filtrate from the reaction mixture was then diluted with water (2142 mL, 10 vol). The solid that formed was then collected by filtration. The solid was washed well with water then dried at the pump to yield the title compound. LC-MS m/z 516 (M+H)⁺, 2.77 min (ret time). It was used without further purification although corresponding sulfoxide was present (about 10%).

227b) 3-[2-[(3-aminopropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (497 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1,3-propyldiamine (0.251 mL, 3.0 mL). The mixture was stirred over night. The mixture was concentrated and separated by flash chromatography to afford the title compound (395 mg, 78%). LC-MS m/z 510 (M+H)⁺.

227c) 3-[2-[(3-aminopropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide trifluoroacetate

To 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (497 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1,3-propyldiamine (0.251 mL, 3.0 mL). The mixture was stirred over night. The mixture was concentrated and initial separation was carried out with flash chromatography affording the title compound as a free base (395 mg, 78%). Additional purification with a Gilson HPLC (with 0.1% TFA) then afforded the title compound (129.9 mg). LC-MS m/z 510 (M+H)⁺; ¹H-NMR (MeOD) δ 0.96 (t, J=7.40 Hz, 3H), 1.56-1.66 (m, 3H), 1.72 (br. s, 2H), 2.31 (s, 3H), 2.77 (br. s, 2H), 3.22 (br. s, 2H), 3.33 (t, J=7.15 Hz, 2H), 4.12 (br. s, 2H), 7.16 (t, J=8.41 Hz, 2H), 7.44-7.59 (m, 2H), 7.73 (s, 1H), 7.87 (d, J=8.03 Hz, 1H).

Example 228 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid 228a) 5-chloro-7-{[3-(diethylamino)propyl]amino}-1-(2,6-difluorophenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one trifluoroacetate

To 5-chloro-1-(2,6-difluorophenyl)-7-(methylsulfinyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (275 mg, 0.767 mmol) in dichloromethane (15 mL) was added N,N-diethyl-1,3-propyldiamine (0.181 mL, 1.15 mmol) and triethylamine (0.215 mL, 1.53 mmol). The mixture was stirred over night. The mixture was concentrated and separated by Gilson HPLC (with 0.1% TFA) to afford the title compound (207 mg, 64%).

228b) 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid

To 5-chloro-7-{[3-(diethylamino)propyl]amino}-1-(2,6-difluorophenyl)-3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one (207 mg, 0.488 mmol) in 1,4-dioxane (7.5 mL) and water (2.5 mL) was added 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (0.192 g, 0.733 mmol), tetrakis(triphenylphosphine)-palladium(0) (28.3 mg, 0.024 mmol), and potassium carbonate (270 mg, 1.95 mmol). The mixture was heated with microwave for 15 min at 150° C., and then allowed to cool to room temperature. The mixture was concentrated and separated by HPLC to afford the title compound (66 mg, 26%). LC-MS m/z 525 (M+H)⁺.

Example 229 N-(8-(2,6-difluorophenyl)-4-{2-methyl-5-[(propylamino)carbonyl]phenyl}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl)-β-alanine

To 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (100 mg, 0.2 mmol) in DMF (1 mL) was added β-alanine (35.6 mg, 0.4 mmol) and triethylamine (56.2 uL, 0.4 mmol). The mixture was heated with microwave at 100° C. for 2 hrs. The mixture was separated by HPLC to afford the title compound (45 mg, 43%). LC-MS m/z 525 (M+H)⁺.

Example 230 3-(8-(2,6-difluorophenyl)-2-{[3-(ethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-propylbenzamide and the corresponding trifluoroacetate salt 230a) 3-[2-[(3-chloropropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide

To 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (206 mg, 0.4 mmol) in DMF (4 mL) was added (3-chloropropyl)amine hydrochloride (78 mg, 0.6 mmol) and triethylamine (112 uL, 0.8 mmol). The mixture was heated with microwave at 60° C. for 2 hrs. The mixture was separated by flash chromatography to afford the title compound (100 mg, 47%). 230b) 3-(8-(2,6-difluorophenyl)-2-{[3-(ethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-propylbenzamide trifluoroacetate

To 3-[2-[(3-chloropropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (100 mg, 0.189 mmol) in DMF (2 mL) was added ethylamine (0.189 mL, 2.0 M in THF, 0.378 mmol) and potassium carbonate (0.104 g, 0.756 mmol). The mixture was heated with microwave irradiations at 100° C. for about 30 min. The mixture was concentrated and separated by Gilson HPLC (with 0.1% TFA) affording the title compound (11 mg, 11%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 1.02 (t, J=7.30 Hz, 3H), 1.08 (t, J=6.92 Hz, 3H), 1.63-1.74 (m, 2H), 1.98-2.07 (m, 2H), 2.34 (s, 3H), 3.10-3.19 (m, 2H), 3.39 (t, J=6.80 Hz, 4H), 3.43-3.52 (m, 1H), 3.53-3.64 (m, 1H), 3.78 (d, J=15.86 Hz, 1H), 4.19 (d, J=16.11 Hz, 1H), 7.13 (t, J=8.31 Hz, 2H), 7.34-7.48 (m, 1H), 7.63 (d, J=7.81 Hz, 1H), 7.79 (s, 1H), 7.99 (d, J=8.06 Hz, 1H).

230c) 3-(8-(2,6-difluorophenyl)-2-{[3-(ethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-propylbenzamide

To 3-[2-[(3-chloropropyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide (265 mg, 0.50 mmol) in DMF (10 mL) was added ethylamine (1.25 mL, 2.0 M in THF, 2.5 mmol) and potassium carbonate (0.276 g, 2.0 mmol). The mixture was heated at 50° C. for about 20 hours, then at 80° C. for about 4 hours. The mixture was diluted with EtOAc (50 mL), washed with H₂O (30 mL+15 mL×2) and brine (20 mL). The organic layers were collected and concentrated. Flash chromatograph afforded the title compound (134 mg, 50%). LC-MS m/z 538 (M+H)⁺; ¹H-NMR (MeOD) δ 0.96-1.02 (m, 6H), 1.61-1.72 (m, 2H), 1.85-1.96 (m, 2H), 2.30 (s, 3H), 3.07 (q, J=7.11 Hz, 2H), 3.19-3.29 (m, 3H), 3.33-3.40 (m, 3H), 3.83 (d, 1H), 3.90 (d, 1H), 6.83-6.99 (m, 3H), 7.51 (d, J=8.03 Hz, 1H), 7.69 (d, J=1.76 Hz, 1H), 7.87 (dd, J=7.91, 1.88 Hz, 1H).

Methods of Treatment

The compounds of (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (Iva), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages.

For purposes herein, compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII) and (VIIIa), (IX) and (IXa), (A), (A1), (B), and (B1), etc. will all be referred to as compounds of Formula (I) herein unless otherwise indicated.

Compounds of Formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF and are therefore of use in therapy. IL-1, IL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.

Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy. These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme. Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I). This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX-1 thereby inhibiting prostaglandins essential for cytoprotective effects. Thus inhibition of these pro-inflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states. Most notably these inflammatory mediators, in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema. This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain. Compounds of Formula (I) or a pharmaceutically acceptable salt thereof, are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.

Accordingly, the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.

In particular, compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-6, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and/or macrophages.

Accordingly, in another aspect, this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, stroke, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes, pancreatic B cell diseases and Alzheimer's disease.

Use of a CSAID inhibitor compound for the treatment of CSBP mediated disease states, can include, but not be limited to neurodegenerative diseases, such as Alzheimer's disease (as noted above), Parkinson's disease and multiple sclerosis, etc.

In a further aspect, this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, chronic pulmonary inflammatory disease and chronic obstructive pulmonary disease, silicosis, pulmonary sarcoidosis, bone resorption diseases, such as osteoporosis, cardiac, brain and renal reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, brain infections including encephalitis (including HIV-induced forms), cerebral malaria, meningitis, ischemic and hemorrhagic stroke, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, inflammatory bowel disease, Crohn's disease, ulcerative colitis and pyresis.

Compounds of Formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of Formula (I). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, Herpes Zoster and Herpes Simplex. Accordingly, in a further aspect, this invention relates to a method of treating a mammal afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

It is also recognized that both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of common cold and exacerbation of asthma associated with HRV infection (Turner et al. (1998), Clin. Infec. Dis., Vol. 26, p 840; Teren et al. (1997), Am. J. Respir. Crit. Care Med., Vol. 155, p 1362; Grunberg et al. (1997), Am. J. Respir. Crit. Care Med. Vol. 156, p 609 and Zhu et al, J Clin. Invest (1996), 97:421). It has also been demonstrated in vitro that infection of pulmonary epithelial cells with HRV results in production of IL-6 and IL-8 (Subauste et al., J. Clin. Invest. 1995, 96:549.) Epithelial cells represent the primary site of infection of HRV. Therefore another aspect of the present invention is a method of treatment to reduce inflammation associated with a rhinovirus infection, not necessarily a direct effect on virus itself.

Compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.

The compounds of Formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. Periodontal disease has also been implemented in cytokine production, both topically and systemically. Hence use of compounds of Formula (I) to control the inflammation associated with cytokine production in such peroral diseases such as gingivitis and periodontitis is another aspect of the present invention.

Compounds of Formula (I) have also been shown to inhibit the production of IL-8 (Interleukin-8, NAP). Accordingly, in a further aspect, this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases are characterized by massive neutrophil infiltration such as, psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8 production which is responsible for the chemotaxis of neutrophils into the inflammatory site. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutrophil infiltration.

The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-6, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state. Abnormal levels of IL-1, IL-6, IL-8 or TNF, for instance in the context of the present invention, constitute: (i) levels of free (not cell bound) IL-1, IL-6, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-6, IL-8 or TNF; or (iii) the presence of IL-1, IL-6, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL-1, IL-6, IL-8 or TNF, respectively, is produced.

The discovery that the compounds of Formula (I) are inhibitors of cytokines, specifically IL-1, IL-6, IL-8 and TNF is based upon the effects of the compounds of Formulas (I) on the production of the IL-1, IL-8 and TNF in in vitro assays which are described herein.

As used herein, the term “inhibiting the production of IL-1 (IL-6, IL-8 or TNF)” refers to:

a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in release of the cytokine by all cells, including but not limited to monocytes or macrophages;

b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels;

c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL-1, IL-6, IL-8 or TNF) as a posttranslational event; or

d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels.

As used herein, the term “TNF mediated disease or disease state” refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease stated mediated by TNF.

As used herein, the term “cytokine” refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidural keratinocytes and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNF-β).

As used herein, the term “cytokine interfering” or “cytokine suppressive amount” refers to an effective amount of a compound of Formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production.

As used herein, the cytokine referred to in the phrase “inhibition of a cytokine, for use in the treatment of a HIV-infected human” is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.

As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as “TNF” unless specifically delineated otherwise.

A member of the MAP kinase family, alternatively termed CSBP, p38, or RK, has been identified independently by several laboratories. Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin-1 and tumor necrosis factor. The cytokine biosynthesis inhibitors, of the present invention, compounds of Formula (I) have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. It has been found that some of the compounds of Formula I exhibit reversible time-dependent inhibition of the p38 kinase due to the kinetics of slow binding and/or slow dissociation, resulting in an improved apparent IC50 when a compound has been preincubated with the enzyme or with cells. This slow, tight binding property may contribute to enhanced potency of such compounds both in vitro and in vivo.

These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages. In addition to those diseases already noted, treatment of stroke, neurotrauma, cardiac and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, chronic renal failure, angiogenesis & related processes, such as cancer, thrombosis, glomerulonephritis, diabetes and pancreatic β cells, multiple sclerosis, muscle degeneration, eczema, psoriasis, sunburn, and conjunctivitis are also included.

The CSBP inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies. Most notable are its effectiveness in the collagen-induced arthritis model and inhibition of TNF production in the endotoxic shock model. In the latter study, the reduction in plasma level of TNF correlated with survival and protection from endotoxic shock related mortality. Also of great importance is the compounds effectiveness in inhibiting bone resorption in a rat fetal long bone organ culture system. Griswold et al., (1988) Arthritis Rheum. 31:1406-1412; Badger, et al., (1989) Circ. Shock 27, 51-61; Votta et al., (1994) in vitro. Bone 15, 533-538; Lee et al., (1993). B Ann. N.Y. Acad. Sci. 696, 149-170.

Chronic diseases which have an inappropriate angiogenic component are various ocular neovascularizations, such as diabetic retinopathy and macular degeneration. Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore CSBP kinase inhibitors will be of utility in the blocking of the angiogenic component of these disease states.

The term “excessive or increased proliferation of vasculature inappropriate angiogenesis” as used herein includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases.

The term “inappropriate angiogenesis” as used herein includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis.

Accordingly, the present invention provides a method of treating a CSBP kinase mediated disease in a mammal in need thereof, preferably a human, which comprises administering to said mammal, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.

Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about 1 g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of Formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Compounds of Formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

In one embodiment of the present invention, the agents of the present invention are delivered via oral inhalation or intranasal administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

For administration by inhalation the compounds may be delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as tetrafluoroethane or heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di or poly-saccharides (e.g. lactose or starch). Use of lactose is preferred.

Each capsule or cartridge may generally contain between 20 μg-10 mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient. Alternatively, the compound of the invention may be presented without excipients.

Suitably, the packing/medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI).

By reservoir dry powder inhaler (RDPI) it is meant an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position. The metering means may for example comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.

By multi-dose dry powder inhaler (MDPI) is meant an inhaler suitable for dispensing medicament in dry powder form, wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple, define doses (or parts thereof) of medicament. In a preferred aspect, the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.

In the case of multi-dose delivery, the formulation can be pre-metered (e.g. as in Diskus, see GB 2242134, U.S. Pat. Nos. 6,632,666, 5,860,419, 5,873,360 and 5,590,645 or Diskhaler, see GB 2178965, 2129691 and 2169265, U.S. Pat. Nos. 4,778,054, 4,811,731, 5,035,237, the disclosures of which are hereby incorporated by reference) or metered in use (e.g. as in Turbuhaler, see EP 69715 or in the devices described in U.S. Pat. No. 6,321,747 the disclosures of which are hereby incorporated by reference). An example of a unit-dose device is Rotahaler (see GB 2064336 and U.S. Pat. No. 4,353,656, the disclosures of which are hereby incorporated by reference).

The Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) or (Ia) preferably combined with lactose. Preferably, the strip is sufficiently flexible to be wound into a roll. The lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width. The lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.

In one aspect, the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in dry powder form. The blisters are typically arranged in regular fashion for ease of release of medicament there from.

In one aspect, the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disc-form blister pack. In another aspect, the multi-dose blister pack is elongate in form, for example comprising a strip or a tape.

In one aspect, the multi-dose blister pack is defined between two members peelably secured to one another. U.S. Pat. Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type. In this aspect, the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose. Suitably, the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station.

By metered dose inhaler (MDI) it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised in an aerosol container suitable for containing a propellant-based aerosol medicament formulation. The aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient. The aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary.

Where the medicament container is an aerosol container, the valve typically comprises a valve body having an inlet port through which a medicament aerosol formulation may enter said valve body, an outlet port through which the aerosol may exit the valve body and an open/close mechanism by means of which flow through said outlet port is controllable.

The valve may be a slide valve wherein the open/close mechanism comprises a sealing ring and receivable by the sealing ring a valve stem having a dispensing passage, the valve stem being slidably movable within the ring from a valve-closed to a valve-open position in which the interior of the valve body is in communication with the exterior of the valve body via the dispensing passage.

Typically, the valve is a metering valve. The metering volumes are typically from 10 to 100 μl, such as 25 μl, 50 μl or 63 μl. Suitably, the valve body defines a metering chamber for metering an amount of medicament formulation and an open/close mechanism by means of which the flow through the inlet port to the metering chamber is controllable. Preferably, the valve body has a sampling chamber in communication with the metering chamber via a second inlet port, said inlet port being controllable by means of an open/close mechanism thereby regulating the flow of medicament formulation into the metering chamber.

The valve may also comprise a ‘free flow aerosol valve’ having a chamber and a valve stem extending into the chamber and movable relative to the chamber between dispensing and non-dispensing positions. The valve stem has a configuration and the chamber has an internal configuration such that a metered volume is defined there between and such that during movement between is non-dispensing and dispensing positions the valve stem sequentially: (i) allows free flow of aerosol formulation into the chamber, (ii) defines a closed metered volume for pressurized aerosol formulation between the external surface of the valve stem and internal surface of the chamber, and (iii) moves with the closed metered volume within the chamber without decreasing the volume of the closed metered volume until the metered volume communicates with an outlet passage thereby allowing dispensing of the metered volume of pressurized aerosol formulation. A valve of this type is described in U.S. Pat. No. 5,772,085. Additionally, intra-nasal delivery of the present compounds is effective.

To formulate an effective pharmaceutical nasal composition, the medicament must be delivered readily to all portions of the nasal cavities (the target tissues) where it performs its pharmacological function. Additionally, the medicament should remain in contact with the target tissues for relatively long periods of time. The longer the medicament remains in contact with the target tissues, the medicament must be capable of resisting those forces in the nasal passages that function to remove particles from the nose. Such forces, referred to as ‘mucociliary clearance’, are recognised as being extremely effective in removing particles from the nose in a rapid manner, for example, within 10-30 minutes from the time the particles enter the nose.

Other desired characteristics of a nasal composition are that it must not contain ingredients which cause the user discomfort, that it has satisfactory stability and shelf-life properties, and that it does not include constituents that are considered to be detrimental to the environment, for example ozone depletors.

A suitable dosing regime for the formulation of the present invention when administered to the nose would be for the patient to inhale deeply subsequent to the nasal cavity being cleared. During inhalation the formulation would be applied to one nostril while the other is manually compressed. This procedure would then be repeated for the other nostril.

In one embodiment, the means for applying a formulation of the present invention to the nasal passages is by use of a pre-compression pump. Most preferably, the pre-compression pump will be a VP7 model manufactured by Valois SA. Such a pump is beneficial as it will ensure that the formulation is not released until a sufficient force has been applied, otherwise smaller doses may be applied. Another advantage of the pre-compression pump is that atomisation of the spray is ensured as it will not release the formulation until the threshold pressure for effectively atomising the spray has been achieved. Typically, the VP7 model may be used with a bottle capable of holding 10-50 ml of a formulation. Each spray will typically deliver 50-100 μl of such a formulation, therefore, the VP7 model is capable of providing at least 100 metered doses.

Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant. Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of Formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane or a mixture thereof. Carbon dioxide or other suitable gas may also be used as propellant. The aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants, e.g., oleic acid or lecithin and cosolvents, e.g. ethanol. Pressurised formulations will generally be retained in a canister (e.g. an aluminium canister) closed with a valve (e.g. a metering valve) and fitted into an actuator provided with a mouthpiece.

Medicaments for administration by inhalation desirably have a controlled particle size. The optimum particle size for inhalation into the bronchial system is usually 1-10 μm, preferably 2-5 μm. Particles having a size above 20 μm are generally too large when inhaled to reach the small airways. To achieve these particle sizes the particles of the active ingredient as produced may be size reduced by conventional means e.g., by micronization. The desired fraction may be separated out by air classification or sieving. Suitably, the particles will be crystalline in form. When an excipient such as lactose is employed, generally, the particle size of the excipient will be much greater than the inhaled medicament within the present invention. When the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90 μm and not less than 15% will have a MMD of less than 15 μm.

Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.

Solutions for inhalation by nebulization may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.

For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 0.05 to about 80 mg/kg of total body weight, preferably from about 0.1 to 30 mg/kg, more preferably from about 0.5 mg to 15 mg/kg, administered in one or more daily doses. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15 mg/kg, administered in one or more daily doses. The daily topical dosage regimen will preferably be from 0.01 mg to 150 mg, administered one to four times daily. The daily inhalation dosage regimen will preferably be from about 0.05 microgram/kg to about 1 mg/kg per day, more preferably from about 0.2 microgram/kg to about 20 microgram/kg, administered in one or more daily doses. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

The novel compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of CSBP/p38 or cytokine inhibition or production. In particular, CSBP/p38 mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.

Another aspect of the present invention is a method of treating, the common cold or respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human in need thereof which method comprises administering to said human an effective amount of a CBSP/p38 inhibitor.

Another aspect of the present invention is a method of treating, including prophylaxis, of influenza induced pneumonia in a human in need thereof which method comprises administering to said human an effective amount of a CBSP/p38 inhibitor

The present invention also relates to the use of the CSBP/p38 kinase inhibitor for the treatment, including prophylaxis, of inflammation associated with a viral infection of a human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus.

In particular, the present invention is directed to the treatment of a viral infection in a human, which is caused by the human rhinovirus (HRV), other enterovirus, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or an adenovirus. In particular the invention is directed to respiratory viral infections that exacerbate asthma (induced by such infections), chronic bronchitis, chronic obstructive pulmonary disease, otitis media, and sinusitis. While inhibiting IL-8 or other cytokines may be beneficial in treating a rhinovirus may be known, the use of an inhibitor of the p38 kinase for treating HRV or other respiratory viral infections causing the common cold is believed novel.

It should be noted that the respiratory viral infection treated herein may also be associated with a secondary bacterial infection, such as otitis media, sinusitis, or pneumonia.

For use herein treatment may include prophylaxis for use in a treatment group susceptible to such infections. It may also include reducing the symptoms of, ameliorating the symptoms of, reducing the severity of, reducing the incidence of, or any other change in the condition of the patient, which improves the therapeutic outcome.

It should be noted that the treatment herein is not directed to the elimination or treatment of the viral organism itself but is directed to treatment of the respiratory viral infection that exacerbates other diseases or symptoms of disease, such as asthma (induced by such infections), chronic bronchitis, chronic obstructive pulmonary disease, otitis media, and sinusitis.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents, or those for inhalation may include carriers, such as lactose.

The compounds and pharmaceutical formulations according to the invention may be used in combination with or include one or more other therapeutic agents, for example selected from anti-inflammatory agents, anticholinergic agents (particularly an M₁, M₂, M₁/M₂ or M₃ receptor antagonist), β₂-adrenoreceptor agonists, antiinfective agents (e.g. antibiotics, antivirals), or antihistamines. The invention thus provides, in a further aspect, a combination comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with one or more other therapeutically active agents, for example selected from an anti-inflammatory agent (for example a corticosteroid or an NSAID), an anticholinergic agent, β₂-adrenoreceptor agonist, an antiinfective agent (e.g. an antibiotic or an antiviral), or an antihistamine. One aspect of the present invention are combinations comprising a compound of Formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof together with a corticosteroid, and/or an anticholinergic, and/or a PDE-4 inhibitor. Preferred combinations are those comprising one or two other therapeutic agents.

It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, (e.g. as alkali metal or amine salts or as acid addition salts), or prodrugs, or as esters (e.g. lower alkyl esters), or as solvates (e.g. hydrates) to optimise the activity and/or stability and/or physical characteristics (e.g. solubility) of the therapeutic ingredient. It will be clear also that where appropriate, the therapeutic ingredients may be used in optically pure form.

One suitable combination of the present invention comprises of compound of the invention together with a β₂-adrenoreceptor agonist.

Examples of β₂-adrenoreceptor agonists include salmeterol (which may be a racemate or a single enantiomer, such as the R-enantiomer), salbutamol, formoterol, salmefamol, fenoterol or terbutaline and salts thereof, for example the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the fumarate salt of formoterol. Long-acting β₂-adrenoreceptor agonists are preferred, especially those having a therapeutic effect over a 24 hour period, such as salmeterol or formoterol.

Suitable long acting β₂-adrenoreceptor agonists include those described in WO02/66422A, WO02/270490, WO02/076933, WO03/024439, WO03/072539, WO 03/091204, WO04/016578, WO04/022547, WO04/037807, WO04/037773, WO04/037768, WO04/039762, WO04/039766, WO01/42193 and WO03/042160, whose disclosures are incorporated by reference herein.

Preferred long-acting β₂-adrenoreceptor agonists are:

-   3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)     hexyl]oxy}butyl)benzenesulfonamide; -   3-(3-{[7-({(2R)-2-hydroxy-2-[4-hydroxy-3-hydroxymethyl)phenyl]ethyl}-amino)heptyl]oxy}propyl)benzenesulfonamide; -   4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; -   4-{(1R)-2-[(6-{4-[3-(cyclopentylsulfonyl)phenyl]butoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; -   N-[2-hydroxyl-5-[(1R)-1-hydroxy-2-[[2-4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethyl]amino]ethyl]phenyl]foramide,     and -   N-2     {2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-2-hydroxy-2-(8-hydroxy-2(1H)-quinolinon-5-yl)ethylamine.

Suitable anti-inflammatory agents include corticosteroids. Suitable corticosteroids which may be used in combination with the compounds of the invention are those oral and inhaled corticosteroids and their pro-drugs which have anti-inflammatory activity. Examples include methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester, 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxy-androsta-1,4-diene-17β-carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl)ester, 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-(1-methylcylopropylcarbonyl)oxy-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester, 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-(2,2,3,3-tetramethylcyclopropylcarbonyl)oxy-androsta-1,4-diene-17β-carboxylic acid cyanomethyl ester, beclomethasone esters (such as the 17-propionate ester or the 17,21-dipropionate ester), budesonide, flunisolide, mometasone esters (such as the furoate ester), triamcinolone acetonide, rofleponide, ciclesonide, (16α,17-[[(R)-cyclohexylmethylene]bis(oxy)]-11β,21-dihydroxy-pregna-1,4-diene-3,20-dione), butixocort propionate, RPR-106541, and ST-126. Preferred corticosteroids include fluticasone propionate, 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester and 6α,9α-difluoro-17β-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester, more preferably 6α,9α-difluoro-17β-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester.

Non-steroidal compounds having glucocorticoid agonism that may possess selectivity for transrepression over transactivation and that may be useful in combination therapy include those covered in the following patents: WO03/082827, WO01/10143, WO98/54159, WO04/005229, WO04/009016, WO04/009017, WO04/018429, WO03/104195, WO03/082787, WO03/082280, WO03/059899, WO03/101932, WO02/02565, WOO/16128, WO00/66590, WO03/086294, WO04/026248, WO03/061651, WO03/08277.

Suitable anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAID's).

Suitable NSAID's include sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors (for example, theophylline, PDE4 inhibitors or mixed PDE3/PDE4 inhibitors), leukotriene antagonists, inhibitors of leukotriene synthesis (for example, montelukast), iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists and adenosine receptor agonists or antagonists (for example, adenosine 2a agonists), cytokine antagonists (for example, chemokine antagonists, such as a CCR3 antagonist) or inhibitors of cytokine synthesis, or 5-lipoxygenase inhibitors. Suitable other β₂-adrenoreceptor agonists include salmeterol (for example, as the xinafoate), salbutamol (for example, as the sulphate or the free base), formoterol (for example, as the fumarate), fenoterol or terbutaline and salts thereof. An iNOS (inducible nitric oxide synthase inhibitor) is preferably for oral administration. Suitable iNOS inhibitors include those disclosed in WO93/13055, WO98/30537, WO02/50021, WO95/34534 and WO99/62875. Suitable CCR3 inhibitors include those disclosed in WO02/26722.

Another embodiment of the invention is the use of the compound of a Formula (I) or (Ia) in combination with a phosphodiesterase 4 (PDE4) inhibitor or a mixed PDE3/PDE4 inhibitor. The PDE4-specific inhibitor useful in this aspect of the invention may be any compound that is known to inhibit the PDE4 enzyme or which is discovered to act as a PDE4 inhibitor, and which are only PDE4 inhibitors, not compounds which inhibit other members of the PDE family as well as PDE4. Generally it is preferred to use a PDE4 inhibitor which has an IC₅₀ ratio of about 0.1 or greater as regards the IC₅₀ for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC₅₀ for the form which binds rolipram with a low affinity. For the purposes of this disclosure, the cAMP catalytic site which binds R and S rolipram with a low affinity is denominated the “low affinity” binding site (LPDE 4) and the other form of this catalytic site which binds rolipram with a high affinity is denominated the “high affinity” binding site (HPDE 4). This term “HPDE4” should not be confused with the term “hPDE4” which is used to denote human PDE4.

A method for determining IC₅₀s ratios is set out in U.S. Pat. No. 5,998,428 which is incorporated herein in full by reference as though set out herein. See also PCT application WO 00/51599 for another description of said assay. In one embodiment, PDE4 inhibitors of use in this invention will be those compounds which have a salutary therapeutic ratio, i.e., compounds which preferentially inhibit cAMP catalytic activity where the enzyme is in the form that binds rolipram with a low affinity, thereby reducing the side effects which apparently are linked to inhibiting the form which binds rolipram with a high affinity. Another way to state this is that the compounds will have an IC₅₀ ratio of about 0.1 or greater as regards the IC₅₀ for the PDE4 catalytic form which binds rolipram with a high affinity divided by the IC₅₀ for the form which binds rolipram with a low affinity.

A further refinement of this standard is that of one wherein the PDE4 inhibitor has an IC₅₀ ratio of about 0.1 or greater; said ratio is the ratio of the IC₅₀ value for competing with the binding of 1 nM of [³H]R-rolipram to a form of PDE4 which binds rolipram with a high affinity over the IC₅₀ value for inhibiting the PDE4 catalytic activity of a form which binds rolipram with a low affinity using 1 μM[³H]-cAMP as the substrate.

Suitable PDE compounds are cis 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carboxylic acid, 2-carbomethoxy-4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-one and cis-[4-cyano-4-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)cyclohexan-1-ol]; these are examples of compounds which bind preferentially to the low affinity binding site and which have an IC₅₀ ratio of 0.1 or greater.

Other compounds of interest include: Compounds set out in U.S. Pat. No. 5,552,438 issued 3 Sep., 1996; this patent and the compounds it discloses are incorporated herein in full by reference. The compound of particular interest, which is disclosed in U.S. Pat. No. 5,552,438, is cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid (also known as cilomalast) and its salts, esters, pro-drugs or physical forms; AWD-12-281 from elbion (Hofgen, N. et al. 15th EFMC Int. Symp. Med. Chem. (September 6-10, Edinburgh) 1998, Abst. P. 98; CAS reference No. 247584020-9); a 9-benzyladenine derivative nominated NCS-613 (INSERM); D-4418 from Chiroscience and Schering-Plough; a benzodiazepine PDE4 inhibitor identified as CI-1018 (PD-168787) and attributed to Pfizer; a benzodioxole derivative disclosed by Kyowa Hakko in WO99/16766; K-34 from Kyowa Hakko; V-11294A from Napp (Landells, L. J. et al. Eur Resp J [Annu Cong Eur Resp Soc (September 19-23, Geneva) 1998] 1998, 12 (Suppl. 28): Abst P2393); roflumilast (CAS reference No 162401-32-3) and a phthalazinone (WO99/47505, the disclosure of which is hereby incorporated by reference) from Byk-Gulden; Pumafentrine, (−)-p-[(4aR*,10bS*)-9-ethoxy-1,2,3,4,4a,10b-hexahydro-8-methoxy-2-methylbenzo[c][1,6]naphthyridin-6-yl]-N,N-diisopropylbenzamide which is a mixed PDE3/PDE4 inhibitor which has been prepared and published on by Byk-Gulden, now Altana; arofylline under development by Almirall-Prodesfarma; VM554/UM565 from Vernalis; or T-440 (Tanabe Seiyaku; Fuji, K. et al. J Pharmacol Exp Ther, 1998, 284(1): 162), and T2585. Other possible PDE-4 and mixed PDE3/PDE4 inhibitors include those listed in WO01/13953, the disclosure of which is hereby incorporated by reference.

Suitable anticholinergic agents are those compounds that act as antagonists at the muscarinic receptor, in particular those compounds which are antagonists of the M₁ and M₂ receptors. Exemplary compounds include the alkaloids of the belladonna plants as illustrated by the likes of atropine, scopolamine, homatropine, hyoscyamine; these compounds are normally administered as a salt, being tertiary amines. These drugs, particularly the salt forms, are readily available from a number of commercial sources or can be made or prepared from literature data via, to with:

Atropine —CAS-51-55-8 or CAS-51-48-1 (anhydrous form), atropine sulfate —CAS-5908-99-6; atropine oxide —CAS-4438-22-6 or its HCl salt —CAS-4574-60-1 and methylatropine nitrate —CAS-52-88-0; Homatropine —CAS-87-00-3, hydrobromide salt —CAS-51-56-9, methylbromide salt —CAS-80-49-9; Hyoscyamine (d, l)—CAS-101-31-5, hydrobromide salt—CAS-306-03-6 and sulfate salt —CAS-6835-16-1; and Scopolamine —CAS-51-34-3, hydrobromide salt —CAS-6533-68-2, methylbromide salt —CAS-155-41-9.

Suitable anticholinergics for use herein include, but are not limited to, ipratropium (e.g. as the bromide), sold under the name Atrovent, oxitropium (e.g. as the bromide) and tiotropium (e.g. as the bromide) (CAS-139404-48-1). Also of interest are: methantheline (CAS-53-46-3), propantheline bromide (CAS-50-34-9), anisotropine methyl bromide or Valpin 50 (CAS-80-50-2), clidinium bromide (Quarzan, CAS-3485-62-9), copyrrolate (Robinul), isopropamide iodide (CAS-71-81-8), mepenzolate bromide (U.S. Pat. No. 2,918,408), tridihexethyl chloride (Pathilone, CAS-4310-35-4), and hexocyclium methylsulfate (Tral, CAS-115-63-9). See also cyclopentolate hydrochloride (CAS-5870-29-1), tropicamide (CAS-1508-75-4), trihexyphenidyl hydrochloride (CAS-144-11-6), pirenzepine (CAS-29868-97-1), telenzepine (CAS-80880-90-9), AF-DX 116, or methoctramine, and the compounds disclosed in WO 01/04118, the disclosure of which is hereby incorporated by reference.

Other suitable anticholinergic agents include compounds of formula (XXI), which are disclosed in U.S. patent application 60/487,981:

in which the preferred orientation of the alkyl chain attached to the tropane ring is endo;

-   R³¹ and R³² are, independently, selected from the group consisting     of straight or branched chain lower alkyl groups having preferably     from 1 to 6 carbon atoms, cycloalkyl groups having from 5 to 6     carbon atoms, cycloalkyl-alkyl having 6 to 10 carbon atoms,     2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group     having not in excess of 4 carbon atoms and phenyl substituted with     an alkoxy group having not in excess of 4 carbon atoms; -   X⁻ represents an anion associated with the positive charge of the N     atom. -   X⁻ includes, but is not limited to chloride, bromide, iodide,     sulfate, benzene sulfonate, and toluene sulfonate.     Suitably, this includes the following exemplifications: -   (3-endo)-3-(2,2-di-2-thienylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane     bromide; -   (3-endo)-3-(2,2-diphenylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane     bromide; -   (3-endo)-3-(2,2-diphenylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane     4-methylbenzenesulfonate; -   (3-endo)-8,8-dimethyl-3-[2-phenyl-2-(2-thienyl)ethenyl]-8-azoniabicyclo[3.2.1]octane     bromide; and/or -   (3-endo)-8,8-dimethyl-3-[2-phenyl-2-(2-pyridinyl)ethenyl]-8-azoniabicyclo[3.2.1]octane     bromide.

Further suitable anticholinergic agents include compounds of formula (XXII) or (XXIII), which are disclosed in U.S. patent application 60/511,009:

wherein: the H atom indicated is in the exo position;

-   R⁴¹ represents an anion associated with the positive charge of the N     atom., R⁴¹ may be, but is not limited to, chloride, bromide, iodide,     sulfate, benzene sulfonate and toluene sulfonate; -   R⁴² and R⁴³ are independently selected from the group consisting of     straight or branched chain lower alkyl groups (having preferably     from 1 to 6 carbon atoms), cycloalkyl groups (having from 5 to 6     carbon atoms), cycloalkyl-alkyl (having 6 to 10 carbon atoms),     heterocycloalkyl (having 5 to 6 carbon atoms) and N or O as the     heteroatom, heterocycloalkyl-alkyl (having 6 to 10 carbon atoms) and     N or O as the heteroatom, aryl, optionally substituted aryl,     heteroaryl, and optionally substituted heteroaryl; -   R⁴⁴ is selected from the group consisting of (C₁-C₆)alkyl,     (C₃-C₁₂)cycloalkyl, (C₃-C₇)heterocycloalkyl,     (C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, (C₁-C₆)alkyl(C₃-C₇)heterocycloalkyl,     aryl, heteroaryl, (C₁-C₆)alkyl-aryl, (C₁-C₆)alkyl-heteroaryl, —OR⁴⁵,     —CH₂OR⁴⁵, —CH₂OH, —CN, —CF₃, —CH₂O(CO)R⁴⁶, —CO₂R⁴⁷, —CH₂NH₂,     —CH₂N(R⁴⁷)SO₂R⁴⁵, —SO₂N(R⁴⁷)(R⁴⁸), —CON(R⁴⁷)(R⁴⁸),     —CH₂N(R⁴⁸)CO(R⁴⁶), —CH₂N(R⁴⁸)SO₂(R⁴⁶), —CH₂N(R⁴⁸)CO₂(R⁴⁵),     —CH₂N(R⁴⁸)CONH(R⁴⁷); -   R⁴⁵ is selected from the group consisting of (C₁-C₆)alkyl,     (C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, (C₁-C₆)alkyl(C₃-C₇)heterocycloalkyl,     (C₁-C₆)alkyl-aryl, (C₁-C₆)alkyl-heteroaryl; -   R⁴⁶ is selected from the group consisting of (C₁-C₆)alkyl,     (C₃-C₁₂)cycloalkyl, (C₃-C₇)heterocycloalkyl,     (C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, (C₁-C₆)alkyl(C₃-C₇)heterocycloalkyl,     aryl, heteroaryl, (C₁-C₆)alkyl-aryl, (C₁-C₆)alkyl-heteroaryl; -   R⁴⁷ and R⁴⁸ are, independently, selected from the group consisting     of H, (C₁-C₆)alkyl, (C₃-C₁₂)cycloalkyl, (C₃-C₇)heterocycloalkyl,     (C₁-C₆)alkyl(C₃-C₁₂)cycloalkyl, (C₁-C₆)alkyl(C₃-C₇)heterocycloalkyl,     (C₁-C₆)alkyl-aryl, and (C₁-C₆)alkyl-heteroaryl.     Representative examples included are: -   (Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionitrile; -   (Endo)-8-methyl-3-(2,2,2-triphenyl-ethyl)-8-aza-bicyclo[3.2.1]octane; -   3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionamide; -   3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionic     acid; -   (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     bromide; -   3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propan-1-ol; -   N-Benzyl-3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propionamide; -   (Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   1-Benzyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea; -   1-Ethyl-3-[3-((endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea; -   N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-acetamide; -   N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzamide; -   3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-di-thiophen-2-yl-propionitrile; -   (Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-benzenesulfonamide; -   [3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-urea; -   N-[3-((Endo)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-2,2-diphenyl-propyl]-methanesulfonamide;     and/or -   (Endo)-3-{2,2-diphenyl-3-[(1-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     bromide.     Preferred compounds useful in the present invention include: -   (Endo)-3-(2-methoxy-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   (Endo)-3-(2-cyano-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     bromide; -   (Endo)-3-(2-carbamoyl-2,2-diphenyl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; -   (Endo)-3-(2-cyano-2,2-di-thiophen-2-yl-ethyl)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     iodide; and/or -   (Endo)-3-{2,2-diphenyl-3-[(1-phenyl-methanoyl)-amino]-propyl}-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane     bromide.

Suitable antihistamines (also referred to as H₁-receptor antagonists) include any one or more of the numerous antagonists known which inhibit H₁-receptors, and are safe for human use. All are reversible, competitive inhibitors of the interaction of histamine with H₁-receptors. The majority of these inhibitors, mostly first generation antagonists, have a core structure, which can be represented by the following formula:

This generalized structure represents three types of antihistamines generally available: ethanolamines, ethylenediamines, and alkylamines. In addition, other first generation antihistamines include those which can be characterized as based on piperizine and phenothiazines. Second generation antagonists, which are non-sedating, have a similar structure-activity relationship in that they retain the core ethylene group (the alkylamines) or mimic the tertiary amine group with piperizine or piperidine. Exemplary antagonists are as follows:

Ethanolamines: carbinoxamine maleate, clemastine fumarate, diphenylhydramine hydrochloride, and dimenhydrinate. Ethylenediamines: pyrilamine maleate, tripelennamine HCl, and tripelennamine citrate. Alkylamines: chloropheniramine and its salts such as the maleate salt, and acrivastine. Piperazines: hydroxyzine HCl, hydroxyzine pamoate, cyclizine HCl, cyclizine lactate, meclizine HCl, and cetirizine HCl. Piperidines: Astemizole, levocabastine HCl, loratadine or its descarboethoxy analogue, and terfenadine and fexofenadine hydrochloride or another pharmaceutically acceptable salt.

Azelastine hydrochloride is yet another H₁ receptor antagonist which may be used in combination with a PDE4 inhibitor.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a physiologically acceptable diluent or carrier represent a further aspect of the invention.

The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.

The invention will now be described by reference to the following biological examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

Biological Examples

The cytokine-inhibiting effects of compounds of the present invention may be determined by the following in vitro assays:

Assays for Interleukin-1 (IL-1beta), Interleukin-8 (IL-8), and Tumour Necrosis Factor (TNFalpha) are well known in the art, and may be found in a number of publications, and patents. Representative suitable assays for use herein are described in Adams et al., U.S. Pat. No. 5,593,992, whose disclosure is incorporated by reference in its entirety.

It is recognized that the respective assays herein may have been run multiple times for particular compounds of Formula (I) or (Ia), etc. as described herein. The determination of activity, as reported in these assays, will be based upon a mean or median of these values.

Interleukin-1 (IL-1)

Human peripheral blood monocytes are isolated and purified from either fresh blood preparations from volunteer donors, or from blood bank buffy coats, according to the procedure of Colotta et al, J Immunol, 132, 936 (1984), or another suitable procedure such as positive selection using MACS CD14+ beads. These monocytes (1×10⁶) are plated in 24, 48, 96 or 384-well plates at a concentration of 1-2 million/ml per well. The cells are allowed to adhere for 2 hours, after which time non-adherent cells can be removed by gentle washing. Test compounds are then added to the cells for 1 h before the addition of lipopolysaccharide (50-200 ng/ml), and the cultures are incubated at 37° C. for an additional 24 h. At the end of this period, culture supernatants are removed and clarified of cells and all debris. IL-1beta levels in the cell-free supernatant are then determined by enzyme-linked immunoassay (ELISA) or other antibody based procedure.

In Vivo TNF Assay:

(1) Griswold et al., Drugs Under Exp. and Clinical Res., XIX (6), 243-248 (1993); or

(2) Boehm, et al., Journal Of Medicinal Chemistry 39, 3929-3937 (1996) whose disclosures are incorporated by reference herein in their entirety.

LPS-Induced TNFα Production in Mice and Rats

In order to evaluate in vivo inhibition of LPS-induced TNFα production in rodents, both mice or rats are injected with LPS.

Mouse Method

Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-B5, Sigma Chemical Co., St Louis, Mo.) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO₂ inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at −20° C. until assayed for TNFα by ELISA.

Rat Method

Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-B5, Sigma Chemical Co., St Louis, Mo.) 3.0 mg/kg intraperitoneally. The rats are killed by CO₂ inhalation and heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection. The blood samples are centrifuged and the plasma collected for analysis by ELISA for TNFα levels.

ELISA Method

TNFα levels were measured using a sandwich ELISA, Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incorporated by reference in its entirety herein, using a hamster monoclonal antimurine TNFα (Genzyme, Boston, Mass.) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody. For detection, a peroxidase-conjugated goat antirabbit antibody (Pierce, Rockford, Ill.) was added, followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 1% urea peroxide). TNFα levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNFα (Genzyme).

LPS-Stimulated Cytokine Production in Human Whole Blood

Assay: Test compound concentrations were prepared at 10× concentrations and LPS prepared at 1 ug/ml (final conc. of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes. Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes or multiwell plates containing compounds and LPS in 0.2-0.4 mL volumes and the tubes incubated at 37 C. In some studies, compound was incubated with blood for up to 30 min prior to addition of LPS. Following a 4 hour incubation, the tubes or plates were centrifuged to remove cells and plasma was withdrawn and frozen at −80 C. Cytokine measurement: IL-1beta and/or TNFalpha were quantified using a standardized ELISA, or similar technology. Concentrations of IL-1beta or TNFalpha were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis.

Results

Compounds would be considered active in this assay if they demonstrated a IC50 of less than 10 uM up to about an IC50 of less than 0.0001 uM. Representative compounds of Formula (I) and (Ia) as described in Examples 7(c), 8(c), 9, 10(e), 11, 13, 14, 17, 18, 23(c) and (e), 24, 26, 28, 29(c), 53, 58, 69-72, 74-76, 78, 91, 115, 118(c), 119, 121, 123, 124, 126, 127, 130, 131, 133, 136-140, 142, 144, 146, 163(a) and (c), 165-167, 169-176, 180-181, 184, 192, 205, 206, 211, 213-219, and 223, 224 were tested in the above assay and found active. Compounds of Examples 66-68, 73, 117, 128-129, 141, 143, 161, 162, 163(b), and 226 demonstrated an IC50 of greater than 1.0 uM in this assay. Example 111(c) upon multiple runs provided a range of data, ranging from an IC50 of 0.040 uM to an IC50 of greater than 0.1 uM in this assay. While these compounds were found to be inhibit greater than 50% at a 1 uM of TNF-alpha, some of these compounds would be expected upon retesting with increasing concentrations to reach 50% inhibition.

CSBP/p38 Kinase Assay:

This assay measures the CSBP/p38-catalyzed transfer of ³²P from [a-³²P]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPLTPSGEAPNQALLR (residues 661-681). (See Gallagher et al., “Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSBP Kinase”, BioOrganic & Medicinal Chemistry, 1997, 5, 49-64).

Reactions were carried in round bottom 96 well plate (from Corning) in a 30 ml volume. Reactions contained (in final concentration): 25 mM Hepes, pH 7.5; 8 mM MgCl₂; 0.17 mM ATP (the Km_([ATP]) of p38 (see Lee et al., Nature 300, n72 pg. 639-746 (December 1994)); 2.5 uCi of [g-32P]ATP; 0.2 mM sodium orthovanadate; 1 mM DTT; 0.1% BSA; 10% glycerol; 0.67 mM T669 peptide; and 2-4 nM of yeast-expressed, activated and purified p38. Reactions were initiated by the addition of [gamma-32P]Mg/ATP, and incubated for 25 min. at 37° C. Inhibitors (dissolved in DMSO) were incubated with the reaction mixture on ice for 30 minutes prior to adding the 32P-ATP. Final DMSO concentration was 0.16%. Reactions were terminated by adding 10 ul of 0.3 M phosphoric acid, and phosphorylated peptide was isolated from the reactions by capturing it on p81 phosphocellulose filters. Filters were washed with 75 mM phosphoric acids, and incorporated 32P was quantified using beta scintillation counter. Under these conditions, the specific activity of p38 was 400-450 pmol/pmol enzyme, and the activity was linear for up to 2 hours of incubation. The kinase activity values were obtained after subtracting values generated in the absence of substrate which were 10-15% of total values.

Fluorescence Anisotropy Kinase Binding Assay—Standard Volume

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10×K_(i)) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be >2×K_(f). The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration.

The fluorescent ligand is the following compound:

-   -   which is derived from         5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol         and rhodamine green.         Recombinant human p38α was expressed as a GST-tagged protein. To         activate this protein, 3.5 μM unactivated p38α was incubated in         50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.1         mM sodium vanadate, 10 mM MgAc, 0.1 mM ATP with 200 nM MBP-MKK6         DD at 30 degrees for 30 mins. Following activation p38α was         re-purified and the activity assessed using a standard         filter-binding assay.         Protocol: All components are dissolved in buffer of composition         62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1 mM DTT, 12.5 mM MgCl₂         with final concentrations of 12 nM p38α and 5 nM fluorescent         ligand. 30 μl of this reaction mixture is added to wells         containing 1 μl of various concentrations of test compound (0.28         nM-16.6 μM final) or DMSO vehicle (3% final) in NUNC 384 well         black microtitre plate and equilibrated for 30-60 mins at room         temperature. Fluorescence anisotropy is read in Molecular         Devices Acquest (excitation 485 nm/emission 535 nm).         Definitions: Ki=dissociation constant for inhibitor binding     -   Kf=dissociation constant for fluorescent ligand binding

Fluorescence Anisotropy Kinase Binding Low Volume Assay

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10×Ki) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be 2×Kf. The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration. The fluorescent ligand is the following compound:

which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green. Recombinant human p38α was expressed as a GST-tagged protein. To activate this protein, 3.5 μM unactivated p38α was incubated in 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.1 mM sodium vanadate, 10 mM MgAc, 0.1 mM ATP with 200 nM MBP-MKK6 DD at 30 degrees for 30 mins. Following activation p38α was re-purified and the activity assessed using a standard filter-binding assay. Protocol: All components are dissolved in buffer of composition 62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1 mM DTT, 12.5 mM MgCl₂ with final concentrations of 12 nM p38α and 5 nM fluorescent ligand. 30 μl of this reaction mixture is added to wells containing 0.1 μl of various concentrations of test compound (0.02 nM-25 μM final) or DMSO vehicle (1.7% final) in Greiner low volume 384 well black microtitre plate and equilibrated for 30-60 mins at room temperature. Fluorescence anisotropy is read in Molecular Devices Acquest (excitation 485 nm/emission 535 nm). Definitions: Ki dissociation constant for inhibitor binding

-   -   Kf=dissociation constant for fluorescent ligand binding         It is noted that there are two assay formats shown above for the         Fluorescence anisotropy kinase binding assay. The only         difference between these two assays is the volume used and the         plate type. It has been demonstrated that there is no difference         in potency between the two formats, and that the assays are         considered to be equivalent. The results described herein may         have been performed in either assay format and are not         differentiated as to which.

Results

Compounds are considered active in this assay if they demonstrate a pIC50 of greater than 4.6 up to about a pIC50 of 9.0. Representative compounds of Formula (I) and (Ia) as described in the Examples 1(d), 1(g), 2(b), 3(b), 4(c), 5, 6(b), 7(c), 7(d), 8(c), 10(b), (c) and (e), 11 to 14, 15(a), (b), and (c), 16 to 18, 19(b), 20, 21(a) and (b), 22, 23(c), (d), and (e), 24 to 26, 27(b), 28, 29(c), 30(c), 31(b), 32, 33(b), 34(d), 35 to 37, 38(b), 39 to 55, 57 to 60, 62 to 83, 85, 86(c), 87(b), 88(c), 89 to 95, 96(b), 117, 118(c), 119 to 140, 142 to 148, 149(a) and (c), 150 to 152, 154, 155, 156(a), (b) and (c), 157 to 159, 161, 163(a), (b) and (c), 164 to 226 are active in this assay. Compounds of Examples 19(a), 97, 98, 100 to 103, 104(c), 105 to 108, 110, 153, 160 demonstrated an apparent pIC50 of less than 4.8 in this assay. The compound of Example 84 upon multiple runs provided a broad range of data, ranging from 5.3 to less than 5.75 of a pIC50 in this assay. Compounds of Examples 99, 141, and 162 upon multiple runs provided a broad range of data, ranging from 5.9 to less than 4.8 of a pIC50 in this assay.

TR-FRET Assay Time-Resolved Fluorescence Resonance Energy Transfer Kinase Standard Assay

Recombinant human p38α was expressed as a His-tagged protein. To activate this protein, 3 μM unactivated p38α was incubated in 200 mM Hepes pH 7.4, 625 mM NaCl, 1 mM DTT with 27 nM active MKK6 (Upstate), 1 mM ATP and 10 mM MgCl₂ The activity of the MKK6-activated p38α was assessed using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Biotinylated-GST-ATF2 (residues 19-96, 400 nM final), ATP (125M final) and MgCl2 (5 mM final) in assay buffer (40 mM HEPES pH 7.4, 1 mM DTT) were added to wells containing 1 ul of various concentrations of compound or DMSO vehicle (3% final) in NUNC 384 well black plate. The reaction was initiated by the addition of MKK6-activated p38 (100 pM final) to give a total volume of 30 ul. The reaction was incubated for 120 minutes at room temperature, then terminated by the addition of 15 μl of 100 mM EDTA pH 7.4. Detection reagent (15 μl) in buffer (100 mM HEPES pH 7.4, 150 mM NaCl, 0.1% w/v BSA, 1 mM DTT) containing antiphosphothreonine-ATF2-71 polyclonal antibody (Cell Signalling Technology, Beverly Mass., USA) labelled with W-1024 europium chelate (Wallac OY, Turku, Finland), and APC-labelled streptavidin (Prozyme, San Leandro, Calif., USA) was added and the reaction was further incubated for 60 minutes at room temperature. The degree of phosphorylation of GST-ATF2 was measured using a Packard Discovery plate reader (Perkin-Elmer Life Sciences, Pangbourne, UK) as a ratio of specific 665 nm energy transfer signal to reference europium 620 nm signal.

Time-Resolved Fluorescence Resonance Energy Transfer Kinase Low Volume Assay

Recombinant human p38α was expressed as a His-tagged protein. To activate this protein, 3 μM unactivated p38α was incubated in 200 mM Hepes pH7.4, 625 mM NaCl, 1 mM DTT with 27 nM active MKK6 (Upstate), 1 mM ATP and 10 mM MgCl₂ The activity of the MKK6-activated p38α was assessed using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. Biotinylated-GST-ATF2 (residues 19-96, 400 nM final), ATP (125 μM final) and MgCl₂ (5 mM final) in assay buffer (40 mM HEPES pH 7.4, 1 mM DTT) were added to wells containing 0.1 μl of various concentrations of compound or DMSO vehicle (1.7% final) in Greiner low volume 384 well black plate. The reaction was initiated by the addition of MKK6-activated p38α (100 pM final) to give a total volume of 6 μl. The reaction was incubated for 120 minutes at room temperature, then terminated by the addition of 3 μl of detection reagent in buffer (100 mM HEPES pH 7.4, 150 mM NaCl, 0.1% w/v BSA, 1 mM DTT, 100 mM EDTA) containing antiphosphothreonine-ATF2-71 polyclonal antibody (Cell Signalling Technology, Beverly Mass., USA) labelled with W-1024 europium chelate (Wallac OY, Turku, Finland), and APC-labelled streptavidin (Prozyme, San Leandro, Calif., USA). The reaction was further incubated for 60 minutes at room temperature. The degree of phosphorylation of GST-ATF2 was measured using a BMG Rubystar plate reader (BMG, UK) as a ratio of specific 665 nm energy transfer signal to reference europium 620 nm signal. It is noted that there are two assay formats shown above for the Time-resolved fluorescence resonance energy transfer kinase assay. The only difference between these two assays is the volume used and the plate type. It has been demonstrated that there is no difference in potency between the two formats, and that the assays are considered to be equivalent. The results described herein may have been performed in either assay format and are not differentiated as to which.

Results

Compounds would be considered active in this assay if they demonstrated a pIC50 of greater than 4.6 up to about a pIC50 of greater than 10.0. Representative compounds of Formula (I) and (Ia) as described in Examples 1(d), 5, 7(c), 8c, 9, 11, 13, 15(c), 16, 17, 19(b), 20, 21(a), 21(b), 22, 24, 26, 29(c), 30(c), 31(b), 32, 33(b), 34(d), 35 to 37, 38(b), 39 to 55, 58, 59, 62 to 85, 86(c), 87(b), 88(c), 89 to 95, 96(b), 98 to 101, 103, 106, 111(c), 112 to 116, 118(c), 119 to 140,142 to 147, 149(a), 149(c), 150 to 152, 156(a), (b) and (c), 157 to 226, 227(b), 228(b), 229, 230(b) were tested in the above assay and found active. Compounds of Examples 18 and 1(g) upon multiple runs provided a broad range of data, ranging from 8.1 to less than 4.8 of a pIC50 in this assay. Compounds of Examples 117, 108, 106, 104(c), 102, 97 upon multiple runs provided a broad range of data, ranging from 6.8 to less than 5.8 of a pIC50 in this assay. Compounds of Examples 105, 107, and 110 have demonstrated a pIC50 of <5.8 in this assay. The compound of Example 27(b) demonstrated a pIC50 of <4.8 in this assay. For purposes herein for the HTRF assay and the Fluorescence anisotropy kinase binding assay:

pIC₅₀ IC₅₀ (nM) IC₅₀ (uM) 4.00 100,000.0 100 5.00 100,000.0 10 6.00 1,000.0 1 7.00 100.0 0.1 8.00 10.0 0.01 9.00 1.0 0.001 10.00 0.1 0.0001 TNF-Stimulated IL-8 Production from Human Neutrophils The effect of test compounds on TNF-stimulated IL8 production by human neutrophils is measured as follows. Neutrophils are prepared from blood obtained from consenting donors, using standard methods. Blood is collected in heparinized syringes and layered over histopaque (30 ml/20 ml). Following centrifugation, the red cell pellet is resuspended in PBS and purified over a dextran gradient. Red blood cells are lysed with water for 40 sec, remaining granulocytes collected by centrifugation and resuspended at 1.5×10̂6 cells/ml. Cells are added (0.5-1 ml) to 48 well plates already containing compound at 1000×final concentration in neat DMSO or 10% DMSO in RPMI1640 with 10% FBS. TNF (final concentration 100 ng/ml) is used as the stimulus. Cells incubated for approximately 20 hrs at 37° C., 5% CO2. Levels of IL-8 in the cell free supernatant are determined by sandwich ELISA, and inhibition relative to a control with DMPO but no compound is calculated.

Results

Compounds would be considered active in this assay if they demonstrated an IC50 of less than 10 uM up to about an IC50 of less than 0.0001 uM, and were screened at concentrations up to 100 nM. Representative compounds of Formula (I) and (Ia) as described in Examples 2(b), 3(b), 7(c) and (d), 8(c), 9, 11-14, 15(c), 16-18, 19(b), 20, 21(b), 22, 23(c) and (e), 24, 26, 27(b), 28, 29(c), 30(c), 31(b), 32, 33(b), 34(d), 35-37, 38(b), 39-48, 51-55, 58, 63-64, 70, 74-83, 85, 86(c), 87(b), 88(c), 89, 91-95, 111(c), 114, 117, 120-122, 124, 127, 130, 148, 151, 177-180, 182-189, 194, 196, 198, 200-201, 203-204, 227(b), and 230(a) were tested in the above assay and found active. Compounds of Examples 4(c), 5, 6(b), 15(b), 23(d), 49-50, 62, 65, 84, 90, 96(b), 98-101, 103, 104(c), 105-110, 113, 116, 125, 146, 149(c), 152-155, 156(a), 156(b), 156(c), 159, 160, 197, 228(b), 229, and 230(b) demonstrated an IC50 of greater than 0.1 uM in this assay. These later compounds were screened at a different top concentration than the above grouping. While these compounds were not found to inhibit the production of IL-8 at greater than 50% at a 100 nM, some of these would be expected upon retesting with increasing concentrations to reach 50% inhibition. Compounds of Examples 71 and 72 demonstrated an IC50 of greater than 0.001 uM in this assay. These later compounds were screened at a different top concentration than the above grouping. Compounds of Examples 1(g), 15(a), 19(a) upon multiple runs provided a broad range of data, ranging from an IC50 of 0.04 uM to an IC50 of greater than 0.1 uM in this assay. Example 115 upon multiple runs provided a broad range of data, ranging from an IC50 of less than 0.001 uM to greater than 0.1 uM in this assay. While these compounds were not found to inhibit the production of IL-8 at greater than 50% at a 100 nM, some of these would be expected upon retesting with increasing concentrations to reach 50% inhibition.

Rat LPS Neutrophilia Model

The effect of compounds on the influx of neutrophils to the lung in LPS-challenged rats is evaluated as follows. The test compound is suspended in one of the following solutions: 0.5% tween 80/PBS, 0.5% tween 80/saline, 10% EtOH/saline (with pH adjusted to 2.0, or 8.0 with HCl, or unadjusted), Saline (pH 2.0, 6.5 or 8.0, 0.5% Tragacanth, 1% DMSO/20% Encapsin/Saline, or acidified 5% Tragacanth. The suspension process may be aided by the use of a glass homogenizer. For intratracheal administration, the animals are anesthetized with inhaled isoflurane and placed in a supine position, the trachea is intubated with a steel gavage needle (1.5 inch, 22 gauge, small ball) or a Penn-Century Microsprayer Aerosolizer (model IA-LB) and 200 ul of dosing solution is delivered. The animals are visually monitored during the recovery process, which typically occurs within two minutes.

Rats treated with compound or vehicle (15 min-24 hours pretreatment) are exposed to an LPS aerosol (100 ug/ml) for 15 min. Four hours later the rats are euthanized with pentobarbital (100 mg/kg, i.p.) and the airways are lavaged with 5 washes of 5 ml of phosphate buffered saline. The harvested cells are stained (Diffquick) and counted to determine total and differential cell data. In a typical study, macrophages represent 40-70% of the total cells, and polymorphonuclear cells 30-60% of the total cells. Inhibition of neutrophil levels relative to no compound controls is calculated based on the differential counts.

The assay has varying conditions, such as concentration, pretreat time, form of the compound (crystalline, amorphous, salts, micronised), and a wet or dry application of the compound.

The data is obtained as % inhibition using a particular concentration and pretreat time. While a number of the compounds were found to be statistically nonsignificant (p>0.05), it is expected that upon retesting with either increasing concentrations, and/or a change in pretreat time that some of them may reach statistical significance (p<0.05).

Representative compounds of the invention have been tested in this assay.

Compounds of Examples 8(c), 11, 29(c), 36, 40, 42, 70, 71, 72, 91, 92, 112, 118(c), 119, 120, 127, 137, 138, 140, 144, and 200 were found to have statistically significant inhibition of neutrophilia in at least one of the range of conditions tested in this assay.

Compounds of Examples 9, 17, 23(e), 24, 28, 32, 34(d), 37, 39, 53, 57, 60, 86(c), 87(b), 93, 124, 134, 148, 151, 166, 172, 176, and 179 were found to have statistically nonsignificant inhibition of neutrophilia in at least one of the range of conditions tested in this assay.

Compounds of Examples 7(c), 23(c), 26, 43, 60, 174, and 175 were found to be inactive in this assay.

TNF-α in Traumatic Brain Injury Assay

This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid-percussion traumatic brain injury (TBI) in rats. Since TNF-α is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF-α plays an important role in both the acute and regenerative response to CNS trauma. A suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference.

CNS Injury Model for IL-b mRNA

This assay characterizes the regional expression of interleukin-1β (IL-1β) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-1β mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-1β play a role in the post-traumatic pathologic or regenerative sequelae of brain injury. A suitable assay may be found in WO 97/35856 whose disclosure is incorporated herein by reference.

Angiogenesis Assay:

Described in WO 97/32583, whose disclosure is incorporated herein by reference, is an assay for determination of inflammatory angiogenesis which may be used to show that cytokine inhibition will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels.

Rhinovirus/Influenza Assay:

Cell lines, rhinovirus serotype 39, and influenza virus A/PR/8/34 were purchased from American Type Culture Collection (ATCC). BEAS-2B cells were cultured according to instructions provided by ATCC using BEGM (bronchial epithelial growth media) purchased from Clonetics Corp. HELA cell cultures, used for detection and titration of virus, were maintained in Eagle's minimum essential media containing 10% fetal calf serum, 2 mM 1-glutamine, and 10 mM HEPES buffer (MEM).

A modification of the method reported by Subauste et al., Supra, for in vitro infection of human bronchial epithelial cells with rhinovirus was used in these studies. BEAS-2B cells (2×10⁵/well) were cultured in collagen-coated wells for 24 hours prior to infection with rhinovirus. Rhinovirus serotype 39 was added to cell cultures for one hour incubation at 34° C. after which inoculum was replaced with fresh media and cultures were incubated for an additional 72 hours at 34° C. Supernatants collected at 72 hours post-infection were assayed for cytokine protein concentration by ELISA using commercially available kits (R&D Systems). Virus yield was also determined from culture supernatants using a microtitration assay in HELA cell cultures (Subauste et al., supra 1995). In cultures treated with p38 kinase inhibitors, drug was added 30 minutes prior to infection. Stocks of compounds were prepared in DMSO (10 mM drug) and stored at −20° C.

For detection of p38 kinase, cultures were incubated in basal media without growth factors and additives to reduce endogenous levels of activated p38 kinase. Cells were harvested at various time points after addition of rhinovirus. Detection of tyrosine phosphorylated p38 kinase by immunoblot was analyzed by a commercially available kit and was performed according to the manufacturer's instructions (PhosphoPlus p38 MAPK Antibody Kit: New England BioLabs Inc.).

In some experiments, BEAS-2B cells were infected with influenza virus (strain A/PR/8/34) in place of rhinovirus. Culture supernatant was harvested 48 and 72 hour post-infection and tested by ELISA for cytokine as described above.

Cells and Virus: Influenza A/PR/8/34 sub type H1N1 (VR-95 American Type Culture Collection, Rockville, Md.) was grown in the allantoic cavity of 10 day old chicken eggs. Following incubation at 37° C., and refrigeration for 2½ hours at 4° C., allantoic fluid was harvested, pooled, and centrifuged (1,000 rcf; 15 min; 4° C.) to remove cells. Supernatant was aliquoted and stored at −70° C. The titer of the stock culture of virus was 1.0×10¹⁰ Tissue Culture Infective Dose/ml (TCID₅₀) Inoculation procedure: Four-six week old female Balb/cAnNcrlBr mice were obtained from Charles River, Raleigh, N.C. Animals were infected intranasally. Mice were anesthetized by intraperitoneal injection of Ketamine (40 mg/kg; Fort Dodge Labs, Fort Dodge, Ia) and Xylazine (5 mg/kg; Miles, Shawnee Mission, Ks) and then inoculated with 100 TCID50 of PR8 diluted in PBS in 20 ul. Animals were observed daily for signs of infection. All animal studies were approved by SmithKline Beecham Pharmaceuticals Institutional Animal Care and Use Committee. Virus titration: At various times post infection, animals were sacrificed and lungs were aseptically harvested. Tissues were homogenized, in vials containing 1 micron glass beads (Biospec Products, Bartlesville, Okla.) and 1 ml. of Eagles minimal essential medium. Cell debris was cleared by centrifugation at 1,000 rcf for 15 minutes at 4° C., and supernatants were serially diluted on Madin-Darby canine kidney (MDCK) cells. After 5 days of incubation at 37° C. (5% CO₂), 50 μl of 0.5% chick red blood cells were added per well, and agglutination was read after 1 hour at room temperature. The virus titer is expressed as 50% tissue culture infective dose (TCID₅₀) calculated by logistic regression. ELISA: Cytokine levels were measured by quantitative ELISA using commercially available kits. Ear samples were homogenized using a tissue minser in PBS. Cell debris was cleared by centrifugation at 14,000 rpm for 5 minutes. The cytokine concentrations and thresholds were determined as described by the manufacturer; IL-6, IFN-γ, and KC (R&D Systems, Minneapolis, Minn.). Myeloperoxidase Assay Myeloperoxidase (MPO) activity was determined kinetically as described by Bradley et al. (1982). Briefly, rabbit cornea were homogenized in Hexadecyl Trimethyl-Ammonium Bromide (HTAB) (Sigma Chemical Co. St. Louis, Mo.) which was dissolved in 0.5 m Potassium phosphate buffer (J. T. Baker Scientific, Phillipsburg, N.J.). Following homogenization, the samples were subjected to freeze-thaw-sonication (Cole-Parmer 8853, Cole-Parmer, Vernon Hills, Ill.) 3 times. Suspensions were then cleared by centrifugation at 12,500×g for 15 minutes at 4° C. MPO enzymatic activity was determined by colormetric change in absorbance during a reaction of O-Dianisidine dihydrochloride (ODI) 0.175 mg/ml (Sigma Chemical Co. St. Louis, Mo.) with 0.0002% Hydrogen peroxide (Sigma Chemical Co. St. Louis, Mo.). Measurements were performed by using a Beckman Du 640 Spectrophotometer (Fullerton, Calif.) fitted with a temperature control device. 50 ul of material to be assayed was added to 950 ul of ODI and change in absorbance was measured at a wave length of 460 nm for 2 minutes at 25° C. Whole Body Plethysomography: Influenza virus infected mice were placed into a whole body plethysomograph box with an internal volume of approximately 350-ml. A bias airflow of one I/min was applied to the box and flow changes were measured and recorded with a Buxco XA data acquisition and respiratory analysis system (Buxco Electronics, Sharon, Conn.). Animals were allowed to acclimate to the plethysmograph box for 2 min. before airflow data was recorded. Airway measurements were calculated as Penh (enhanced pause). Penh has previously been shown as an index of airway obstruction and correlates with increased intrapleural pressure. The algorithm for Penh calculation is as follows: Penh=[(expiratory time/relaxation time)-l]×(peak expiratory flow/peak inspiratory flow) where relaxation time is the amount of time required for 70% of the tidal volume to be expired. Determination of arterial oxygen saturation. A Nonin veterinary hand held pulse oximeter 8500V with lingual sensor (Nonin Medical, Inc., Plymouth Minn.) was used to determine daily arterial oxygen saturation % SpO2 as described (Sidwell et al. 1992 Antimicrobial Agents and Chemotherapy 36:473-476). Additional data and assay modifications may be found in PCT/US00/25386, (WO 01/19322) filed 15 Sep. 2000, whose disclosure is incorporated herein by reference in its entirety.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows. 

1. A compound of the formula:

wherein G₁ and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; G₅ and G₆ are independently selected from nitrogen or CH provided that both of G₅ and G₆ are not CH; and for compounds of (IV) and (IVa) G₅ and G₆ are nitrogen and CH, provided that only one of G5 or G6 is nitrogen and the other is CH; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁— alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is independently selected at each occurrence from 0 or an integer having a value of 1 to 10; m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is independently selected at each occurrence from 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 2. The compound according to claim 1 which is Formula (III), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 3. (canceled)
 4. The compound according to claim 1 wherein R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b) or N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b).
 5. (canceled)
 6. The compound according to claim 4 wherein R_(b) is selected from an optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryl C₁₋₁₀ alkyl, or an optionally substituted C₃₋₇ cycloalkyl C₁₋₁₀ alkyl.
 7. (canceled)
 8. (canceled)
 9. The compound according to claim 6 wherein R_(b) is an optionally substituted aryl or aryl C₁₋₁₀ alkyl moiety, and the aryl ring substituted independently at each occurrence one or more times by halogen, alkyl, cyano, OR₈, SR₅, S(O)₂R₅, C(O)R_(j), C(O)OR_(j), -Z′-(CR₁₀R₂₀)s-Z′, halosubstituted C₁₋₁₀ alkyl, or an optionally substituted aryl; and wherein R₈ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; R_(j) is independently selected at each occurrence from hydrogen, C₁₋₄alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl, heteroaryl C₁₋₄alkyl, heterocyclic, or a heterocyclic C₁₋₄alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; Z′ is independently selected at each occurrence from oxygen, or sulfur; s is an integer having a value of 1, 2, or 3, independently selected at each occurrence.
 10. The compound according to claim 1 wherein R_(b) is phenyl, napthylene, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 2-methyl phenyl, 3-methylphenyl, 4-methylphenyl, 6-methyl phenyl, 2-methyl phenyl, 3-amino phenyl, 3,4-dimethyl phenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, benzyl, phenethyl, phenylpropyl, 2,3-difluoro-benzyl, 3,5-difluoro-benzyl, biphenyl, 4′-fluorobiphenyl, 4-sulfonamino-2-methylphenyl, 3-phenyloxyphenyl, 4-phenyloxyphenyl, 4-(1-piperidinylsulfonyl)-phenyl, or 3-(aminocarbonyl)phenyl.
 11. The compound according to claim 6 wherein R_(b) is a C₁₋₁₀alkyl, or a C₁₋₁₀alkyl substituted one or more times, independently by halogen, cyano, alkoxy, thiol, or hydroxy.
 12. The compound according to claim 6 wherein R_(b) is methyl, ethyl, propyl, isopropyl, t-butyl, butyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, heptyl, 2-methylpropyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, cyanomethyl, cyanoethyl, 2-methoxy-ethyl, 2-hydroxy propyl, serinol, ethylthioethyl, thiazolyl, phenyl, or 4-F phenyl.
 13. The compound according to claim 6 wherein R_(b) is an optionally substituted heteroaryl, heteroaryl C₁₋₁₀alkyl, heterocyclic or heterocyclic C₁₋₁₀alkyl.
 14. The compound according to claim 13 wherein R_(b) is the moiety is a 1,3-thiazol-2-yl, 5-methyl-1,3-thiazol-2-yl, isoquinoline, 3-thiophene, indol-5-yl, pyridine-3-yl, pyridine-4-yl, indazolyl, benzothiazolyl, 2-methyl-1,3-benzothiazol-5-yl, pyrazol-3-yl, 4-morpholino, 2-furanyl, 2-furanylmethyl, 2-thienyl, 2-thienylmethyl, tetrahydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl methyl, tetrahydro-2-furanyl, or tetrahydro-2-furanylmethyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1H-imidazol-4-yl or 1H-imidazol-4-yl-ethyl.
 15. (canceled)
 16. (canceled)
 17. The compound according to claim 16 wherein R_(b) is selected from methyl-1,3-benzothiazol-5-yl, 4′-fluoro-3-biphenyl, 4-fluoro-phenyl, 2-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 4-fluorophenethyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl, 4-acetylphenyl, 4-trifluorophenyl, 4-methyl-3-fluoro-phenyl, 4-thiomethylphenyl, 4-ethyloxyphenyl, 4-methoxyphenyl, 3-phenyloxyphenyl, 3-methylphenyl, 2-methylphenyl, 5-methyl-1,3-thiazol-2-yl, 3-pyridinyl, 4-pyridinyl, 4-cyanophenyl, 3-cyanophenyl, 4-(phenylcarbonyl)phenyl, 1H-indazol-6-yl, or 3-(aminosulfonyl)phenyl.
 18. The compound according to claim 1 wherein the R_(1′) is independently selected from halogen, C₁₋₄ alkyl, or halo-substituted-C₁₋₄ alkyl.
 19. The compound according to claim 18 wherein the substituents are independently fluorine, methyl, or CF₃
 20. The compound according to claim 18 wherein g is
 1. 21. The compound according to claim 1 wherein X is S(O)_(m)R₂.
 22. The compound according to claim 1 wherein X is (CH₂)_(n)NR₄R₁₄, or (CH₂)_(n)N(R_(2′))(R_(2″)).
 23. The compound according to claim 22 wherein X is (CH₂)_(n)NR₄R₁₄, and R₄ and R₁₄ are independently selected from hydrogen, optionally substituted C₁₋₁₀ alkyl, optionally substituted aryl, optionally substituted aryl-C₁₋₄ alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic C₁₋₄ alkyl, optionally substituted heteroaryl or optionally substituted heteroaryl C₁₋₄ alkyl.
 24. The compound according to claim 23 wherein the C₁₋₁₀ alkyl may be substituted one or more times, independently at each occurrence with NR_(4′)R_(14′); halogen, hydroxy, alkoxy, C(O)NR₄R_(4′); or NR_(4′)C(O)C₁₋₁₀alkyl.
 25. The compound according to claim 24 wherein R_(4′) and R_(14′); are independently selected from hydrogen or a C₁₋₄ alkyl.
 26. The compound according to claim 25 wherein X is 3-(diethylamino)propylamino.
 27. The compound according to claim 22 wherein X is (CH₂)_(n)NR₄R₁₄ and one of R₄ and R₁₄ is an optionally substituted heteroaryl C₁₋₄ alkyl or a heterocyclic C₁₋₄ alkyl and the heteroaryl moiety is selected from thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl, and the heterocyclic C₁₋₄ alkyl is selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, diazepinyl, piperazinyl, and morpholino.
 28. (canceled)
 29. (canceled)
 30. (canceled)
 31. The compound according to claim 22 wherein X is (CH₂)_(n)NR₄R₁₄ and R₄ and R₁₄ together with the nitrogen cyclize to form an optionally substituted ring selected from pyrrolidine, piperidine, piperazine, and morpholine.
 32. The compound according to claim 22 wherein the R₄ and R₁₄ cyclized ring is optionally substituted one or more times independently by an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclic, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇, or NR_(4′) R_(14′),
 33. The compound according to claim 32 wherein the optional substituents are selected from phenyl, pyrrolidinyl, morpholino, piperazinyl, 4-methyl-1-piperazinyl, piperidinyl, 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, 5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, diphenylmethyl, methyl, ethyl, propyl, butyl, amino, methylamino, and dimethylamino.
 34. The compound according to claim 1 wherein X is R₂ and R₂ is an optionally substituted heterocyclic or heterocyclic alkyl ring substituted one or more times independently at each occurrence by an optionally substituted heterocyclic, heterocyclic C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀ alkyl, C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.
 35. The compound according to claim 32 wherein R₂ is selected from 1,4′-bipiperin-1-yl, 4-methyl-1,4′-bipiperin-1-yl, 4-piperidinylamino, 4-amino-1-piperidinyl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-methyl-1-piperazinyl, (4-morpholinyl)-1-piperidinyl, (4-methyl-1-piperazinyl)-1-piperidinyl, 4-ethyl-1-piperazinyl, (2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 5-chloro-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, 4-methylhexahydro-1H-1,4-diazepin-1-yl, 4-propyl-1-piperazinyl, or 4-butyl-1-piperazinyl.
 36. The compound according to claim 35 wherein R₂ is 1,4′-bipiperin-1-yl, 4-(1-pyrrolidinyl)-1-piperidinyl, and 4-methyl-1-piperazinyl.
 37. The compound according to claim 1 wherein R₂ is optionally substituted one or more times, independently at each occurrence, with C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenyl C₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R₁₁)S(O)₂R₇, (CR₁₀R₂₀)_(n)NR₄R₁₄, (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR₄R₁₄, (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR₄R₁₄, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR₄R₁₄, (CR₁₀R₂₀)_(n)C(═NOR₆)NR₄R₁₄, (CR₁₀R₂₀)_(n)OC(Z)NR₄R₁₄, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR₄R₁₄, or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; and wherein n is independently selected at each occurrence from 0 or an integer having a value of 1 to 10; R₆ is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl or heteroarylC₁₋₁₀ alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted.
 38. The compound according to claim 36 wherein R₂ is an optionally substituted alkyl.
 39. The compound according to claim 38 wherein the C₁₋₁₀alkyl is optionally substituted by (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)OR₆, or (CR₁₀R₂₀)_(n)NR₄R₁₄.
 40. The compound according to claim 1 wherein R₂ is (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃) and X₁ is oxygen or N(R_(10′)
 41. (canceled)
 42. The compound according to claim 40 wherein at least one of A₁, A₂ or A₃ is substituted by (CR₁₀R₂₀)_(n)OR₆.
 43. The compound according to claim 42 wherein q is 0 and q′ is
 0. 44. The compound according to claim 22 wherein X is (CH₂)_(n)N(R_(2′))(R_(2″)), and R_(2′) is an optionally substituted C₁₋₁₀ alkyl, cycloalkyl, heterocyclic, heterocyclyl C₁₋₁₀ alkyl, heteroarylalkyl.
 45. The compound according to claim 1 wherein the R_(2′) moieties, excluding hydrogen, are optionally substituted 1 to 4 times, independently, at each occurrence, by C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇cycloalkenyl, C₅₋₇ cycloalkenylC₁₋₁₀ alkyl, halogen, —C(O), cyano, nitro, aryl, aryl C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R_(10′))S(O)₂R₇, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄alkylNR_(e)R_(e′), (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR_(e)R_(e′), (CR₁₀R₂₀)_(n)C(═NOR₆)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)OC(Z)NR_(e)R_(e′), (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇—; and wherein R₆ is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl or heteroarylC₁₋₁₀ alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted; R₇ is independently selected at each occurrence from C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heterocyclic, heterocyclylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆alkyl moiety, and wherein each of these moieties may be optionally substituted; R_(e) are R_(e′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety; or R_(e) and R_(e′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; and wherein each of these moieties, excluding hydrogen, may be substituted 1 to 4 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C₁₋₁₀ alkyl; C₁₋₁₀ alkoxy; halosubstituted C₁₋₁₀ alkoxy; amino, mono & di-substituted C₁₋₄ alkyl amino, S(O)_(m)R_(f′); C(O)R_(j); C(O)ORj; (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR_(d)R_(d′); C(O)NR_(4′)R_(14′); NR_(4′)C(O)C₁₋₁₀alkyl; NR_(4′)C(O)aryl; cyano; nitro; C₁₋₁₀ alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl C₁₋₁₀ alkyl; halosubstituted C₁₋₁₀ alkyl; aryl, aryl C₁₋₄ alkyl, heterocyclic, heterocyclicC₁₋₄ alkyl, heteroaryl, or heteroC₁₋₄alkyl, and wherein these aryl, heterocyclic, and heteroaryl containing moieties may be optionally substituted one to two times independently at each occurrence by halogen, C₁₋₄ alkyl, hydroxy, hydroxy substituted C₁₋₄ alkyl, C₁₋₁₀ alkoxy, S(O)_(m)alkyl, amino, mono & di-substituted C₁₋₄ alkyl amino, C₁₋₄ alkyl, or CF₃; R_(f) is independently selected at each occurrence from C₁₋₁₀ alkyl, aryl, aryl C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀alkyl, heterocyclic, or a heterocyclic C₁₋₁₀alkyl moiety, and wherein these moieties may all be optionally substituted; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); R_(j) is independently selected at each occurrence from hydrogen, C₁₋₄alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl, heteroaryl C₁₋₄alkyl, heterocyclic, or a heterocyclic C₁₋₄alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; and n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
 46. The compound according to claim 45 wherein R_(2′) is a heterocyclic ring or heterocyclic alkyl substituted one or more times, independently by C₁₋₁₀ alkyl, aryl, arylalkyl, (CR₁₀R₂₀)_(n)NR_(e)R_(e′), or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇.
 47. The compound according to claim 22 wherein the (CH₂)_(n)N(R_(2′))(R_(2″)) moiety is 1-(phenylmethyl)-4-piperidinamine, 2-[4-(phenylmethyl)-1-piperazinyl]ethylamine, 2-(1-piperidinyl)ethylamine, 2-(1-methyl-2-pyrrolidinyl)ethylamine, 1-[(phenylmethyl)-3-pyrrolidinyl]amine, 3-[(1-pyrrolidinyl)propyl]amine, 3-[(hexahydro-1H-azepin-1-yl)propyl]amine, (1-methyl-4-piperidinyl)amine, 3-[(4-morpholinyl)propyl]amine, 3-[(2-oxo-1-pyrrolidinyl)propyl]amine, 2-[(4-morpholinyl)ethyl]amine, 2-[(1-pyrrolidinyl)ethyl]amine, or [(1-ethyl-2-pyrrolidinyl)methyl]amine.
 48. The compound according to claim 45 wherein R_(2′) is a C₁₋₁₀ alkyl substituted by (CR₁₀R₂₀)_(n)NR_(e)R_(e′) or (CR₁₀R₂₀)_(n)NR_(e)R_(e′)C₁₋₄-alkylNR_(e)R_(e′).
 49. The compound according to claim 48 wherein R_(e) and R_(e′) are independently selected from methyl, ethyl, isopropyl, n-butyl, or t-butyl, and n=0.
 50. The compound according to claim 1, wherein (CH₂)_(n)N(R_(2′))(R_(2″)) is 3-(dimethylamino)propyl(methyl)amine, 3-(diethylamino)propylamine, propylamine, (2,2-dimethylpropyl)amine, (2-hydroxypropyl)amino, 2-(dimethylamino)ethylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(dimethylamino)propylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(diethylamino)propylamine, 2-(methylamino)ethylamine, [(1-methylethyl)amino]ethylamine, 3-(diethylamino)propylamine, 3-(dibutylamino)propylamine, 3-[(1-methylethyl)amino]propylamine, 3-(1,1-dimethylethyl)aminopropylamine, 3-(dimethylamino)-2,2-dimethylpropylamine, 4-(diethylamino)-1-methylbutylamine, or 3-[[3-(dimethylamino)propyl]-(methyl)amino]propyl(methyl)amine.
 51. The compound according to claim 1 to 3 wherein R₃ is an optionally substituted C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, or aryl.
 52. The compound according to claim 51 wherein R₃ is optionally substituted one or more times, independently at each occurrence, with halogen, nitro, C₁₋₁₀ alkyl, halo-substituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀ alkyl, C₅₋₇cycloalkenyl, C₅₋₇cycloalkenylC₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)OR₆, (CR₁₀R₂₀)_(n)SH, (CR₁₀R₂₀)_(n)S(O)_(m)R₇, (CR₁₀R₂₀)_(n)N(R₁₁)S(O)₂R₇, (CR₁₀R₂₀)_(n)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)CN, (CR₁₀R₂₀)_(n)S(O)₂NR₁₆R₂₆, (CR₁₀R₂₀)_(n)C(Z)R₆, (CR₁₀R₂₀)_(n)OC(Z)R₆, (CR₁₀R₂₀)_(n)C(Z)OR₆, (CR₁₀R₂₀)_(n)C(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)R₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(═N(R_(10′)))NR₁₆R₂₆, (CR₁₀R₂₀)_(n)OC(Z)NR₁₆R₂₆, (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)NR₁₆R₂₆, or (CR₁₀R₂₀)_(n)N(R_(10′))C(Z)OR₇; and wherein R₆ is independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, heterocyclyl, heterocyclyl C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl or heteroarylC₁₋₁₀ alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted; R₇ is independently selected at each occurrence from C₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heterocyclic, heterocyclylC₁₋₆ alkyl, heteroaryl, or heteroarylC₁₋₆alkyl moiety, and wherein each of these moieties may be optionally substituted; and n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
 53. The compound according to claim 52 wherein the R₃ is an optionally substituted aryl.
 54. The compound according to claim 53 wherein the aryl is a phenyl substituted one or more times independently at each occurrence by halogen, (CR₁₀R₂₀)_(n)OR₆, C₁₋₁₀ alkyl, (CR₁₀R₂₀)_(n)NR₁₆R₂₆, or halosubstituted alkyl.
 55. The compound according claim 54 wherein the phenyl is substituted one or more times independently by halogen, hydroxy, alkoxy, amino, alkyl, or CF₃.
 56. The compound according to claim 55 wherein the phenyl is disubstituted independently at each occurrence by halogen or methyl.
 57. The compound according to claim 56 wherein R₃ is 2,6-difluorophenyl.
 58. The compound according to claim 1 wherein R₃ is a 2,6-difluoro phenyl, R_(1′) is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), R_(b) is C₁₋₁₀ alkyl or an optionally substituted aryl; X is (CH₂)_(n)N(R_(2′))(R_(2″)), n is 0, and R_(2′) is an alkyl substituted by (CR₁₀R₂₀)_(n)NR_(e)R_(e′). 59-64. (canceled)
 65. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 1 and a pharmaceutically acceptable carrier or diluent.
 66. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative according to claim 1, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
 67. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 1. 68. The method according to claim 67 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and brain and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, thrombosis, glomerularnephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, atherosclerosis, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenerative disease, muscle degeneration, atherosclerosis, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, influenza induced pneumonia, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.
 69. (canceled)
 70. (canceled)
 71. A method of treating inflammation in a mammal in need thereof comprising administering to said mammal an effective amount of a compound according to claim
 1. 72-74. (canceled)
 75. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; one of G₅, G6, G₇ and G₈ is nitrogen and the others are CH; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁— alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is independently selected at each occurrence from 0 or an integer having a value of 1 to 10; m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is independently selected at each occurrence from 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 76. (canceled)
 77. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 75, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
 78. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative according to claim 75 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
 79. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 75. 80-134. (canceled)
 135. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; G₅ and G₆ are nitrogen; and G₇ and G₈ are CH; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₁₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 136. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 135 and a pharmaceutically acceptable carrier or diluent.
 137. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 135. 138. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; G₆ and G₈ are nitrogen; G₅ and G₇ are CH; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₁₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 139. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 138 and a pharmaceutically acceptable carrier or diluent.
 140. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 138. 141. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; G₅ and G₈ are nitrogen; G₆ and G₇ are CH; R¹ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₁₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 142. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 141 and a pharmaceutically acceptable carrier or diluent.
 143. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 141. 144. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; G₆ and G₇ are nitrogen; G₅ and G₈ are CH; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R_(10′))C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₋₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₁₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 145. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 144 and a pharmaceutically acceptable carrier or diluent.
 146. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 144. 147. A compound of the formula:

wherein G₁, and G₂ are independently nitrogen; G₃ is NH; G₄ is nitrogen; Y is C(R_(x))(R_(z)), C(O), N(R_(z)), N(R_(w))C(R_(y))(R_(z)), oxygen, OC(R_(y))(R_(z)), S(O)m, or S(O)_(m)C(R_(y))(R_(z)); R_(x) is hydrogen, C₁₋₂ alkyl, N(R_(v))₂, hydroxy, thio, C₁₋₂ alkoxy, or S(O)_(m)C₁₋₂ alkyl; R_(y) is hydrogen or C₁₋₂ alkyl; R_(z) is hydrogen or C₁₋₂ alkyl; R_(w) is hydrogen or C₁₋₂ alkyl; R_(v) is independently selected from hydrogen or C₁₋₂ alkyl; R₁ is C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b), C(Z)O(CR₁₀R₂₀)_(v)R_(b), N(R₁₀)C(Z)(CR₁₀R₂₀)_(v)R_(b); N(R_(10′))C(Z)N(R_(10′))(CR₁₀R₂₀)_(v)R_(b); or N(R_(10′))OC(Z)(CR₁₀R₂₀)_(v)R_(b); R_(1′) is independently selected at each occurrence from halogen, C₁₋₄ alkyl, halo-substituted-C₁₋₄ alkyl, cyano, nitro, (CR₁₀R₂₀)_(v′)NR_(d)R_(d′), (CR₁₀R₂₀)_(v′)C(O)R₁₂, SR₅, S(O)R₅, S(O)₂R₅, or (CR₁₀R₂₀)_(v′)OR₁₃; R_(b) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀ alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or heterocyclylC₁₀ alkyl moiety, which moieties excluding hydrogen, may all be optionally substituted; X is R₂, OR_(2′), S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))S(O)_(m)R_(2′), (CH₂)_(n′)N(R_(10′))C(O)R_(2′), (CH₂)_(n′)NR₄R₁₄, (CH₂)_(n′)N(R_(2′))(R_(2″)), or N(R_(10′))—R_(h)—NH—C(═N—CN)NR_(q)R_(q′); X₁ is N(R₁₁), O, S(O)_(m), or CR₁₀R₂₀; R_(h) is selected from an optionally substituted C₁₋₁₀ alkyl, —CH₂—C(O)—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—C(O)N(R_(10′))CH₂—CH₂—, —CH₂—N(R_(10′))C(O)CH₂—, —CH₂—CH(OR_(10′))—CH₂, —CH₂—C(O)O—CH₂—CH₂—, or —CH₂—CH₂—O—C(O)CH₂—; R_(q) and R_(q′) are independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, C₅₋₇ cycloalkenyl-C₁₋₁₀alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, wherein all of the moieties, excluding hydrogen, are optionally substituted, or R_(q) and R_(q′) together with the nitrogen to which they are attached form a 5 to 7 membered optionally substituted ring, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R₂ is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R₂ is the moiety (CR₁₀R₂₀)_(q′)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃), or (CR₁₀R₂₀)_(q′)C(A₁)(A₂)(A₃); R_(2′) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(2″) is hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁— alkyl, heterocyclic, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; or wherein R_(2″) is the moiety (CR₁₀R₂₀)_(t)X₁(CR₁₀R₂₀)_(q)C(A₁)(A₂)(A₃); A₁ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₂ is an optionally substituted C₁₋₁₀ alkyl, heterocyclic, heterocyclic C₁₋₁₀ alkyl, heteroaryl, heteroaryl C₁₋₁₀ alkyl, aryl, or aryl C₁₋₁₀ alkyl; A₃ is hydrogen or is an optionally substituted C₁₋₁₀ alkyl; R₃ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroarylC₁₋₁₀ alkyl, or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted; R₄ and R₁₄ are each independently selected at each occurrence from hydrogen, C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₄alkyl, aryl, aryl-C₁₋₄ alkyl, heterocyclic, heterocyclic C₁₋₄ alkyl, heteroaryl or a heteroaryl C₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or the R₄ and R₁₄ together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; R_(4′) and R_(14′) are each independently selected at each occurrence from hydrogen or C₁₋₄ alkyl, or R_(4′) and R_(14′) together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members, which ring optionally contains an additional heteroatom selected from NR_(9′); R₅ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl or NR_(4′)R_(14′), excluding the moieties SR₅ being SNR_(4′)R_(14′), S(O)₂R₅ being SO₂H and S(O)R₅ being SOH; R_(9′) is independently selected at each occurrence from hydrogen, or C₁₋₄ alkyl; R₁₀ and R₂₀ are independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R_(10′) is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₁ is independently selected at each occurrence from hydrogen or C₁₋₄alkyl; R₁₂ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R₁₃ is independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, halo-substituted C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇cycloalkylC₁₋₄ alkyl, C₅₋₇ cycloalkenyl, C₅₋₇cycloalkenyl C₁₋₄ alkyl, aryl, arylC₁₋₄ alkyl, heteroaryl, heteroarylC₁₋₄ alkyl, heterocyclyl, or a heterocyclylC₁₋₄ alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; R_(d) and R_(d′) are each independently selected at each occurrence from hydrogen, C₁₋₄ alkyl, C₃₋₆ cycloalkyl, C₃₋₆ cycloalkylC₁₋₄alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or R_(d) and R_(d′) together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR_(9′); g is 0 or an integer having a value of 1, 2, 3, or 4; n′ is 0 or an integer having a value of 1 to 10; m is 0 or an integer having a value of 1 or 2; q is 0 or an integer having a value of 1 to 10; q′ is 0, or an integer having a value of 1 to 6; t is an integer having a value of 2 to 6; v is 0 or an integer having a value of 1 or 2; v′ is 0 or an integer having a value of 1 or 2; Z is independently selected at each occurrence from oxygen or sulfur; and a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
 148. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 147 and a pharmaceutically acceptable carrier or diluent.
 149. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim
 147. 